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Malignant melanoma is one of the most aggressive types of human skin cancer, characterized 
by high mortality  due to its resistance to current therapies. Thus, there is an imperative need 
to develop more effective therapeutic approaches. To this end, isothiocyanates (ITCs), the 
biologically active plant secondary metabolites of glucosinolates, have been shown to act as 
promising anti-melanoma agents, mediating various biological effects, including modulation 
of detoxifying enzymes, induction of oxidative stress, apoptosis as well as modulation of the 
epigenome among others. This study aimed to characterize the effect of 5 ITCs 
[Sulforaphane (SFN); Iberin (IBN); Allyl- (AITC); Benzyl- (BITC) and Phenethyl-
Isothiocyanate (PEITC)] on lysine acetylation and methylation marks as a potential 
epigenetic-induced anti-melanoma modality. An in vitro model of malignant melanoma was 
utilized, consisting of (i) human (A375) and (ii) murine (B16-F10) malignant melanoma 
cells; human metastatic melanoma cells derived from (iii) brain (VMM1) and (iv) lymph 
node (Hs 294T); (v) non-melanoma epidermoid carcinoma (A431) cells and (vi) 
immortalized keratinocyte (HaCaT) cells. All cell lines were subjected to treatments with 
varying doses and time frames for each of the 5 ITCs and various cytotoxicity end points 
were determined [cell viability (by Resazurin assay), levels of reactive oxygen species 
(ROS), total glutathione (GSH), cell cycle distribution and apoptosis (by flow cytometry)]. 
Furthermore, western immunoblotting was used to determine the expression of specific 
histone acetyltransferases (HAT), deacetylases (HDAC) and methyltransferases (HMT) 
together with acetylation and methylation marks on histones. Overall, we demonstrate that 
all five ITCs were able to reduce cell viability, decrease GSH levels, and promote G2/M cell 
cycle arrest and apoptosis. Moreover, utilizing a real-time PCR microarray based gene 
expression profiling platfrom, we found several genes implicated in apoptosis-related 
processes. Finally, all 5 ITCs showed to influence histone acetylation and methylation 
patterns by modulating several key enzymes (HDACs, HATs and HMTs) that mediate these 
epigenetic processes and consequently the acetylation and methylation status of specific 
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1.1 General Introduction: Epigenetics, Cancer and Nutrition 
1.1.1 Overview of Epigenetic Mechanisms 
“Epigenetics” refers to hereditary and reversible modulations in gene transcriptional activity 
independently from the DNA sequence itself (Javaid & Choi, 2017; Probst et al., 2009). 
These modifications occur at an early stage in life (during cell differentiation) and contribute 
to the different phenotypes and functions of the cellular subtypes in various tissues and 
organs. The epigenome is the main modulator of gene expression that contributes to such 
cellular diversity via modifications that take place at the level of both DNA and proteins 
(Margueron & Reinberg, 2010). Such alterations include the addition of methyl- and acetyl-
groups, on DNA bases. These kind of modifications also occur on specific amino acids on 
histone tails. Other well known alterations that take place on the tails of histone proteins 
include phosphorylation, sumoylation, ubiquitinationpoly (ADP-ribosylation)  (Probst et al., 
2009).  
Among them, the best characterized epigenetic alterations include DNA methylation at 
cytosine residues, posttranslational modifications on the amino (N)-terminal tails of histones 
and alterations in non-coding RNA profiles, especially in micro-RNAs (mi-RNAs) activity 
(Bonasio et al., 2010; Golbabapour et al., 2011; Margueron & Reinberg, 2010). All these 
modifications function together to regulate the transcriptional activity and thus are crucial 
for various cellular processes including those for normal development and preservation of 
tissue-specific gene expression (Avner & Heard, 2001; Ferguson-Smith & Surani, 2001; 
Hemberger, 2007; Li et al., 1993; Maltepe et al., 2010; Panning & Jaenisch, 1998). 
At DNA level, the most important and well-studied modification is methylation which, in 
turn, involves the addition of methyl-groups in cytosine bases resulting in the production of 
5-methylcytosine (5mC) residues. It mainly occurs at specific regions that are rich in CpG 
dinucleotides called CpG islands (Kulis & Esteller, 2010; Tsai & Baylin, 2011). Generally, 
methylation of CpG dinucleotides (primarily found on transcriptional start sites such as in 
the case of gene promoters) lead to the transcriptional inactivation of genes, since the 
presence of methyl groups blocks the access of these regions to transcription factors (Moore 





Figure 1.1: Methylation of CpG dinucleotides and role in gene transcription. CpG 
islands are regions rich in guanine and cytosine residues that are spread across the genome. 
They are frequently located in the promoter regions of the genes and they can be methylated 
by enzymes called DNA methyltransferases (DNMTs). Generally CpG islands are hypo-
methylated thus allowing the binding of transcription factors and subsequently gene 
transcription. The addition of methyl groups on the other hand, block the access on cellular 
molecules and downstream genes remain silenced.  Black circles stands for methylated CpG 
islands, while white circles for unmethylated ones.  
The transfer of the methyl-groups into the C residues is catalyzed by a group of enzymes, 
called DNA methyltransferases (DNMTs). The most important of these enzymes are 
DNMT1 (DNA methyltransferase 1), DNMT3A (DNA methyltransferase 3A) and DNMT3B 
(DNA methyltransferase 3B). DNMT3A and DNMT3B are de novo methyltransferases that 
preferentially catalyse the addition of methyl groups on non-methylated cytosines. DNMT1 
is a maintenance methyltransferase that recognizes hemi-methylated DNA and mainly 
provides sustenance for the mitotic inheritance of methylated DNA bases (Moore et al., 
2013). Apart from their role in establishing and maintaining methylation marks on CpG 
dinucleotides, DNMTs are also implicated in chromatin conformational changes since they 
mediate the recruitment of molecules such as methyl binding domain proteins (MBDs), 
histone modifying enzymes and other effector proteins. This shows that there is a cross-talk 




proteins (Fuks et al., 2003; Klose & Bird, 2006; Moore et al., 2013; Siegfried & Simon, 
2010). 
A range of modifications including methylation, acetylation, phosphorylation, 
ubiquitination, poly (ADP-ribosylation) and sumoylation take place at the N-terminal tails 
of these proteins around which the DNA is wrapped, thus forming the nucleosomes (Fig. 
1.2) (Berger, 2007; Lawrence et al., 2016; Rice & Allis, 2001). Specifically, nucleosomes 
are made by an octamer, composed of two copies each of the four core histone proteins 
(H2A, H2B, H3 and H4), rounded by 147 base pairs long DNA sequence. Sequential units 
of nucleosomes are the basic components of a higher organization, known as chromatin 
(Javaid & Choi, 2017; Margueron & Reinberg, 2010), a structure characterized by a complex 
and multilayer regulatory network linked to unique cellular responses, such as the regulation 
of gene expression and the protection of genomic integrity and stability (being involved in 
functions, including DNA replication, transcription, recombination and repair) (Berger, 
2007; Martin & Zhang, 2005). Both DNA and histone proteins undergo various 
modifications  either directly affect nucleosome positioning (and the state of chromatin 
compression) or influence the binding of proteins that interact with DNA and histones 
(which have undergone specific conformational alterations) thereby, affecting gene 
expression (Dawson & Kouzarides, 2012; Lawrence et al., 2016). Generally, when 
chromatin is condensed and compact, (termed “heterochromatin”), gene expression is 
silenced. In contrast, when the chromatin is in an “open” state (known as “euchromatin”) 
then cellular components are able to bind to gene promoters and consequently initiate the 
transcriptional process (Woodcock & Ghosh, 2010). Nucleosome position and spacing are 
modulated by ATP-dependent chromatin regulators which hydrolyze ATP in order to alter 
the position of the nucleosomes or promote nucleosome exchange for the incorporation of 





Figure 1.2: Posttranslational modifications on the N-terminal tail of histone proteins. 
The DNA in the nucleus is wrapped around an octamer consisting of two copies of each of 
the 4 core histone proteins (H2A, H2B, H3, H4) forming a complex known as nucleosome. 
The amino (N) terminal tail of the histones undergo various post-translational modifications 
such as methylation, acetylation, phosphorylation and ubiquitination all of which can 
regulate the nucleosome structure. In addition, specific sites in specific amino acids [K: 
Lysine, R: Arginine, T: Threonine, S: Serine] are shown where these modifications take 
place on particular histone tails.     
Among the various modifications on histone proteins, the best characterized ones are 
methylation and acetylation. The key enzymes that catalyze these modifications are histone 
methyltransferases (HMTs) and histone acetyltransferases (HATs) respectively (Wang et al., 
2009). Histone acetylation mainly occurs in lysines and is generally considered to result in 
gene activation (Wang et al., 2009). There are three major families of HATs: i) the GNAT 
(Gcn5-related N-acetyltransferases), ii) the MYST [the acronym derives from the four 
founding members of this HAT family: mammalian MOZ (males absent on the first), yeast 
Y bf2/Sas3 and Sas2, and mammalian Tip60 (TAT-interacting protein 60)]  and iii) the 
CBP/p300 (cAMP response element binding protein). Each family has a different specificity 
towards their histone and amino acid targets and are generally categorized into Type A and 
Type B both of which are located in the nucleus and cytoplasm, respectively. Histones on 




have a housekeeping role by acetylating newly synthesized histones found in the cytoplasm 
(Biswas & Rao, 2017; Javaid & Choi, 2017). 
Histone methylation takes place on arginine and lysine amino acids and is associated with 
either reactivation or silencing of genes, based on the specific site and extent of the 
modification itself (Li et al., 2007; Yan & Boyd, 2006). The methylation of histone proteins 
is catalyzed by three distinct families of enzymes: i) the SET-domain containing protein 
family (Su(var)3-9, Enhacer-of-zeste and Trithorax), ii) the non-SET domain protein family 
and iii) the protein arginine methyltransferases (PRMT1) family (Biswas & Rao, 2017; Greer 
& Shi, 2012).   
Finally, non-coding RNAs (ncRNAs) are functional RNA molecules which do not translate 
into proteins and are important regulators of the expression of gene targets at the 
transcriptional and post-transcriptional level. There are two main groups of ncRNAs, namely 
short (<30 nucleotides) and long (>200 nucleotides) ncRNAs. The short ones are further 
divided into three major classes: i) micro-RNAs (mi-RNAs), ii) short interfering RNAs 
(siRNAs), and ii) P-element-induced wimpy testis (piwi)-interacting RNAs (piRNAs) 
(Srijyothi et al., 2018; Zhang et al., 2019). Both groups are involved in epigenetic processes 
including heterochromatin formation, histone modifications, targeting of DNA methylation 
and gene silencing (Peschansky & Wahlestedt, 2014).  
Among them, mi-RNAs (21-26 nucleotides in length) are the most studied and well 
characterized. They are transcribed, by RNA polymerase II, as non-coding primary miRNA 
(pri-miRNA) transcripts and are processed into precursor miRNA (pre-miRNA) under the 
activity of a microprocessor complex. This complex consists of  Drosha and the DiGeorge 
syndrome critical region in gene 8 (DGCR8) which are found into the nucleus where the pre-
miRNAs produced are transported into the cytoplasm where they are finally transformed 
into  mature and functional miRNA by  Dicer (Srijyothi et al., 2018). mi-RNAs are key 
regulators of gene expression through binding to the 3' untranslated region (UTR) of their 
target messenger RNAs (mRNAs), as a complex with Argonaute (AGO) family proteins, 
forming the so called miRNA-induced silencing complex (miRISC). According to the degree 
of complementarity between mi-RNA on miRISC and mRNA target, mi-RNAs either 
suppress the translation or induce the cleavage or degradation of the latter (Fig. 1.3) (O'Brien 
et al., 2018; Shukla et al., 2011; Valencia-Sanchez et al., 2006). In addition to their regulatory 
function in gene transcriptional activity, they play pivotal roles in various biological 




2010).  Advances in this field, have shown that these molecules are also implicated in the 
regulation of the epigenetic machinery by controlling DNA methylation and histone 
modifications. For instance, it has been reported that these molecules can target and 
modulate the activity of genes that transcribe epigenetic modifying enzymes such as DNMTs 
and histone deacetylases (HDACs). DNA methylation and histone modifications have been 
associated with the regulation of mi-RNAs expression, suggesting that there is a feedback 
loop that control the activity of the epigenetic network (Chuang & Jones, 2007; Moutinho & 
Esteller, 2017; Yao et al., 2019).   
 
Figure 1.3: mi-RNA biosynthetic process. mi-RNAs are functional, short, non-coding 
RNAs (21-26 nucleotides) that are important in gene transcriptional regulation. They are 
transcribed by RNA polymerase II into primary mi-RNAs (pri-miRNA) and are further 
processed into precursor mi-RNAs (pre-miRNA) under the activity of Drosha and DGR8. 
Pre-miRNAs are then exported to the cytoplasm by exportin 5, where under Dicer activity 
are transformed into mature mi-RNA. The mi-RNAs produced are loaded into the Argonaut 
(AGO) family of proteins and form a miRNA-induced silencing complex (mi-RISC) which 




complementarity is complete the mRNA target is cleaved, while incomplete 
complementarity result in translational suppression (Srijyothi et al., 2018).   
All the above mentioned modifications act in a coordinative manner in order to regulate the 
genetic information. It is obvious that there is a crosstalk among the components of the 
epigenetic machinery thereby creating a highly organized and complex network for the 
regulation of gene expression (Biswas & Rao, 2017; Chuang & Jones, 2007; Kondo, 2009; 
Murr, 2010). Abnormalities in normal cellular  epigenetic patterns are associated with the 
disruption of the normal function of genes thus resulting in a wide range of pathologies, 
including malignant transformation (Egger et al., 2004; Ziech et al., 2010).  
1.1.2 Epigenetics in Cancer 
Until relatively recently, carcinogenesis was considered to be a primarily genetic condition, 
it is now known that epigenetic dysregulation alongside with multiple genetic lesions are 
responsible for inducing cellular transformation (Dawson & Kouzarides, 2012; Taby & Issa, 
2010). The rapid evolution of the cancer epigenetics field led to important observations 
regarding the alterations that occur in the epigenetic landscape of transformed cells in 
comparison to normal cells. Global changes and reprogramming of the epigenetic machinery 
have been reported to be part of the initiation, progression and metastatic stages of 
carcinogenesis (Nebbioso et al., 2018; Sandoval & Esteller, 2012; Taby & Issa, 2010). 
The involvement of the epigenome in malignant transformation was, first, introduced by the 
identification of alterations in the pattern of DNA methylation patterns in various human 
cancers (Feinberg & Vogelstein, 1983). For instance, hypo-methylation of CpG islands 
across the genome is considered as a hallmark of cancer. Tumorigenesis is generally 
characterized by  global hypo-methylation at multiple genomic regions as well as hyper-
methylation at specific sites [mostly in the promoter and/or the first exon region as well as 
in satellite sequences, transposable elements and repetitive genomic sequences [e.g. long 
interspersed element (LINE), short interspersed nuclear elements (SINEs), Alu elements, 
centromeric repeats etc.] (Kulis & Esteller, 2010; Sharma et al., 2010). Global loss of 
methylation is usually associated with the induction of various proto-oncogenes and 
transposomal translocation, resulting in genomic and chromosomal instability (Berdasco & 
Esteller, 2010; Eden et al., 2003; Sharma et al., 2010). In contrast, hyper-methylation of 
specific promoter regions  leads to repressive chromatin structures that block access to 
transcription factors and result in transcriptional silencing of tumour suppressor genes 




epigenetically inactivated due to hyper-methylation of their promoter. These genes are of 
particular importance for the maintenance of cell homeostasis, since they are involved in 
various physiological processes including DNA repair, cell cycle regulation and metastasis. 
Thus, their down-regulation is a critical step in carcinogenesis (Moison et al., 2014). The 
first one to be reported was the Retinoblastoma gene (RB), associated with sporadic and 
hereditary retinoblastomas (Greger et al., 1989). Furthermore, hyper-methylation indirectly 
affects gene transcription by recruiting molecules that bind to methylated regions, such as 
HDACs and methylated-binding proteins, causing changes in the organization of chromatin. 
(Costello & Plass, 2001; Gokul & Khosla, 2013).   
Apart from DNA methylation, abnormalities in the pattern of epigenetic marks on histone 
proteins are also implicated in tumorigenesis (Sawan & Herceg, 2010). Histone alterations 
are dynamic and co-ordinately regulated and reversed under the activity of opposing 
enzymes. An imbalance in the function of these enzymes disrupts gene transcription, leading 
to aberrant gene activation and consequently to tumorigenesis (Hassler & Egger, 2012).  
Malignant cells are characterized by global modulations in both acetylated and methylated 
histone marks. The evolution of the cancer epigenetic field led to the identification of 
specific histone alterations that are currently considered as a distinctive feature of cancer. 
For instance, genome-wide hypo-acetylation of lysine 16 accompanied with the loss of tri-
methylation at lysine 20 of histone H4 were  the first epigenetic marks documented to be 
differentially distributed in various cancer types (Füllgrabe et al., 2011). Moreover, 
alterations in the methylation pattern of H3K4, H3K9 and H3K27 have been reported during 
cancer development (Chakravarthi et al., 2016). In line, the enzymes responsible for the 
formation of these epigenetic marks are also deregulated in cancer. HDACs (responsible for 
the removal of acetyl groups from histone tails) have been observed to be over-expressed in 
tumour cells (Kanwal & Gupta, 2012). Similarly, HMTs are also abnormally expressed in 
tumour cells (Albert & Helin, 2010). A characteristic example is the Ezh2 (Enhancer of zeste 
homolog 2) gene which is documented to be highly expressed in various malignancies. Ezh2 
catalyses the methylation of lysine 27 at histone H3 (H3K27me), a mark commonly observed 
in carcinomas being associated with repression of various genes, including genes involved 
in the Wnt/β catenin signalling pathway, in chemo-resistance, through regulation of DNA 
damage mechanisms [e.g. BRCA-1, recombinase RAD51, X-ray repair cross complementing 
2 and 3 (XRCC2 and XRCC3) etc.]  as well as in cellular proliferation and differentiation 
[e.g. Runt-related transcription factor 3 (RUNX3), Cyclin dependent kinase inhibitor 1C 




cadherin, Forkhead box C1 (FOXC1), Disabled homolog 2-Interacting Protein (DAB2IP), 
Raf Kinase Inhibitory Protein (RKIP), Microseminoprotein Beta (MSMB), tissue inhibitors 
of metalloproteinases (TIMPs) etc.] and neovascularization [e.g. vasohibin1 (VASH1), 
KLF2, MSMB, TIMPs etc.]. In addition, a number of  anti-metastatic microRNAs (including 
miR-101, let-7c, miR-200b, miR-139-5p, and miR-125b) have been also reported to be 
epigenetically silenced by Ezh2 (Crea et al., 2012; Deb et al., 2013; McCabe et al., 2012).   
Other important constituents of the epigenetic network implicated in driving the behavior of 
tumor growth are mi-RNAs. Their genomic localization, transcriptional regulation and 
processing are all factors reported to be involved in carcinogenesis (Farazi et al., 2011; 
Malumbres, 2013; Ohtsuka et al., 2015). The first report of their involvement in human 
tumorigenesis came from  studies where miR-15a and miR-16-1 were shown to be down-
regulated in chronic lymphocytic leukaemia patients  (Calin et al., 2002). Since then, various 
studies have reported multiple mi-RNAs being differentially expressed in cancer cells 
compared to normal ones (Lu et al., 2005; Mar-Aguilar et al., 2013; Ratert et al., 2013; Tian 
et al., 2018; Volinia et al., 2006; Zhou et al., 2014). For example, in a mi-RNA expression 
profile analysis, the mir-17-92 cluster was found to be significantly over-expressed in human 
lung cancers and was also shown to be associated with increased cell proliferation (Hayashita 
et al., 2005). Other mi-RNAs that were shown to be implicated in carcinogenesis are mir-
27a, mir-96, and mir-182 which were markedly expressed in breast cancer cells resulted in 
repression of tumor-related Forkhead box protein O1 (FOXO1) involved in the regulation of 
apoptotic response, cell cycle checkpoints, and cellular metabolism (Guttilla & White, 
2009). Interestingly, their expression seems to be regulated by other epigenetic modulators, 
especially DNA methylation as well as specific histone alterations (Baer et al., 2013; 
Malumbres, 2013). Typical examples are mir-9, mir-148, mir-124, mir-137, mir-34, mir-127 
and mir-512 that were frequently documented to be suppressed in a number of malignancies 
associated with CpG hyper-methylation (Liu et al., 2013; Sato et al., 2011). Generally, 
oncogenic mi-RNAs are usually over-expressed in malignancies whereas tumour 
suppressors ones are found to be silenced.  However, mi-RNA implication in tumorigenesis 
is more complex, since there are mi-RNAs having a dual role in the tumorigenic process 
(acting either as tumour suppressors or oncogenes) based on their targets (Jansson & Lund, 
2012; Li et al., 2010). Characteristic example is that of the mir-148 family which was 
reported to be upregulated in multiple myeloma and hepatocellular carcinoma while found 




Due to the reversible nature of the epigenetic modifications, the scientific community has 
focused in the identification of agents that could restore the epigenetic pattern observed in 
cancers back to a “normal” landscape. Thus, epigenetic modulators are currently considered 
as potential and promising targets for therapeutic interventions. Recent advances in the 
epigenetic therapy field have already led to the development of a number of small molecule 
inhibitors against epigenetic regulators, whereas several others (such as azacitidine, 
decitabine, vorinostat, romidepsin, panobinostat and belinostat) have recently been approved 
by the Food and Drug Administration (FDA) and are used in the clinical setting for the 
treatment of various human cancers (Boumber & Issa, 2011; Dawson & Kouzarides, 2012; 
Nebbioso et al., 2018; Qi et al., 2016). These are basically DNMT and HDAC inhibitors and 
constitute the first generation of epigenetic drugs. Research is currently focused in producing 
a ‘second generation’ of inhibitors that target other epigenetic enzymes, such as HMTs, 
HATs, histone demethylases (HDMs) as well as methyl- and acetyl-binding proteins 
(Boumber & Issa, 2011; Qi et al., 2016). In this direction, among the various molecules that 
are tested, phytochemicals have emerged as particularly attractive, because of their potential 
to target epigenetic components and the expectation that these plant-derived molecules will 
have fewer side effects than conventional chemotherapeutics  (Ullah et al., 2014)     
1.1.3 Nutrition, Cancer and Epigenetics 
The onset of cancer depends not only on the interplay of genetic and epigenetic lesions but 
also on environmental factors such as nutrition (Bishop, 2015). Nutrition is an important 
factor influencing health and it is mainly implicated in the prevention of chronic disease 
development including carcinogenesis (Russo, 2007; Slawson et al., 2013). According to the 
estimations of the World Cancer Research Fund (WCRF) and the American Institute for 
Cancer Research (AICR), around 30-40% of cancer incidence worldwide could be avoided 
by adopting healthy eating habits, weight control and physical activity (Donaldson, 2004; 
Gonzalez, 2006; Wiseman, 2019). Since then, the protective effect from the consumption of 
plant-derived products has been well established in numerous epidemiological studies. 
Numerous case-control and cohort studies have shown a link between fruit and vegetable 
consumption and reduced risk for various cancers like lung, colorectal, prostate, breast and 
gastric (Gonzalez, 2006). However the data obtained from these type of studies are 
controversial and also lack an understanding of the underlined mechanism(s) by which 
dietary factors influence cancer risk (Sapienza & Issa, 2016; Willett, 2010). New 
technologies and approaches enabled the exploration of the complex interaction of nutrition 




epigenetics (Mayne et al., 2016). The current notion on a relationship between diet and 
cancer arises from the association between specific dietary consumption patterns and an 
individual’s risk for developing cancer (Bishop & Ferguson, 2015; Sapienza & Issa, 2016).  
In this respect, natural products are known to offer various health benefits by exerting 
pleiotropic protective mechanisms and thus have gained scientific interest (Di Domenico et 
al., 2012; Ziech et al., 2012). The potential of these molecules in disease prevention is mainly 
attributed to their capacity to prevent, reverse and/or suppress the multi-stage tumorigenic 
process and thus stimulate an interest in the context of chemoprevention (Kang et al., 2011; 
Weng & Yen, 2012).  
In particular, attention has been focused on compounds derived from fruits and vegetables 
specifically citrus fruits, dark green and cruciferous vegetables, etc. The association between 
higher consumption of these foods and reduced cancer risk  has been suggested to result 
from their high content of particular phytochemicals, such as lignans, curcumin, 
anthocyanin, quercetin, gingerol, limonene, indole-3-carbinol, genistein, apigenin, saponins, 
resveratrol, coumarins, epigallocatechin gallate, lutein, isothiocyanates and many others. 
These bioactive constituents are documented to exhibit a variety of biological properties 
including anti-inflammatory, anti-infectious, anti-oxidant and anti-cancer (Fitsiou et al., 
2016; Issa et al., 2006; Johnson, 2007; Li et al., 2014; Nohynek et al., 2006). In addition, 
emerging evidence shows that these nutraceuticals influence gene expression by modulating 
epigenetic regulators implicated in CpG island methylation, histone protein modifications 
and mi-RNA induction (Rupasinghe et al., 2016; Supic et al., 2013). Such phytochemicals 
correspond to a wide range of biologically-active secondary metabolites and are classified 
(according to their functional and chemical activities) into phenolics, carotenoids, alkaloids, 
nitrogen-containing and organosulfur compounds  (Liu, 2004).  
1.2 Cruciferous Vegetables, Glucosinolates and Isothiocyanates 
Cruciferous vegetables belong to  the Brassica family (e.g. broccoli, watercress, Brussels 
sprouts, cabbage, horseradish, cauliflower, mustard, etc.) and are rich sources of an 
important group of phytochemicals called glucosinolates (GLs) (Verkerk et al., 2009). GLs 
are characterized by a common structure consisted of a β-thioglucosilated moiety which is 
linked to a sulfonated aldoxime and a variable aglucone side chain (R). This R chain derives 
from eight selected amino acids: alanine, leucine, isoleucine, valine, phenylalanine, tyrosine, 
tryptophan and methionine (and possibly glutamic acid) (Agerbirk & Olsen, 2012; 




generally determine the classification of GLs into aromatic, heterocyclic (indoles), aliphatic, 
multiple glycosylated, benzoate and sulfur-containing GLs (Clarke, 2010; Fahey et al., 
2001).  
The type and content of GLs in plants differ within as well as between the Brassicaceae 
family members. Various environmental factors are  responsible for the content and type of 
GLs, including climate, cultivation, genotype, region, even the part and developmental stage 
of the plant (Charron et al., 2005; Kliebenstein et al., 2001; Velasco et al., 2007; 
Śmiechowska et al., 2010). About 200 different GL structures have been identified (Clarke, 
2010) which, upon hydrolysis, give rise to multiple bioactive secondary metabolites 
including ITCs. The type and corresponding breakdown products of GLs are determined to 
a large extent by the eight amino acid precursors of their side chain. For example, ITCs are 
produced by the hydrolysis of aliphatic or aromatic GLs that are usually derived from 
methionine and phenylalanine residues respectively (Cancer, 2004). These are the main 
mediators of the multiple health benefits derived from the consumption of cruciferous 
vegetables  (Dinkova-Kostova & Kostov, 2012; Wagner et al., 2013).  
In particular, ITCs are highly reactive electrophiles that all share an R-N=C=S core structure. 
The R in the structure represents a variable side chain, which consists of allyl or alkyl groups 
and reversibly interacts with the thiol group of cystine residues, forming dithiocarbamates 
(Zhang, 2012b). Examples of well-characterized cancer chemopreventive ITCs include 
sulphoraphane (SFN), iberin (IBN), allyl-ITC (AITC), benzyl-ITC (BITC) and phenethyl-
ITC (PEITC) all of  which represent the most frequent ones found in commonly eaten 





Figure 1.4: The structure of major ITCs Adapted from (Mitsiogianni et al., 2019) 
1.2.1 GLs Biosynthesis and Metabolism 
Studies utilizing the model species Arapidopsis Thaliana led to the identification of genes 
involved in the GLs biosynthetic process. This pathway occurs in three stages: i) side chain 
elongation; ii) formation of the glycone moiety and iii) secondary modifications in the side 
chain (Grubb & Abel, 2006; Halkier & Du, 1997; Wittstock & Halkier, 2002). Briefly, 
during the first step, the side chain elongation  starts with the transamination of the α-amino 
acid to form an α-keto acid which then undergoes condensation with acetyl coenzyme A 
(Graser et al., 2000). After isomerization, oxidation takes place which is followed by 
decarboxylation to form a 2-oxo acid with an additional methylene group. This cycle can be 
repeated a number of times resulting to the addition of a carbon atom each time (Graser et 
al., 2000; Sønderby et al., 2010) (Fig. 1.5a). The second step in the process, is the formation 
of the core structure of GLs. Oxidation of the amino acid precursor by cytochrome P450 
enzymes give rise to an N-hydroxyl amino acid, in the presence of NADPH. This reaction 




al., 2000). In general, oxime is converted to an aci-nitrol compound which can accept thiol 
groups (Grubb & Abel, 2006; Wang et al., 2011; Wittstock & Halkier, 2002). At first, it was 
proposed that the donor of the thiol group was cysteine (Cys) but recently glutathione (GSH) 
has been shown to act as such donor. This is followed by the cleavage of cysteine by a C-S 
lyase to form thiohydroximate (Geu-Flores et al., 2011; Sønderby et al., 2010). Then, S-
thioglucosilation of the thiohydroximate, by  UDPG: thiohydroximate glucosyltransferase, 
generates desulfoglycosinolate (Mithen et al., 2000). Finally, the complete glucosinolate is 
yielded after the sulfation of desulfoglucosinolate by 3′phosphoadenosine 5′-phosphosulfate 
(PAPS) which  serves as the sulphate donor for the reaction (Koprivova & Kopriva, 2016; 
Mugford et al., 2009) (Fig, 1.5b).  
 
Figure 1.5: Biosynthetic process of Glucosinolates (GLs). The biosynthetic pathway 
involves two main stages: a) side chain elongation and b) formation of the core structure of 
GL.  a) During the first stage, an amino acid precursor undergoes transamination leading to 
the formation of a 2-keto acid, which then, through a condensation process, produce a 2-




produce a 2-keto acid with an additional methylene group. b) The second step of GLs 
biosynthesis, starts with the oxidation of the amino acid, in the presence of cytochrome P450 
enzymes and NADPH, resulting in the formation of an unstable intermediate (aldoxime). 
The oxidation of this aldoxime, give rise to an aci-nitrol compound which is then conjugated 
with a nitric oxide, forming an S-alkyl-thiohydroximate. Next, S-alkyl-thiohydroximate is 
cleaved by a C-S lyase to form a thiohydroximate, followed by S-thioglucosilation to 
generate a desulfoglycosinolate. Final step in the process is the sulfation of the 
desulfoglucosinolate and the complete glucosinolate is produced. In this figure, R stands for 
the specific functional side chain of each amino acid, UDPG for UDPG: thiohydroximate 
glucosyltransferase and PAPs for 3′phosphoadenosine 5′-phosphosulfate. 
The third and final step involves secondary modifications like hydroxylation, methoxylation, 
desaturation, sulphation and glucosylation, all of which are responsible for forming the wide 
range of known GLs. Other factors that contribute to such diversity are the presence of 
different types of side chains (simple and branched alkyl, ω-methylthioalkyl, aryl or 
heterocyclic) and differences in amino acid elongation (Wittstock & Halkier, 2002).  
1.2.2 GL Metabolism- Mustard Oil Bomb 
Myrosinase was first discovered by Bussy in 1839 as a protein essential for the release of 
essential oil from mustard seed. Later,  it was reported that myrosinase is the enzyme 
responsible for the hydrolysis of GLs  (Andréasson & Jørgensen, 2003). There are a number 
of genes (a gene family comprising at least three differentially expressed subfamilies of 
myrosinase genes) responsible for the transcription of distinct isoforms of myrosinase. 
Different isoforms of this enzyme have been found with diverse activities while their 
distribution appears to be organ- and species-specific. Finally, differences in activity levels 
have been also observed among different plant species (del Carmen Martinez-Ballesta & 
Carvajal, 2015; Thangstad et al., 2004).  
Hydrolysis of GLs starts with the disruption of plant integrity, after chewing or cutting it. 
Then, myrosinase is released and comes in contact with its substrates. In doing so, it acts as 
a β-thioglucosidase and breaks down the sulfur group of the glucosidic bond (Agerbirk & 
Olsen, 2012; Angelino & Jeffery, 2014). Within the plant, myrosinase is generally 
considered to be physically isolated from GLs, located in idioblastic cells. However, their 





Studies on the compartmentalization of myrosinase were conducted in Arapidopsis thaliana 
indicating that while GL-containing cells, known as S-cells, were found between the phloem 
and the endoderm of the plant, myrosinase itself was found to be in close proximity with the 
phloem parenchyma of myrosin cells (Andréasson et al., 2001; del Carmen Martinez-
Ballesta & Carvajal, 2015; Koroleva et al., 2000). This physical isolation of GLs allows the 
degradation of GLs, by myrosinase, to take place only when the plant is stressed.  
Once the myrosinase-glucosinolate system (also known as mustard oil bomb) is activated, 
an aglycone unstable intermediate metabolite is formed, called thiohydroximate-O-
sulfonate. Next, a non-enzymatic reaction occurs followed by a simultaneous rearrangement 
of the core structure of GLs, resulting in the production of biologically and chemically 
distinct compounds including thiocyanates, isothiocyanates, nitriles and indoles (Fig. 1.6) 
(Barba et al., 2016; Bones & Rossiter, 2006; Grubb & Abel, 2006). A subsequent lossen 
rearrangement usually promotes ITCs formation (Agerbirk & Olsen, 2012; Bones & 
Rossiter, 2006; Mithen et al., 2000; Thornalley, 2004). The outcome of this process, is 
largely based on many factors like temperature, availability of ferrous ions and 
epithiospecifier proteins (ESP), pH, presence of proteins that interact with myrosinase as 
well as the type of GLs. For example, at pH 7.0, ITCs are preferentially formed whereas at 
more acidic conditions (or when ESPs are present) the synthesis of nitriles is promoted 





Figure 1.6: Hydrolysis of GLs by myrosinase. Upon tissue disruption, myrosinase is 
released and interacts with its GL substrates by catalyzing their hydrolysis. As a result, the 
formation of an aglycone unstable intermediate product is formed and subsequently a non-
enzymatic reaction occurs followed by a simultaneous rearrangement of their core structure, 
leading to the production of diverse metabolites including ITCs, thiocyanates, nitriles and 
indoles. Adapted from (Mitsiogianni et al., 2018) 
1.2.3 ITC Metabolism 
As already mentioned above, GLs are converted into a range of compounds, including ITCs, 
which are readily absorbed in the gastro-intestinal (GI) tract. ITCs are electrophiles and thus 
are eliminated from the body via the mercapturic acid pathway (Angelino & Jeffery, 2014; 
Grzywa et al., 2016). Briefly, ITCs are produced in the gut and then are diffused into the 
blood circulation through the GI. Once inside the cells, ITCs bind reversibly, but with high 
affinity, to glutathione (GSH) and a GSH-ITC conjugation product is formed catalysed by 
glutathione S transferases (GSTs). The conjugates are further metabolized in the liver (where 
the GSH moiety is enzymatically modified) forming cysteinyl-glycine (Cys-Gly) and 
cysteine (Cys) conjugates by the action of gamma glutamyltranspeptidase (GTP) and 
cysteinylglycinase (CGase) enzymes, respectively. Then, the metabolites are transferred in 
the kidney where the final N-acetylcysteine-(NAC-) conjugates (mercapturic acids) are 
produced by the activity of N-acetyltransferase (NAT). Finally, the mercapturic acids are 




al., 2018; Zhang, 2012b) (Fig. 1.7). The overall metabolic process largely depends on GST 
isoenzyme polymorphisms, often present, since binding of ITC-GSH by GSTs is the first 
step in this process (Nakamura et al., 2018). ITCs circulate through the body, as different 
conjugates, thereby exerting their health-promoting benefits (Angelino & Jeffery, 2014; 
Grzywa et al., 2016; Palliyaguru et al., 2018). 
 
Figure 1.7: ITCs metabolism through the mercapturic acid pathway. After consumption 
of cruciferous vegetables, ITCs are produced in the gut and are further eliminated from the 
body through the mercapturic acid pathway. Briefly, once produced, they are absorbed in 
the gastro-intestinal (GI) track and they are diffused in the cells, where they bind with high 
affinity and reversibly with glutathione (GSH), under the activity of glutathione S transferase 
(GST), forming GSH-ITC conjugates. These conjugates are then transferred, through the 
blood circulation in the liver where the GSH moiety is further modified, yielding cysteinyl-
glycine (Cys-Gly) and cysteine (Cys) conjugates, modifications catalyzed by gamma 
glutamyltranspeptidase (GTP) and cysteinylglycinase (CGase) enzymes, respectively. 
Cysteine-conjugates are then transferred in the kidneys, where the mercapturic acids [N-
acetylcysteine-(NAC-) conjugates] are formed by the action of N-acetyltransferase (NAT) 




The amount of ITCs produced and absorbed in the body is dependent on various factors such 
as from the total GL content in the plant all the way to how Brassica vegetables were 
processed (Palliyaguru et al., 2018). In general, food processing is crucial and could result 
in lower levels of ITCs mainly due to i) endogenous myrosinase inactivation, ii) release of 
GLs in the heating media and the iii) unstable nature of GLs that are degraded after exposure 
to higher cooking temperatures. Thermal-induced degradation of GLs, affects the formation 
of the final product depending on the temperature applied as well as the pH and the presence 
of ferrous ions. For example, at 100oC upwards the formation of the more thermo-stable 
nitriles is favoured (Hanschen et al., 2012). Many other factors also determine the amount 
of GLs (and therefore their concentration and intake) including cultivation, storage and post-
harvest processing (Ciska et al., 2000; Deng et al., 2015; Song & Thornalley, 2007). 
However, it is noteworthy that lower levels of ITCs can be formed through hydrolysis of 
GLs, by bacterial myrosinases, in the colon. When the vegetables are consumed, after 
cooking, the endogenous myrosinase is destroyed and ITCs formation is basically promoted 
by the microbiome in the intestinal track, a rather “poor” process that leads to a much lower  





Figure 1.8: Schematic presentation of the fate of GLs and their metabolites in the 
human gut Adapted from (Barba et al., 2016). 
The intake of cruciferous vegetable is generally estimated by measuring the levels of 
mercapturic acids (i.e. selective biomarkers of total ITCs consumption) that are excreted in 
urine (Barba et al., 2016; Nakamura et al., 2018). Finally, experimentally, the gold-standard 
methodology for ITC quantification is the cyclocondensation assay which calculates the total 
yield of ITCs in plant extracts, plasma and urine, without differentiating into the diverse 
types of ITCs present. The assay is based in the interaction of 1,2-benzenedithiole with the 
carbon moiety in the -N=C=S structure, shared by all ITCs, leading to the formation of 1,3-
benzodithiole-2-thione, which can be spectroscopically measured, and is proportional to 
ITCs quantity (Egner et al., 2008; Nakamura et al., 2018; Zhang, 2012a). Individual ITCs 
are measured using more sensitive analytical methodologies such as high-performance liquid 
chromatography (HPLC), gas chromatography (GC) and mass spectrometry (MS) 




1.3 Biological Activities of ITCs: Anti-microbial, Anti-oxidant and Anti-inflammatory 
Functions 
ITCs exert a plurality of biological functions, ranging from defence against pathogens to 
cancer prevention (Grubb & Abel, 2006). Among them, their anti-microbial, anti-oxidant, 
anti-inflammatory and anti-cancer properties are of particular importance and consequently 
have been extensively studied (Fig, 1.9).  
 
Figure 1.9: Biological activities exerted by ITCs. ITCs exert a wide range of biological 
properties, including anti-microbial, anti-inflammatory and anti-oxidant properties. ITCs 
reported to exert a protective effect against bacteria and fungi via multiple mechanisms 
including disruption of cell membrane, deregulation of key functional processes and 
induction of heat shock proteins and oxidative stress. They are also able to modulate the 
activity of various enzymes involved in anti-oxidant and metabolic processes through 
activation of the nuclear factor erythroid-derived 2-like 2 (Nrf2) pathway, which is crucial 
for the overall ITC antioxidant capacity. Moreover, the capacity of these nutraceuticals to 
abrogate inflammatory responses is another key aspect of their protective role. ITCs educe 
the activity of the nuclear factor-kappa B (NF-κB) pathway and consequently down-regulate 




oxide synthase (iNOS)] and anti-apoptotic proteins (such as Bcl-Xl, Bcl-2, Bcl-3), which are 
mediated by this pathway. 
1.3.1 Anti-microbial activity 
Many studies have reported an anti-microbial potency of ITCs against bacteria (Borges et 
al., 2014; Freitas et al., 2013; Kaiser et al., 2017; Ko et al., 2016; Kurepina et al., 2013; Lin 
et al., 2000) as well as fungi (Drobnica et al., 1967; Kurepina et al., 2013; Manyes et al., 
2015). These studies strongly suggest the potential use of ITCs as natural antibiotic agents, 
natural additives in foods and/or natural pesticides. Many mechanisms have been reported 
to contribute to their anti-microbial properties including i) disruption of cell membrane, ii) 
deregulation of regulatory, respiratory and enzymatic processes and iii) induction of heat 
shock proteins and oxidative stress (Dufour et al., 2015). The potency of ITCs against 
pathogens seem to depend on their chemical structure (e.g. presence of sulfinyl group, length 
of the side chain, lipophilic and electrophilic activities, etc.) as well as the bacterial strains 
since some of them appear to be more resistant than others (Dias et al., 2014; Wilson et al., 
2013). 
1.3.2 Anti-oxidant activity 
This is another important function of ITCs which has been extensively reviewed. They have 
been shown to directly interact and modulate the activity of various anti-oxidant enzymes in 
addition to acting indirectly through activation of the nuclear factor erythroid-derived 2-like 
2 (Nrf2) pathway. More specifically, exposure to ITCs induces the activation of Nrf2 which 
is then conjugated with the Kelch-like ECH-associated protein 1 (Keap1). This is 
orchestrated in a series of events where ITCs first interact with the sulfhydryl residues of 
Keap 1 and then Nrf2 is released into the cytoplasm followed by transfer to the nucleus. In 
there, Nrf2 induces the transcription of phase II detoxifying enzymes [e.g. glutathione S-
transferases (GSTs), NAD(P)H quinine oxidoreductase 1 (NQO-1), heme oxygenase 1 (HO-
1), glutamate cysteine ligase (GCL) and gamma glutamylcysteine synthetase (γGCS)] by 
binding to the antioxidant response element (ARE) on their promoters (Fuentes et al., 2015; 
de Figueiredo et al., 2015). ITCs can also increase Nrf2 activity indirectly through the 
induction of other signalling cascades that mediate Nrf2 phosphorylation  thereby inducing 
ARE transcriptional activity (Cheung & Kong, 2010). Several pathways have been shown 
to mediate ITC-induced activation of Nrf2 including extracellular-signal-regulated kinase 
(ERK),  c-Jun N-terminal kinase (JNK) and Protein kinase B (PKB, also known as Akt) in 




et al., 2006). The significant role of the Nrf2 factor in contributing to the overall ITC 
antioxidant capacity is demonstrated in the McWalter study where treatment with ITCs 
enhanced the activation of detoxifying enzymes in wild type mice and murine cell lines but 
not in Nrf2 deficient ones (McWalter et al., 2004). In line to these observations, elevated 
levels of antioxidants and metabolizing enzymes was reported to be mediated by Nrf2 
activity in HePG2 cells as well after exposure to Wasabi-derived SFN and SFN analogues 
(Trio et al., 2017).  
On another note, it should be mentioned that although transient and regulated activation of 
Nrf2 can exert a protective effect, in healthy individuals, constitutive activation of the 
pathway could be detrimental in fully-developed cancers (Catanzaro et al., 2017). Ectopic 
expression of the Nrf2 pathway could be potentially of an advantage to cancer cells. 
Persistent Nrf2 activity can create an environment that promotes cell growth and survival 
and also can impair the metabolic processes of some anti-cancer drugs thus leading to 
chemo-resistance (Furfaro et al., 2016; Jaramillo & Zhang, 2013; No et al., 2014).  
1.3.3 Anti-inflammatory activity 
As far as the anti-inflammatory properties of ITCs are concerned, they were thought to be 
mainly mediated by the down-regulation of the nuclear factor-kappa B (NF-κB) pathway 
which, in turn, regulates the expression of pro-inflammatory factors [e.g. cyclooxygenase 2 
(COX-2) and inducible nitric oxide synthase (iNOS)] as well as anti-apoptotic proteins (e.g. 
Bcl-Xl, Bcl-2, Bcl-3) (Del Prete et al., 2011; Shan et al., 2012; Surh & Na, 2008). Briefly, 
NF-κB activation is triggered by various pro-inflammatory stimuli such as cytokines, growth 
factors and DNA-damaging agents resulting in the inactivation of I-κB through regulation 
of kinases and phosphatases upstream of the pathway (Lin-Feng & Greene, 2004). Once NF-
κB is free, it translocates to the nucleus and binds in the promoter of target genes thereby 
inducing their transcription (Ghosh & Karin, 2002; Surh & Na, 2008). It has been shown 
that ITCs can inhibit the phosphorylation of IκBα and IκB kinases which remain in complex 
with NF-κB thus deterring its transfer to the nucleus. The inhibitory effect of ITCs in NF-κB 
expression is also associated with the induction of various signalling cascades. For instance, 
exposure of endothelial cells to SFN i) down-regulates the toll-like receptor (TLR)-4 
signalling pathway by affecting downstream effectors such as p38 mitogen-activated protein 
kinase (MAPK) and JNK and ii) suppresses NF-κB-mediated expression of adhesion 
molecules to prevent inflammatory insult to endothelial cells (Shan et al., 2012). It has been 




pathway which has been shown to interact with the NF-κB signalling pathway (although the 
exact mechanism is not yet fully understood) (Cuadrado et al., 2014; Li et al., 2016; Li et 
al., 2008). Recently, studies proposed the involvement of the epigenome (Qu et al., 2015; 
Yang et al., 2016) and the macrophage migration inhibitory factor (MIF) pathway (Crichlow 
et al., 2012; Spencer et al., 2015), as novel targets of ITC-induced anti-inflammatory 
responses. MIF is a pro-inflammatory cytokine implicated in pro-tumorigenic, pro-
angiogenic, and anti-apoptotic processes and thus it contributes in the development of 
various inflammatory diseases (e.g. rheumatoid arthritis and atherosclerosis) as well as in 
diverse stages of tumorigenesis, including proliferation and angiogenesis (Crichlow et al., 
2012; Spencer et al., 2015; Tyndall et al., 2012). Finally, another novel anti-inflammatory 
role of ITC has been proposed recently. Specifically, SFN-treatment have been shown to 
inhibit the formation of multiple inflammasomes in an Nrf2-independent manner, suggesting 
that SFN can serve as an effective anti-inflammatory factor against inflammasome-
originated diseases (Greaney et al., 2016).  
1.4 ITCs in Cancer: Chemo-preventive Properties  
ITCs ability to act as chemo-preventive agents has been well-documented in a number of 
studies. More specifically, in various epidemiological studies have reported that a diet rich 
in cruciferous vegetables can gradually decrease the risk of tumour development 
(Ambrosone et al., 2004; Cohen et al., 2000; Jain et al., 1999; Romagnolo & Selmin, 2012; 
Tang et al., 2010; J. Wang et al., 2014; Yang et al., 2010). However, contradicting data have 
emerged over the last years, with studies supporting a weak correlation between cruciferous 
vegetable consumption and cancer risk (Fowke et al., 2011; Wu et al., 2014). To this end, 
low consumption of cruciferous vegetables was not significantly associated with lung cancer 
susceptibility among smoking women (209 incident lung cancer cases and 787 individually 
matched non-smoking controls), although a meta-analysis reported a correlation between 
urinary levels of ITCs, GSTM1 genotype, and risk for lung cancer (Fowke et al., 2011). 
Although, these observations are ambiguous, most of the scientific outcomes strongly 
support an inverse relationship between intake of ITCs (through dietary consumption of 
cruciferous vegetables) and the overall susceptibility to cancer development. 
Such a protective effect is considered to depend on an individual’s genetic variation in GST 
genes coding for enzymes that catalyse the conjugation of ITCs, with GSH, a metabolic 
process crucial for the elimination of ITCs and the deactivation of xenobiotics (Brennan et 




result in longer exposure of tissues to ITCs and in a significantly lower risk for disease 
development. For instance, individuals that acquired two null variants of the GSTM1 and 
GSTT1 alleles found to be more resistant against cancer development due to longer ITC 
exposure (Higdon et al., 2007; Seow et al., 2005; Zhao et al., 2001). In contrast to these 
observations, there are studies that currently support the correlation between GSTs-null 
polymorphism with an increased cancer risk (Cai et al., 2014; Yang et al., 2015; Zhao et al., 
2015) while others suggest that there is no correlation between cancer susceptibility and 
GSTs polymorphisms (Tan et al., 2013; Vogtmann et al., 2014). It is obvious that the 
influence of GST genotype on cancer susceptibility is still not well defined, due to many 
contradictory and inconsistent data in this field of research. 
1.5 ITCs in Cancer Therapy: Anti-cancer Activities  
A number of in vitro and in vivo studies have documented the ability of ITCs to act as anti-
tumorigenic agents in various cancer types, including breast (Jensen et al., 2019; Pledgie-
Tracy et al., 2007; Xiao et al., 2008; Xiao et al., 2006; Xie et al., 2017), prostate (Cho et al., 
2016; Khurana et al., 2017; Zhang et al., 2016), brain glioblastoma (Chou et al., 2015), colon 
(Liu et al., 2017; Pappa et al., 2006) and skin (Abel et al., 2013; Kerr et al., 2018; Mantso et 
al., 2016). The potential of these compounds to act as cytotoxic agents is attributed to a wide 
range of mechanisms including i) modulations of phase I and phase II detoxifying enzymes, 
ii) suppression of cell growth via induction of cell cycle arrest and cell death, iii) repression 
of metastatic and angiogenetic processes and iv) modifications of the epigenetic 
mechanisms. The overall proposed mechanism of ITC-induced cytotoxicity is summarized 





Figure 1.10: Cellular pathways targeted by ITCs. The effect of ITCs in cell proliferation 
and survival is mediated via modulation of multiple pathways, including various signaling 
transduction cascades (e.g. PI3K/AKT, MAPKKs, etc.), increased oxidative stress (ROS) 
and enhanced mitochondrial dysfunction, resulting in modulation of phase I and II enzymatic 
activity, induction of growth arrest and apoptosis, inhibition of metastatic processes and 
impaired activity of the epigenetic machinery. Adapted from (Mitsiogianni et al., 2019) 
1.5.1 Inhibition of Phase I and Induction of Phase II Enzymes 
Phase I and II enzymes are essential regulators of the xenobiotic-metabolizing system by 
interacting with numerous chemicals such as toxins, xenobiotics and carcinogens and thus 
mediate their metabolism and excretion from the body. Phase I enzymes [which belong to 
the cytochrome P450 (CYP450) family] are enzymes that either promote the deactivation or 
in some cases the activation of pro-carcinogens, to their active form. On the other hand, 
phase II enzymes (e.g. glutathione S-transferases, GSTs, UDP-glucuronosyl transferase, 
NADPH quinine reductases and glutamate cysteine ligase) exert a predominantly protective 
role by interacting with carcinogens thereby influencing their solubility and elimination from 




modulate carcinogen metabolism. In general, these compounds decrease phase I enzymes, 
to prevent the activation of carcinogens, while upregulate phase II enzymes in order to 
increase the detoxification process and inhibit ROS-induced damage (Keum et al., 2004; 
Talalay & Fahey, 2001).  
The effect of ITCs (mainly SFN, AITC, BITC, PEITC and IBN) in the activity levels of the 
detoxifying enzymes has been reported in a range of cancers, including acute myeloid 
leukaemia (Gao et al., 2010), bladder (Munday, 2002), breast (Wang et al., 2005), liver 
(Basten et al., 2002) and skin (Dinkova-Kostova et al., 2006). The Nrf2 pathway, as already 
mentioned above, is a key mediator of the ITC-triggered detoxification process including 
phase II detoxifying enzymes (Boddupalli et al., 2012; Hu et al., 2006). For example, SFN 
has been shown to deactivate CYP2B, CYP3A2 and CYP1A2 as well as triggering the 
expression of quinone and glutathione reductase phase II enzymes in rats (Yoxall et al., 
2005). PEITC also found to decrease nicotinamide N-methyltransferase (NNMT) levels in 
rats by increasing the UDP-glucuronosyltransferase UGT1A6 expression and modulating 
CYP2B15 activity (Telang & Morris, 2010). In another study, both BITC and PEITC 
prevented the metabolic process of nicotine and tobacco-specific nitrosamine 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) through a NADPH-dependent 
inhibition of CYP2A6 and CYP2A13 activation, respectively (von Weymarn et al., 2006). In 
addition, SFN  enhanced the activation of several GSTs (A3, A4, M1, P1 and T1) involved 
in the inactivation of aflatoxin B1-8,9-epoxide (AFBO) in murine AML 12 cells (Gao et al., 
2010). In line with these observations, treatment of  lung adenocarcinoma (A549) cells and 
primary normal human bronchial epithelial (NHBE) cells with both broccoli sprout extracts 
as well as SFN, BITC and PEITC, upregulated GSTP1 (Glutathione S-transferase P) and 
NQO1 (NAD(P)H dehydrogenase [quinone] 1) enzymes (Tan et al., 2010).  
1.5.2 Cell Cycle Arrest and Apoptotic Induction 
It is now well-established from both in vivo (Bhattacharya et al., 2010; Boreddy et al., 2011; 
Cho et al., 2016; Srivastava et al., 2003) and in vitro (Chen et al., 2012; Cheng et al., 2016; 
Parnaud et al., 2004; Stan et al., 2014; Tsai et al., 2012; Xiao et al., 2006) studies that ITC-
induced cytotoxicity is mediated by cell cycle growth arrest and apoptotic induction.  
Generally, ITCs have been reported to perturb the cell cycle by modulating the expression 
levels of various molecules that regulate its progression (Chen et al., 2012; Cheng et al., 
2016; Fimognari et al., 2004; Herman-Antosiewicz et al., 2007; Jun-Hee et al., 2009; Matsui 




namely G1, S, G2 and M. There is also a resting phase (G0) where cells progress from rest 
to proliferation and back to G0 phase. Cellular progression from one phase to the next is 
very organized, in a series of steps, and highly controlled by the so-called cell cycle 
regulators [e.g. cyclins, cyclin-dependent kinases (CDKs) and CDK inhibitors (such as p21 
and p27)] most of which have been shown to be deregulated in cancer  (Diaz-Moralli et al., 
2013; Otto & Sicinski, 2017). In this respect, ITCs can inhibit cell cycle progression by 
modulating the activity of cell cycle regulators. More specifically, treatment of human colon 
carcinoma (HT29) cells with SFN increased the number of cells arrested in the G2/M phase 
by activating  p21 and cdc2 kinases (Parnaud et al., 2004). Furthermore, human cervical 
cancer cells were  also growth arrested at the G2/M phase, under SFN exposure, an effect 
associated with inhibition of Cyclin B1 and disruption of cyclin B1/CDC2 conjugate (Cheng 
et al., 2016). In addition, SFN induced cell cycle arrest (at G0/G1 phase) and apoptosis in 
T24 bladder cancer cells through enhanced expression of the CDK inhibitor p27 (Shan et al., 
2006).  In another study, PEITC modulated the activities of p53, p21, p17, CDK2 and cyclin 
E leading to growth inhibition of the human oral carcinoma (HSC-3) cells at the G0/G1 
phase (Chen et al., 2012). Moreover, AITC and BITC have also been shown to increase the 
accumulation of cells at the G2/M phase by modulating the expression of various regulatory 
proteins (e.g. Cyclin B1, Cdk1, Cdc25B and p21), important in cell cycle progression, using 
human prostate (Xiao et al., 2003), pancreatic (Zhang et al., 2006) and leukemic  cancer cell 
lines (Miyoshi et al., 2004). Finally, deregulation of cell cycle progression has been proposed 
to gradually result in the induction of apoptosis (Parnaud et al., 2004).  
The role of ITCs in apoptotic induction has been extensively studied and reported (Mi et al., 
2011; Rudolf et al., 2009; Wu et al., 2009). Apoptosis is a genetically programmed cell death 
and the whole process is complex and regulated by various proteins including, but not limited 
to, several caspases, proteins that belong to the B cell lymphoma 2-family (Bcl2) and the 
tumour-related p53 gene. Deregulation of apoptosis results in cancer survival and thus, 
molecules that can modulate specific targets in critical cellular pathways are considered as 
promising therapeutic agents (Fernald & Kurokawa, 2013; Zörnig et al., 2001). In this 
context, modifications in the activity of pro-apoptotic (e.g. Bax, Bid and Bak) and anti-
apoptotic (e.g. Bcl2 and Bcl-XL) agents as well as several caspases have been implicated in 
ITC-mediated cell death. In a characteristic study, exposure of human pancreatic cancer cells 
to PEITC upregulated Bak expression, while downregulated expression of Bcl2 and Bcl-XL, 
thus promoting apoptosis (Stan et al., 2014). In addition, treatment of Jurkat T-leukemia 




et al., 2002). Moreover, AITC-induced apoptosis of human renal carcinoma cells was also 
accompanied with increased levels of Bax and reduced levels of Bcl2 (Jiang et al., 2016). 
Finally, in another study, treatment of human cervical cancer (HeLa) cells with PEITC and 
other structurally related ITCs triggered caspase-3 dependent apoptosis (Yu et al., 1998). 
On another note, ITC-induced anti-proliferative effect is attributed to various regulatory 
cascades, including several signalling transduction pathways (e.g. PI3K/AKT, MAPKKs, c-
jun and mTOR) (Cheung et al., 2008; Mondal et al., 2016; Tsai et al., 2012; Xu et al., 2006), 
increased reactive oxygen species (ROS) production (de Oliveira et al., 2014; Lee & Lee, 
2011; Wu et al., 2011), inhibition of heat-shock proteins (Sarkar et al., 2012) and 
mitochondrial dysfunction (Chen et al., 2012; Rudolf et al., 2009; Sehrawat et al., 2016). 
Characteristic examples are those of AITC and BITC both of which were found to induce an 
oxidative response as well as induction of the ERK signalling pathway thus activating the 
intrinsic apoptotic pathway, accumulation at the G2/M phase, induction of mitochondrial 
depolarization and deregulation of mitochondrial-associated proteins in human breast 
adenocarcinoma cells (Tsai et al., 2012; Xiao et al., 2006). In favour to these observations, 
PEITC inhibited oral squamous carcinoma growth by causing cell cycle inhibition and 
apoptosis through stimulation of the mitochondria-dependent pathway, ROS production and 
calcium (Ca2+) accumulation (Chen et al., 2012). Finally, studies have also shown the 
implication of the epigenetic machinery in ITC-induced cytotoxicity (Ma et al., 2006; Myzak 
et al., 2005; Myzak et al., 2004; Rajendran et al., 2011).  
1.5.3 Autophagy 
This is an important process for cell homeostasis, by which cells remove defective and 
redundant cellular components. In general, at “housekeeping levels”, the induction of 
autophagy promotes cell survival and maintenance. However, under conditions such as 
reduced apoptosis and/or increased levels of autophagy, the autophagic machinery can also 
induce cell death either through self-cannibalization or by promoting apoptosis (Levine, 
2007; Parzych & Klionsky, 2014). In carcinogenesis, it acts either as a tumour suppressor 
mechanism, by scavenging mutated proteins and faulty organelles, or  as a mechanism that 
favours cancer cell survival and proliferation (Amaravadi et al., 2016; White, 2012). 
Alternatively, ectopic autophagic activation in cancer cells could act as a pro-death signal 
and/or activate T cell-dependent immune responses to inhibit cancer cell growth. It is 
obvious that autophagy implication in malignancy is complicated and ambiguous (Pietrocola 




rather new idea. Evidence currently supports this notion, however this autophagic induction 
seems to be controversial by having either a protective role (Chen et al., 2018; Hee Kim et 
al., 2016; Herman-Antosiewicz et al., 2006; Horwacik et al., 2015; Lee & Lee, 2017; Lin et 
al., 2012; Lin et al., 2017; Pawlik et al., 2017; Wang et al., 2018; Zhang et al., 2017) or 
promoting cell death (Bommareddy et al., 2009; Liu et al., 2018; Milczarek et al., 2018; Xiao 
et al., 2012; Yang et al., 2018), depending on tumour type, stage and genetic context. For 
instance, exposure of human lung cancer cells to BITC resulted in endoplasmatic reticulum 
(ER) stress-mediated induction of autophagy which was shown to have a protective effect 
against BITC-induced inhibition of cell growth. The suppressive effect of BITC in cell 
growth was increased when cells were pre-treated with an inhibitor of the autophagic 
process, strongly supporting the cyto-protective role of the autophagic activation (Zhang et 
al., 2017). In contrast, in human prostate cancer cells, PEITC promoted cell death through 
Atg5-induced activation of autophagy and apoptosis (Bommareddy et al., 2009).  
1.5.4 Anti-metastatic and Anti-angiogenic Properties 
ITCs also protect against cancer progression by supressing angiogenic and metastatic 
processes. New capillary formation is critical for cancer progression by promoting tumour 
growth, invasion and metastasis, supporting the high demands of tumours for oxygen and 
nutrients (Moserle & Casanovas, 2013). Metastasis, it is a complex process mainly regulated 
by genes essential in modifying the interplay between cells and extracellular matrix (Rudek 
et al., 2002). In this respect, ITCs were shown to modulate various agents implicated in 
metastasis and angiogenesis, including metalloproteinases (MMPs), plasminogen activators 
(PAs) and vascular endothelial growth factor (VEGF) (Boreddy, Sahu, et al., 2011; Gupta et 
al., 2013; Jackson et al., 2007; Kim et al., 2015; Thejass & Kuttan, 2007a; Wang et al., 2015; 
Zhu et al., 2014). To these ends, AITC and PITC diminished various pro-inflammatory 
cytokines [e.g. interleukin (IL)-1β, IL-6, tumour necrosis factor (TNF)-alpha] and VEGF 
while upregulated the tissue inhibitor of metalloproteinases (TIMP) in human umbilical vein 
endothelial (HUVECs) cells thus preventing tube formation, invasion and migration 
(Thejass & Kuttan, 2007a). Similarly, PEITC inhibited VEGF and prevented new 
vascularization in vitro (e.g. HUVECs and PC3 prostate cancer cells) and ex vivo (Xiao & 
Singh, 2007). BITC also effectively suppressed the formation of new capillaries and invasion 
of human glioma cells through inhibition of MMPs-2 and -9 and VE-cadherin while growth 
arrested cells at the G2/M phase via modulation of molecules that are involved in cell cycle 




The anti-angiogenic and anti-metastatic capacity of ITCs have been also associated with 
modulation in the activity of major signalling pathways (e.g. PI3K/Akt, p38/MAPK, NF-κB, 
and mTOR) (Boreddy, Sahu, et al., 2011; Gupta et al., 2013; Lai et al., 2010; Lai et al., 2014; 
Milkiewicz et al., 2011; Wang et al., 2015; Xu et al., 2005). For example, exposure of human 
colon cancer cells to AITC (Lai et al., 2014) and BITC (Lai et al., 2010) inhibited cell growth 
and altered cell metastatic potential via reduction of matrix metalloproteinases (mainly 
MMP-2 and MMP-9), mediated by PKC and MAPK signalling pathways. In addition, post-
translational modifications were shown to be involved in the anti-angiogenic effect of ITCs. 
Specifically, BITC, SFN and PEITC were shown to modulate the expression pattern of 
tumour suppressor (miR144, miR-122, miR-194) and oncogenic mi-RNAs (miR-181b, miR-
9, miR-616-5p) thus inhibiting the formation of new capillaries as well as the invasion 
potential of human glioma (Zhu et al., 2014), non-small cell lung cancer (NSCLC) (Wang 
et al., 2017) and prostate cancer (Zhang et al., 2016) cells. 
1.5.5 Epigenetic Modulation 
ITCs can also exert their anti-tumorigenic activities by interfering with various components 
of the epigenetic network, including HDACs, DNMTs and mi-RNAs (Navarro et al., 2011). 
In general, HDACs are associated with gene transcriptional silencing but ITCs have been 
identified as potent inhibitors of this family of enzymes. HDAC inhibitors are considered to 
be promising therapeutic agents against malignant transformation by inhibiting cancer cell 
growth, progression and invasion (Eckschlager et al., 2017; Ho et al., 2009). In particular 
ITCs, have been reported to inhibit HDAC activity and thus induce Nrf2-mediated activation 
of phase II detoxifying enzymes, cell cycle repression and apoptosis as well as modulate the 
angiogenic and metastatic potential (Batra et al., 2010; Rajendran et al., 2013; Su et al., 2014; 
Wang et al., 2008; Yuanfeng et al., 2015). More specifically, SFN found to act as efficient 
HDAC inhibitor and diminished the expression of specific HDACs, triggering growth arrest 
and apoptotic death in multiple cancer cell lines including those of murine melanoma, human 
glioma (Yuanfeng et al., 2015), prostate (Myzak et al., 2005), colon (Rajendran et al., 2013), 
lung (Jiang et al., 2016) and bladder (Abbaoui et al., 2017) origin. In particular, PEITC 
inhibited cell cycle progression of prostate cancer cells by increasing acetylation of H3 
which was associated with increased expression of p21 (Wang et al., 2008). In addition, 
BITC also reduced HDAC1/HDAC3 activity thus resulting in deactivation of NF-kB and 
cyclin D1 as well as growth inhibition (Batra et al., 2010). Finally, SFN showed to decrease  




blocking HDAC activation in vivo. Diminished activity of HDACs was also reported in the 
peripheral blood mononuclear cells of healthy individuals after broccoli sprouts 
consumption (at a single dose of 68g, approximately 105mg of SFN and equivalent to about 
570g of mature broccoli) (Myzak et al., 2007). 
Similarly, ITCs have been documented to modulate DNMT expression pattern thus leading 
to aberrant expression of genes important in malignant transformation (Kaufman-Szymczyk 
et al., 2015). In particular, ITCs have been demonstrated to exert an inhibitory effect on 
DNMTs (Hsu et al., 2011; Wong et al., 2014) usually accompanied with repression of 
histone deacetylation (Jiang et al., 2010; Kaufman-Szymczyk et al., 2015; Meeran et al., 
2012; Meeran et al., 2010; Su et al., 2014; Zhang et al., 2013). To this end, it has been 
demonstrated that SFN-mediated impairment of DNMT1 activation was associated with 
HDAC inhibition leading to reduced histone deacetylation and re-activation of p21 
(Kaufman-Szymczyk et al., 2015). In line to these observations, human breast cancer cells 
exposed to SFN, induced apoptosis through reduction of DNMTs 1 and 3a expression and 
HDAC activity. Decreased levels of DNA methylation and histone deacetylation in these 
SFN-treated cells suppressed the induction of the human telomerase reverse transcriptase 
(hTERT), a gene commonly found up-regulated in various cancers (Meeran et al., 2010). 
Similar observations made in estrogen receptor (ER)-negative breast cancer cells treated 
with SFN, suggesting it’s potential use as a therapeutic factor for the better management of 
ER-negative breast cancer patients (Meeran et al., 2012). Moreover, PEITC altered the 
activity of DNMTs and HDACs, in prostate cancer cells, influencing the reactivation of the 
tumour suppressor RASSF1A (Ras-association domain family 1 isoform A) and apoptotic 
induction  (Boyanapalli et al., 2016).  
Another significant aspect of ITCs interaction with the epigenome is their modulatory effect 
on specific miRNAs involved in cancer development and invasiveness. This is evident in a 
wide range of malignancies, including prostate  (Xiao et al., 2012; Yu et al., 2013; Zhang et 
al., 2016), colon (Slaby et al., 2013), bladder (Shan et al., 2013) and glioblastoma (Lan et 
al., 2015). For instance, SFN and IBN upregulated the levels of tumour suppressors mir-23b, 
mir-27b while downregulated mir-155 in epithelial colon cell lines suggesting that miRNAs 
could be involved in the protective effect of ITCs (Slaby et al., 2013). SFN also found to 
inhibit tumour progression and migration of non-small cell lung cancer cells through down-
regulation of mir-616-5p (Wang et al., 2017). In another study, prostate cancer cells under 




blocking cellular invasion (Zhang et al., 2016). Finally, SFN also found to increase the 
expression of mir-200c, in human bladder cancer cells, which is then partly implicated in the 
inhibition of epithelial-to-mesenchymal transition (EMT) and of COX-2 and MMPs 2, 9 gene 
expression all of which are important for cellular migration (Shan et al., 2013). 
1.6 Skin Cancer and ITCs: The Case of Melanoma 
Skin cancer is considered as one of the most common types of cancer worldwide (Diepgen 
& Mahler, 2002; Nguyen & Ho, 2002). Its incidence is increasing rapidly over the years and 
its clinical picture generally appears as precancerous that over time can become malignant 
(Gordon, 2013).  
The disease  refers to three main types  namely i) basal-cell skin cancer (BCC), ii) squamous-
cell skin cancer (SCC) and iii) melanoma (Erb et al., 2008). Among them, BCC and SCC 
are generally known as non-melanoma skin cancers (NMSCs) and are the most common 
ones, with BCC accounting for about 80% of skin cancer incidence (Baxter et al., 2012; 
Madan et al., 2010). The classification in one of these types depends on the cells that are 
primarily affected. In particular, BCC is originated from keratinocytes of the basal layer or 
the hair follicles, SCC from keratinocytes at the top layer of epidermis, while melanoma 
originates from melanocytes, the cells known to produce melanin (Erb et al., 2008). In 
general, NMSCs (especially those diagnosed at an early stage) have a better prognosis, in 
contrast to malignant melanoma, which is a more aggressive and lethal type of cancer 
(Gordon, 2013). 
1.6.1 Skin Cancer Aetiology and Pathophysiology 
Skin cancer occurrence is multifactorial, including innate predisposition and inheritable 
traits (e.g. fair skin, sun sensitivity, red hair, freckles, presence of multiple naevi), 
environmental agents (e.g. exposure to UV radiation and/or chemical carcinogens such as 
tobacco) and geographical with white populations being at higher risk (Chang et al., 2010; 
Diepgen & Mahler, 2002; Martin-Gorgojo et al., 2017; Moan et al., 2015; Narayanan et al., 
2010; Ting et al., 2007). In addition, various medical conditions (e.g. immunosuppression, 
chronic ulcers, human papillomavirus infection and genetic syndromes such as xeroderma 
pigmentosum, albinism, epidermodysplasia) are all considered risk factors (Devine et al., 
2017; Diepgen & Mahler, 2002).  
Among all these risk factors, UVR (Ultraviolet radiation) is considered to be the main cause 
of skin cancer occurrence (Pfeifer & Besaratinia, 2012). In general, UV light photons, that 




in the skin cells and consequently the accumulation of mutations in genes important for skin 
homeostasis. In particular, UV radiation directly affects DNA by influencing cytosines to 
thymines or CC to TT substitutions. This mutational pattern is also known as “UV signature 
mutations” and it is frequently observed in skin cancer patients (Goto et al., 2015; Kim et 
al., 2013; Wikonkal & Brash, 1999). In addition, the UVA spectrum has also an indirect 
effect on the DNA sequence by causing photo-oxidative damage in bases, especially 
guanines leading to the formation of 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG) 
adducts (Madan et al., 2010; Pfeifer & Besaratinia, 2012; Rünger, 2008; Sage et al., 2012; 
Seebode et al., 2016). UV-associated lesions result in the deregulation of genes involved in 
pathways important for cell growth and survival, such as the tumour suppressor p53, the 
Hedgehog pathway related protein patched homolog 1 (PTCH1) gene and the cyclin-
dependent kinase inhibitor (CDKN2) (Brash, 2015; Freije et al., 2014; Luo et al., 2001). In 
addition, UVR is a potent modulator of skin immune responses (Schwarz et al., 2010; Welsh 
et al., 2011; Yu et al., 2014) and also strongly contributes to immunosuppression through 
induction of pro-inflammatory immunosuppressive cytokines (such as IL-10 and TNF-a) 
(Kanavy & Gerstenblith, 2011; Norval & Halliday, 2011). Subsequently, it causes further 
damage to the cells, genomic instability and suppression of repair pathways (Halliday, 2005; 
Meeran et al., 2008).  
A number of genes and pathways have been shown to be deregulated in skin cancer thus 
potentially serving as important etiological, prognostic and therapeutic markers (Bosserhoff, 
2006; Greinert, 2009; Hocker et al., 2008). For instance, aberrant activation of the sonic 
hedgehog signalling pathway has been associated with BCC occurrence (Athar et al., 2014) 
while SCC incidence is attributed mainly to the deregulation of  p53-mediated pathways 
(Emmert et al., 2014) as well as to mutations in RAS and pl6INK4a genes, although at a lower 
frequency (Emmert et al., 2014; Xie, 2008). Moreover, mutations in particular genes (e.g. 
BRAF, NRAS, PTEN) involved in cell cycle progression and apoptosis as well as 
deregulation of various signalling pathways (e.g. p38/JNK/ERK/MAPK, 
PI3Kinase/Akt/mTOR, β-catenin and WNT) account for the increased survival and 
proliferation of melanoma cells (Dahl & Guldberg, 2007; Hocker et al., 2008; Ko & Fisher, 
2011; Shtivelman et al., 2014). Among them, the RAS-ERK pathway is of particular 
importance, as specific mutations on the BRAF gene (i.e. theV600E one) are the most 
common lesions observed in melanoma patients (Shtivelman et al., 2014). Finally, epigenetic 
abnormalities also contribute to skin carcinogenesis, with most studies being focused on 




1.6.2 Skin Cancer Epigenetics  
Genome-wide hypo-methylation together with hyper-methylation of tumour suppressor 
genes have been associated with the onset and progression of skin cancer (Greenberg et al., 
2014; Kamalika Saha et al., 2013). A number of tumour suppressor genes (e.g.MLT-1 
(Mucosa-associated lymphoid tissue lymphoma translocation protein 1), Snail (Zinc finger 
protein SNAI1), MGMT (O-6-methylguanine-DNA methyltransferase)], adhesion 
molecules like (E-Cadherin) (Fraga et al., 2004; Murao et al., 2006; J. Wu et al., 2014) and 
cell cycle regulators (p16INK4a and p14ARF) (Brown et al., 2004; D'Arcangelo et al., 2017; J. 
Wu et al., 2014) have been found to be silenced due to extensive methylation on their 
promoters, thereby associated with early and advanced stages of both BCCs and SCCs. In 
addition, an increase in the activity of DNMTs has also been reported to accompany the 
increased methylation levels observed in NMSCs compared to normal skin (Nandakumar et 
al., 2011). In addition, in melanoma, promoter-hyper-methylation appears to be the 
mechanism of suppression for various critical genes including the WNT inhibitory factor 1 
(WIF1), tissue factor pathway inhibitor 2 (TFPI2), ras association domain family 1 isoform 
A (RASSF1A), suppressor of cytokine signaling 1 (SOCS1) (Tanemura et al., 2009), O6-
methylguanine DNA methyltransferase  (MGMT) (Kohonen-Corish et al., 2006), 
transcriptional activator estrogen receptor a (ER-a) (Mori et al., 2006) and CDKN2A 
(Straume et al., 2002). The latter, in particular, is associated with melanoma progression and 
poor prognosis of the disease as it is found to be hyper-methylated in 19% of melanoma 
patients (Straume et al., 2002). Excessive loss of methylation is also observed in skin 
carcinogenesis including melanoma (Schinke et al., 2010). Overexpression of the melanoma 
antigen, MAGE, is a typical example of  hypo-methylation-induced activation of genes  
which is associated with down-regulation of DNMT1 (Loriot et al., 2006; Tellez et al., 2009). 
On the other hand, genome-wide hypo-acetylation is generally observed in melanoma 
resulting in silencing of tumour-associated gene expression (Sarkar et al., 2015; van den 
Hurk et al., 2012). Abnormal activation of HAT and HDAC enzymes, during melanogenesis, 
contribute to the down-regulation of pro-apoptotic proteins (e.g. Bax, Bak, Bim, caspases 
8/9, TNFRSF10A and TNFRSF10B) as well as the up-regulation of anti-apoptotic proteins 
(e.g. Bcl-2 and Bcl-xl) thereby favouring malignant cell survival (Penta et al., 2018; Sigalotti 
et al., 2010). Similarly, repression of the p16 INK4a and RASSF1A tumour related genes in 
NMSC was mediated by reduced acetylation on H3 and H4 and the recruitment of chromatin 
remodelling proteins [e.g. methyl CpG binding protein 2 (MeCP2) and Methyl-CpG-binding 




model, depletion of Sirt-2 deacetylase disturbed cell cycle through increased acetylation of 
Lys 16 on histone H4 (H4K16Ac) and PR-Set7 (Histone-lysine N-methyltransferase pr-set7) 
thus promoting malignant transformation (Serrano et al., 2013). In addition to histone 
acetylation, the methylation status of these proteins have also been implicated in malignant 
transformation. Recent evidence showed that enhanced expression of the Ezh2 (Enhancer of 
zeste homolog 2) methyltransferase (Zingg et al., 2015) and decreased activity of the 
SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodelling complex (Becker et 
al., 2009) enhance the metastatic potential of the disease. 
mi-RNAs are also involved in skin tumorigenesis. Aberrant expression levels of Drosha and 
Dicer, the two main enzymes, involved in the mi-RNA maturation process  in patients with 
NMSC reflect their importance in skin cell malignant transformation (Sand et al., 2010). 
Various mi-RNAs important in cell proliferation and other cellular processes  including 
hedgehog, MAPK/ERK, PI3K-Akt, WNT and beta-catenin signalling cascades were found to 
be deregulated in skin tumours (Konicke et al., 2018; Sand et al., 2012). Among them, the 
oncogenic mir-21 [which supresses Phosphatase and tensin homolog (PTEN) and 
Programmed cell death protein 4 (PCDC4] tumour-suppressor genes and modulate the 
activity of PI3K/AKT/mTOR pathway, were shown to be upregulated in both BCC 
(Heffelfinger et al., 2012) and SCC  (Darido et al., 2011). In addition, in a mi-RNA 
expression profile analysis study, apart from mir-21, other mi-RNAs were found to be 
deregulated in BCC including the let-7 family, mir-143, mir-182, mir-148a, mir-378 and 
mir-183. In particular, mir-183 is associated with disease invasiveness and metastatic 
potential while lower levels have been identified in infiltrative tumors (Heffelfinger et al., 
2012). In SCC tumors, decreased expression of mir-124 and mir-214 was observed which 
was associated with increased activity of the ERK pathway resulting in aberrant cell 
proliferation, events associated with disease pathogenesis (Yamane et al., 2013). In addition, 
mir-199a-5p (that regulates cell adhesion and migration) is another mi-RNA with an aberrant 
expression in SCC tumours and furthermore associated with disease aggressiveness. (Kim 
et al., 2015; Wang et al., 2016). In addition, low levels of mir-200a (Bustos et al., 2017) and 
mir-375 (Mazar et al., 2011), result in increased malignant melanoma proliferation and 
migration. Moreover, high levels of mir-221 have been reported in melanoma patients, 
compared to healthy controls, resulting in cell cycle deregulation through repression of c-Kit 
and p27 genes thereby favouring the malignant phenotype (Kanemaru et al., 2011). Many 
other mi-RNAs have been implicated in melanoma development, including mir-29c (T. 




mir-137 (Bemis et al., 2008) which regulate genes, like MITF (Microphthalmia-associated 
transcription factor), essential for melanoma cell proliferation and survival. 
To conclude, taking into consideration the important role of the epigenetic machinery in skin 
carcinogenesis (summarized in Fig. 1.11) together with the fact that these modifications are 
reversible, it is understandable that the epigenetic components are promising targets for skin 
therapeutic interventions. 
 
Figure 1.11: Epigenetic mechanisms involved in skin cancer carcinogenesis. A number 
of epigenetic mechanisms reported to be involved in skin carcinogenesis. In particular, 
genome-wide hypo-methylation as well as promoter hyper-methylation, have been 
associated with the onset and progression of skin cancer. Loss of methylation leads on the 
activation of various oncogenes (e.g. melanoma antigen, Mage) that promote tumour 
survival, while increased methylation on the promoter sites of various tumour suppressor 
genes [e.g.MLT-1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1), 
Snail (Zinc finger protein SNAI1), adhesion molecules like (E-Cadherin), cell cycle 
regulators (p16INK4a and p14ARF) etc.] is also usually reported in both melanoma and non-




activation of histone acetylation as well as deacetylation enzymes, during skin 
tumorigenesis, also contribute to the deregulation of a number of genes important in 
malignant cell survival, such as pro-apoptotic proteins (e.g. Bax, Bak, Bim, caspases 8/9, 
TNFRSF10A and TNFRSF10B) as well as anti-apoptotic proteins (e.g. Bcl-2 and Bcl-xl). 
Another important aspect in skin cancer epigenetics is the aberrant expression of various mi-
RNAs that are important in cell proliferation and other cellular processes. All of these are 
usually found deregulated in skin tumours and thus gradually result in abnormalities of 
critical cell processes, including cell growth, proliferation, cell cycle, and apoptosis as well 
as metastatic processes that favour skin cancer cell survival.  
1.6.3 ITCs in NMSC Chemoprevention and Therapy 
Several lines of evidence support the protective role of ITCs against  UV-induced (Dickinson 
et al., 2009; Dinkova-Kostova et al., 2010; Dinkova-Kostova et al., 2007; Dinkova-Kostova 
et al., 2006; Talalay et al., 2007) and chemically-induced (Gills et al., 2006; Xu et al., 2006) 
skin tumorigenesis, with the majority of them focusing on SFN. Topical treatment with SFN, 
on mouse skin, enhances the GSH biosynthetic process, increases GSH S-transferases 
(GST4) and protects against chemically-induced skin mutagenesis (Abel et al., 2013). 
Similarly, SFN blocked 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin cancer 
progression in CD-1 mice by repressing TPA-mediated ornithine decarboxylase activity 
which is an obligatory step in TPA-induced promotion of carcinogenesis (Gills et al., 2006). 
The anti-photo-carcinogenic and anti-photoaging properties of 3-methoxybenzyl 
isothiocyanate (MBITC) have been recently documented in UVB-exposed 3D human skin 
reconstructed tissue where MBITC inhibited UVB-induced cell proliferation, MMPs 
expression, DNA damage and epidermal CPDs formation as well as prevented UVB-induced 
hyperplasia  (Carpenter et al., 2018). In line with these observations, application of SFN 
(prior to irradiation) in the skin of BALB/c mice, exerted a protective effect against UVA-
induced photo-aging, DNA oxidative and connective tissue damage via an Nrf2-dependent 
inhibition of MMP-1 and MAPK/AP-1 signaling cascades (Chaiprasongsuk et al., 2017). 
Moreover, SFN and PEITC induced the expression of cyto-protective proteins in HaCaT 
cells  (Kleszczynski et al., 2013; Wagner et al., 2010) while pro-irradiation treatment (with 
these compounds) of an ex vivo human reconstituted skin tissue model diminished photo-
oxidative  damage  and induced apoptosis through Nrf2 activation (Kleszczynski et al., 
2013). To this end, the importance of the Nrf2 pathway in ITC-mediated protection against 
skin carcinogenesis is well-characterized in studies using Nrf2 deficient mouse models. For 




mutagenesis which was Nrf2-dependent(Saw et al., 2011). These results are in agreement 
with those of another study which has  shown that the protective effect of SFN against 7,12-
dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA)/(TPA)-
induced skin tumorigenesis in C57BL/6 mice is also Nrf2-dependent (Xu et al., 2006). 
Activation of the Nrf2 pathway, through epigenetic reprogramming, and the subsequent 
induction of target genes was also reported to be involved in SFN-mediated suppression of 
tumor transformation. Specifically, Nrf2 re-activation was attributed to promoter hypo-
methylation through repression of DNMTs and HDACs activity. (Su et al., 2014). In 
addition, SFN has been shown to induce growth arrest and apoptosis in skin cancer (SCC-
13) cells due to decreased tri-methylation of lysine 27 of  H3 (H3K27me3), an effect 
associated with inhibition of the polycomb group (PcG) proteins due to enhanced 
proteosomal degradation  (Balasubramanian et al., 2011). Similarly, in another set of 
experiments, SFN found to inhibit epidermal squamous carcinoma cell proliferation, 
invasion and migration in vitro and in vivo by targeting Protein arginine N-methyltransferase 
5 (PRMT5) and methylosome protein 50 (MEP50). In particular, SFN reduces the expression 
of PRMT5/MEP50 through proteosomal degradation thus suppressing the formation of di-
methylated arginine 3 on H4 (H4R3me2), events important for SFN-mediated inhibition of 
metastasis in SCC tumors (Saha et al., 2017). It is noteworthy, that the mode of action of 
SFN is different in normal epidermal keratinocytes compared to cancer ones. For example, 
normal keratinocytes reported to be more resistant to SFN‐induced inhibition of HDAC 
activity (and cellular proliferation) in comparison to the cancer cells (Dickinson et al., 2015). 
In agreement, another study has demonstrated the diverse nature of SFN’s effectiveness in 
normal keratinocytes as compared to skin cancer cells. Specifically, it was shown that SFN 
protected primary normal keratinocytes from damage by slowing their growth while driving 
apoptosis in cancer cells. Furthermore, the mechanism by which SFN controls keratinocyte 
proliferation appears to be p53 dependent (Chew et al., 2012). PEITC was also shown to 
prevent both TPA-and epidermal growth factor (EGF)-induced mouse epidermal JB6 cell 
transformation (through a p53-depend induction of apoptosis) (Huang et al., 1998).  
1.6.4 ITCs in Melanoma Chemoprevention and Therapy 
Growing evidence supports the protective role of ITCs against initiation, progression and 
metastasis of melanoma by utilizing various relevant in vitro models. Generally, such a 
protective effect is mediated by the induction of diverse signal transduction pathways, 
oxidative stress responses, disruption of mitochondrial functions, modulation of the activity 




particular, SFN has been shown to cause morphological changes and DNA fragmentation in 
murine B16F-10 melanoma cells, indicative of apoptotic induction in these cells. SFN 
induced the intrinsic apoptotic pathway and significantly reduced melanoma cell viability 
by activating caspase 3, Bax and p53 proteins while down-regulating the expression levels 
of anti-apoptotic Bcl2 and various pro-inflammatory cytokines (Hamsa et al., 2011). 
Similarly, exposure of human melanoma (Bowes and SK-Mel-28) cells to SFN also 
decreased cell survival and proliferation through activation of mitochondrial mediated 
apoptosis associated with modulation in p38 and p53 activities, induction of oxidative-
mediated DNA damage response and enhanced expression of pro-apoptotic BAX and PUMA  
(Rudolf et al., 2014). In agreement to these observations, BITC also found to increase 
apoptotic cell death in both murine and human PAF-R positive cells, mediated by elevated 
production of ROS and enhanced caspase3/7-like activity. Cells a expressing the platelet-
activating factor receptor (PAF-R) are characterized by a higher metastatic potential and 
found to be more susceptible in BITC-induced apoptosis compared to PAF-R negative ones, 
suggesting that ITCs could be promising agents for  better management of PAF‐R‐positive 
melanoma patients (Sahu, 2015). In another experimental setting it was the induction of 
multiple apoptotic pathways in human A375 malignant melanoma cells treated with SFN, 
BITC and PEITC were reported, as shown by the increased expression of several caspases 
indicative of the intrinsic, extrinsic and endoplasmic reticulum (ER)-based pathways 
(Mantso et al., 2016). In addition, PEITC increased ROS production that disrupted the 
mitochondrial membrane potential in A375.S2 cells, resulted in an increased number of cells 
at the G2/M phase, induced ER stress and mitochondrial-dependent apoptotic pathways 
(Huang et al., 2014). BITC reported to exert a similar effect in A375.S2 cells by inducing a 
ROS-mediated G2/M cell cycle growth arrest as well as apoptosis mediated by multiple 
signaling pathways (e.g. ER stress-, mitochondrial-dependent and death receptor-mediated 
pathways) through alterations in the expression of various  cyclins and CDKs (e.g. cyclin A, 
CDK1, CDC25), proteins of the BCL2 family and various caspases (Huang et al., 2012). In 
agreement, SFN, BITC and PEITC have also been shown to increase the number of A375 
melanoma cells arrested at the G2/M phase by modulating the expression activity of several 





Figure 1.12: Cellular targets of ITCs anti-melanoma effect. The anti-melanoma effect of 
ITCs has been characterized in various studies both in vitro and in vivo. Briefly, ITCs have 
been reported to reduce melanoma cell proliferation and survival as well as to decrease tumor 
development in rodent models through modulations of multiple signaling pathways (e.g. 
p38/MAPK, p53 etc.), enhancement of oxidative responses (ROS) and deregulation of the 
epigenetic machinery, resulting in the induction of DNA damage, mitochondrial dysfunction 
and aberrant acetylation and methylation of core histones. Thus, upregulate the expression 
of various tumor-related genes, while downregulate the expression of oncogenes to promote 
cell cycle arrest, induce various apoptotic pathways (intrinsic, extrinsic, p53-, ER-, 
mitochondria mediated pathways) and block the metastatic, invasiveness and neo-
angiogenic capacity of melanoma cells. 
In addition, ITCs have also been shown to alter the angiogenic and metastatic potential of 
melanoma cells. In this respect, AITC and PITC inhibited the expression and secretion of 
pro-angiogenic factors (e.g. TNF-α and NO) that promote tumour specific vascularization 
both in vitro (B16F-10) and in in vivo ( C57BL/6 mice) (Thejass &  Kuttan, 2007). A similar 
anti-angiogenic effect was also reported in human umbilical vein endothelial cells 




inflammatory cytokines, such as TNF-α and IL-1β (Thejass & Kuttan, 2007a). Moreover, 
the anti-metastatic potential of BITC and PEITC have been studied in murine B16F-10 (Lai 
et al., 2017) as well as in human A375.S2 (Y. S. Ma et al., 2017) cells and it was shown that 
both ITCs reduced viability, mobility and invasion of cells (through down-regulation of 
MMP-2), diminished expression of several proteins involved in the metastatic process and 
affected the MAPK signaling pathway. It should be mentioned though that the two ITCs 
differentially affected the expression of the proteins implicated in the metastatic potential of 
melanoma cells (Lai et al., 2017; Ma et al., 2017). 
In the same context, a number of in vivo studies have also supported the anti-melanoma 
effect of ITCs. For instance, combinational treatment of C57BL/6 mice injected with B16F-
10 cells and then treated with AITC, PEITC and SFN (1:1:1) resulted in reduced tumor 
growth, volume and weight(Bansal et al., 2015). In addition, intraperitoneal injection of both 
PEITC (Ni et al., 2014) and BITC (Ni et al., 2013) significantly declined the weight and size 
of tumours formed in A375.S2 BALB/c xenografts suggesting that both compounds can be 
effective in melanoma therapy. In another study, intraperitoneal administration of  AITC and 
PITC, inhibited  B16F-10-induced metastasis in the lungs of C57BL/6 mice (Manesh & 
Kuttan, 2003). Furthermore, intraperitoneally administration of SFN also prevented the 
migration of metastatic tumour cells in tumour bearing C57BL/6 mice by modulating a cell-
mediated immune response and enhancing the activation of IFN-gamma and IL-2, while 
repressing pro-inflammatory cytokines such as IL-1β, TNF-alpha and granulocyte-
macrophage colony-stimulating factor (GM-CSF) (Thejass & Kuttan, 2007b). Moreover, 
SFN inhibited melanoma proliferation, growth and mobility in B16F10 xenografts via 
decreased expression of MMP-9, an important regulator of tumour growth and invasion 
(Pradhan et al., 2010).  
Additionally, ITCs (especially SFN) have been documented to contribute towards the 
concept of melanoma epigenetic therapy. In a recent study, exposure of A375 cells to AITC 
significantly diminished both HDAC and HAT activities and altered the expression of 
various enzymes (HDACs, HATs and HMTs) that regulate the acetylated and methylated 
status of H3 and H4, suggesting that AITC could act as epigenetic regulator capable of 
inhibiting melanoma progression (Mitsiogianni et al., 2019). In addition, another study has 
reported that SFN was able to inhibit the proliferation and growth of murine B16 and S91 
melanoma cells, in vitro, by decreasing the activity of deacetylating enzymes  while injection 




activity in melanoma tumour-bearing C57BL/6 mice (Do et al., 2010). Furthermore, ITCs 
reduced melanoma stem cells (MCS) viability, a subgroup of malignant melanoma cells 
characterized by high invasive and metastatic potential due to overexpression of the Ezh2 
stem cell survival protein.  Exposure of MCS cells to SFN decreased the expression of Ezh2 
polycomb group protein and H3K27me3 formation thus reducing cell proliferation, invasion 
and migration in these cells. Finally, administration of SFN, in mice injected with A375-
derived MCS cells, diminished tumour formation and growth, an effect which was associated 
with decreased expression levels of Ezh2 , H3K27me3, various MMPs together with 
enhanced expression of metalloproteinase inhibitor 3 (TIMP3) and apoptosis (Fisher et al., 
2016).  
Based on the knowledge acquired up to date, scientists focused on the formation of synthetic 
ITC analogues, having longer side chains or/and substitutions of sulphur group (e.g. by 
selenium), in order to produce structures with more potent anti-cancer efficacy. A number 
of these synthetic analogues have been developed and reported to be effective in repressing 
melanoma survival. It is also noteworthy that these analogues showed specificity towards 
cancer cells only as normal cells were found to be more resistant (Nguyen et al., 2011; 
Sharma et al., 2009; Sharma et al., 2008). For instance, naphthalimide is an example of a  
synthetic ITC analogue which has been found to exert a more potent cytotoxicity in both in 













1.7: Working Hypothesis: Aims and Objectives  
The hypothesis of the present study was that ITCs could act as potent epigenetic modulators, 
in malignant melanoma, thereby acting to promote apoptotic cell death. This, in turn, would 
suggest that ITCs could be promising candidates as “next generation” epigenetic therapeutic 
agents. 
Considering that epigenetic modifications regulate differential gene expression, perhaps in 
this context they could serve as a common mechanism that reflects the plurality of anti-
cancer properties exerted by ITCs, in terms of modulating the behavior of different genes in 
different cellular cascades. Specifically, in this study, we have aimed to characterize the 
effect of specific ITCs (abundant in the most commonly consumed Brassica vegetables) 
namely SFN, IBN, AITC, BITC and PEITC on specific acetylation and methylation marks 
on lysine molecules located on histone proteins H3 and H4 as well as on the expression 
patterns of several critical enzymes responsible for altering the epigenetic landscape. In this 
way, we will study the anti-melanoma properties of the above-mentioned ITCs as part of 
their well-described cytotoxic profile in an experimental in vitro model of human malignant 
melanoma.  
Project objectives: 
 To optimize the experimental conditions of an  in vitro model of human malignant 
melanoma in order to test the cytotoxic effectiveness of ITCs. 
 To assess the profile of the overall therapeutic potential of ITC-induced toxicity, 
characterizing diverse end points of cytotoxicity (viability, cell cycle growth arrest, 
apoptotic and necrotic cell death as well as  ROS generation) in our in vitro model 
of human malignant melanoma. 
 To assess ITCs ability to regulate the apoptotic process by identifying the expression 
pattern of several genes involved in distinct stages of apoptosis in human malignant 
melanoma cells. 
 To characterize the epigenetic profile of each ITC treatment in the context of specific 
histone modifications in human malignant melanoma cells. In particular, to assess 
the expression of various enzymes capable of mediating  lysine acetylation and 





























2.1 Cell Culture Methodologies 
2.1.1 Cell Lines Utilized 
For the purpose of this study we utilized an in vitro model of human malignant melanoma 
consisted of: (i) a human (A375) and (ii) a murine (B16 F10) primary malignant melanoma 
cell line; two human melanoma metastatic cell lines, (iii) one derived from brain (VMM-1) 
and (iv) one from lymph node metastasis (Hs 294T); (v) a human non-melanoma, 
epidermoid carcinoma (A431) cell line and (vi) a human normal immortalized keratinocyte 
(HaCaT) cell line (Table 2.1). All cell lines were authenticated using STR analysis on 2018.  
At this point it should be mentioned that the A375 melanoma cell line was the main cell line 
utilized in all experimental settings throughout the project, while the rest of the cell lines 
were used on particular experimental designs, in the context of profiling the cytotoxic effects 
of ITCs to investigate their specificity towards primary, metastatic, non-melanoma skin 
cacinomas as well as normal cells. 
Table 2.1: Description of all cell lines that constitute our in vitro malignant melanoma 
model 
Cell Line Supplier Description 
A375 Purchased from Sigma-Aldrich (St. 
Louis, MO, USA) 
Human malignant melanoma, 
derived from the skin of a 54 year 
old female – Adherent, epithelial 
cells 
B16 F10 Purchased from ATCC (Manassas, VA, 
USA)  
Mouse melanoma, derived from 
mouse skin - Adherent, mixture of 
spindle-shaped and epithelial-like 
cells 
VMM-1 Purchased from ATCC (Manassas, VA, 
USA) 
Human brain metastatic malignant 
melanoma (Stage IV), derived 
from a metastatic tumor in the 
brain from a 62 years old male 





Hs 294T Purchased from ATCC (Manassas, VA, 
USA) 
Human lymph node metastatic 
malignant melanoma (Stage IV), 
derived from a metastatic tumor 
in the lymph nodes from a 56 
years old male patient – Adherent, 
mixed stellate and polygonal 
A431 Purchased from Sigma-Aldrich (St. 
Louis, MO, USA)  
Human squamous carcinoma, 
derived from an epidermal 
carcinoma of the vulva taken from 
an 85 years old female – 
Adherent, epithelial cells 
HaCaT A kind gift from Dr Sharon Brody 
(Dermal Toxicology and Effects Group; 
Centre for Radiation, Chemical and 
Environmental Hazards; Public Health 
England, UK) 
Human keratinocytes, in vitro 
spontaneously transformed 
keratinocytes from histologically 
normal skin – Adherent, 
monolayer cells 
 
2.1.2 Cell Culture Materials and Reagents 
Cells were incubated either in Dulbecco’s Modified Eagle’s (DMEM) medium or Roswell 
Park Memorial Institute (RPMI-1660) medium, purchased from Labtech International Ltd. 
(East Sussex, UK). Trypsin-EDTA, phosphate-buffered saline (PBS), Foetal Bovine Serum 
(FBS), L-Glutamine and Penicillin/Streptomycin were also obtained from Labtech 
International Ltd. (East Sussex, UK). Resazurin sodium salt, used to assess cell viability was 
purchased from Sigma-Aldrich (St. Louis, MO, USA). All chemicals were of analytical 
grade and supplied from Sigma-Aldrich (St. Louis, MO, USA), Applichem (Darmstadt, 
Germany), Invitrogen (Carlsbad, CA, USA) and Thermo Fisher Scientific (Waltham, MA, 
USA). Bovine Serum Albumin (BSA) was obtained by Affymetrix (Santa Clara, CA, USA) 
Table 2.1: Description of all cell lines that constitute our in vitro malignant 




and Dimethyl sulfoxide (DMSO) and ethanol (EtOH) by Sigma-Aldrich (St. Louis, MO, 
USA) (Table 2.2).  
Table 2.2: List of materials used for cell culture 
Reagents Components 
Complete Growth Media 
for A375, A431 and 
HaCaT cells 
High Glucose DMEM (Dulbecco’s Modified Eagle Medium) 
(Labtech Internationl Ltd, East Sussex, UK), supplemented 
with 10% fetal bovine resume heat-inactivated (Labtech), 2 
mM L-Glutamine (Labtech), and 1% (v/v) 
penicillin/streptomycin mix. 
Complete Growth Media 
for Hs 294T and B16 F10 
High Glucose DMEM (Dulbecco’s Modified Eagle Medium) 
(Labtech Internationl Ltd, East Sussex, UK), supplemented 
with 10% fetal bovine resume heat-inactivated (Labtech), 4 
mM L-Glutamine (Labtech), and 1% (v/v) 
penicillin/streptomycin mix. 
Complete Growth Media 
for VMM-1 
High Glucose RPMI-1640 (Labtech International Ltd, East 
Sussex, UK), supplemented with 10% fetal bovine resume 
heat-inactivated (Labtech), 2 mM L-Glutamine (Labtech), 
and 1% (v/v) penicillin/streptomycin mix. 
Phosphate Buffer Saline 
(PBS) [1X] 
[NaCl]= 140 mM, [KCl]= 2.7 mM, [Na2HPO4]= 10 mM, 
[KH2PO4]= 1.7 mM, pH 7.4 
Trypsin-EDTA Solution 
[1X] 
1X Trypsin-EDTA 0.25% in PBS w/o Mg2+, w/o Ca2+ 
(Labtech) 
Cell Culture plates & 
flasks 
Corning Inc., NY, USA 





2.1.3 Cells Cryopreservation and Recovery 
All cell lines were cryopreserved to avoid contamination, aging, transformation and to 
minimize genetic change in continuous cell lines. Cultured cells were detached from the 
flasks by trypsinization. Once detached, cells were re-suspended in the desired growth 
medium, according to the cell type, and the number of viable cells was counted. Then, the 
suspension centrifuged at ~2000 rpm for about 2 min in order to pellet cells. The supernatant 
was then discarded carefully, without disturbing the pellet, which was then re-suspended in 
appropriate freezing medium [foetal bovine serum (FBS) containing 10% (v/v) DMSO] to a 
concentration of 5 x 106 to 1 x 106 cells/ml. Cells were next aliquoted into cryogenic storage 
vials and stored under vapour phase liquid nitrogen for long term storage.  
Before usage, cells were thawed and re-suspended in 5 mL of the desired growth medium 
and centrifuged at 2000 rpm for 2 min, at room temperature (RT). The freezing media was 
then aspirated and the cell pellet was re-suspended in complete growth medium. Cell 
suspension was then transferred into a 25 cm2 cell culture flask and maintained in a 
humidified atmosphere at 37 °C and 5% v/v CO2. Cells were remained in culture for about 
15-20 passages, after which new stocks were utilized.  
All cell lines used in this study were authenticated with the Short-tandem repeat profiling 
(STR) method and tested for mycoplasma contamination prior to use. 
2.1.4 Cells Propagation 
All cell lines were cultured in 75 cm2 flasks containing the desired complete growth medium 
(see Table 2.2 for appropriate growth media for each cell line) and maintained in a 
humidified atmosphere at 37oC, in incubators providing 5% v/v CO2. Cells were sub-
cultured via trypsinization (2-3 times per week) after reaching 80-90% confluency. In 
particular, growth media was aspirated and cells were then washed with ~5 ml PBS. Next, 
1X trypsin-EDTA was added into the flask (1 ml for A375, B16 F10, VMM-1 and Hs 294T 
cells or 2 mL for HaCaT and A431 cells) and cells were placed back in the incubator until 
they all detach from the flask's surface (5-10 min depending on the cell line). During 
trypsinization, cells were observed under the microscope to ensure that they had all been 
detached and next trypsin was de-activated by adding ~4-5 ml of growth medium into the 
flask. Finally, cells were sub-cultured at a ratio based on the replication rate of each cell line 




2.1.5 Counting and Plating of Cells 
Cells were next transferred into a falcon tube and then centrifuged at 2,000 rpm for 2 min, 
at RT. Media was then aspirated, and cell pellet was thoroughly re-suspended in fresh media 
(5-12 ml according to the size of cell pellet). In order to determine the number of cells, 30 
μl of this cell suspension was transferred into a micro-centrifuge tube and was mixed with 
an equal amount of trypan blue solution [0.4% (w/v); HyClone Inc, South Logan, USA].  
Next, 10 μl of this mixture was loaded into a Neubauer counting chamber (i.e. 
haemocytometer) and the number of viable cells were then counted, under an inverted 
microscope. 
Trypan blue was used to distinguish between viable and dead cells. The assay is based on 
the principle that live cells possess intact cell membranes and do not take up the dye (seen 
as bright/clear under microscope), while dead cells have damaged cell membranes and 
uptake trypan blue (stained blue). 
The central area of the counting chamber is divided into 4 large squares. Each of these are 
further sub-divided into 16 smaller squares (Fig. 2.1). Only cells set within a large square 
and on the border lines on two sides (upper and right-hand boundary line) were counted. The 
number of cells counted in this set of 16 squares was recorded and the haemocytometer was 
moved to the next set until all 4 sets of 16 squares on the haemocytometer have been counted, 
and their values recorded.  
 
Figure 2.1: The central area of the haemocytometer’s counting chamber. The red square 
 indicates one of the 4 sets of 16 square used for cell counting. 





[𝐂𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐥𝐢𝐯𝐞 𝐜𝐞𝐥𝐥𝐬/𝐦𝐥] =  
𝑵
𝟒
𝐱 𝐃𝐅 𝐱 𝟏𝟎𝟒 
Where N= the average number of cells counted in the 4 squares of the counting chamber, 
DF (dilution factor) = 2 (1:1 dilution with trypan blue solution) and 104 = conversion factor 
to convert 104 μl to 1 ml (calculated according to the dimensions of the small square of the 
Neubauer chamber). After calculating the concentration of cells in the suspension, the 
desired number of cells is seeded into cell culture dishes, 96-well plates, etc., based on the 
requirements of the experimental protocols to be performed. 
2.1.6 ITCs Exposure Protocols  
An appropriate number of cells was plated and incubated at 37oC and 5% v/v CO2, overnight. 
All cell lines were seeded in 100 μl of complete medium (depending on type of cell line) 
into 96-well plates (for cell viability assays) and kept in the incubator overnight, prior to 
exposure to each of the ITCs. The density of A375 cells was 8,000 and 4,000 cells/well; of 
B16F-10 cells was 6000 and 3000 cells/well; of VMM1 cells was 9000 and 5000 cells/well; 
of Hs 294T cells was 7000 and 4000 cells/well and for A431 and HaCaT cells 10,000 and 
5,000 cells/well for 24 and 48 h, respectively. On the following day, cells were observed 
under the microscope to ensure that they reached confluency and exposed to a range of 
concentrations of each ITC (2.5-50 µM) for 24 and 48h, while control cells were incubated 
with complete medium only and/or with either 0.1% DMSO or 0.1% EtOH (in which ITCs 
were dissolved). 
Table 3.3: List of ITCs administered in our experimental melanoma model   
ITC company storage 
SFN 
Abcam, Cambridge, UK 
(ab141969) 
Dissolved in DMSO at a concentration of 100 
mM - Aliquots were stored at − 20 °C 
IBN 
Abcam, Cambridge, UK 
(ab141944) 
Dissolved in EtOH at a concentration of 100 
mM - Aliquots were stored at − 20 °C 
AITC 
Sigma-Aldrich, St. Louis, 
MO, USA (W203408) 
Dissolved in DMSO at a concentration of 100 
mM - Aliquots were stored at − 20 °C 
BITC 
Sigma-Aldrich, St. Louis, 
MO, USA (252492) 
Dissolved in DMSO at a concentration of 100 
mM - Aliquots were stored at − 20 °C 
PEITC 
Sigma-Aldrich, St. Louis, 
MO, USA (253731) 
Dissolved in DMSO at a concentration of 100 





For other experimental protocols (flow cytometry, RNA and protein extraction, etc.), cells 
were seeded and allowed to adhere overnight in either 100 mm or 60 mm dishes, with cell 
densities being (100mm dish) for A375 cells, 1.4 × 106  and 0.7 × 106 per dish; for B16-F10, 
2 × 106 and 1 × 106 per dish; for Hs 294T and VMM1, 1 × 106 and 0.8 × 106 per dish;  for 
A431 and HaCaT, 1.8 × 106 and 1 × 106 per dish, for 24 and 48 h, respectively. Next day, 
cells were observed under the microscope to ensure that they reached confluency and 
exposed to 10 µM of each ITC, over different incubation periods. 
Densities of cells seeded in 60 mm dishes were: A375 cells, 0.35 × 106 and 0.25 × 106 per 
dish; for Hs 294T cells, 0.45 × 106 and 0.35 × 106 per dish; for  B16-F10 cells, 0.3 × 106 and 
0.2 × 106 per dish and for VMM1 cells, 0.8 × 106 and 0.6 × 106 per dish for 24 and 48h, 
respectively. 
2.1.7 Determination of Cell Viability: Resazurin Assay 
The Resazurin assay was utilized, in this set of experiments, in order to determine cell 
viability. This assay is based on the ability of live cells to metabolize the non-fluorescent 
indicator dye resazurin into the highly fluorescent resorufin which is then detected by 
absorbance (at 570nm and 600nm as a reference wavelength) or fluorescence 
(excitation/emission maxima at 530-560/590 nm). The detection of the levels of absorbance 
or fluorescence scan is proportional to the number of viable cells.  
All cell lines were seeded in 100 μl of complete medium into 96-well plates and kept in the 
incubator overnight. Next, cells were exposed to each ITC treatment at various 
concentrations, for 24–48h, as described in section 2.1.6 (ITCs Exposure Protocols). At the 
indicated time points, resazurin (resazurin sodium salt dissolved in PBS at a final 
concentration of 1mg/ mL) was added in an amount equal to 1/10 of the volume in each well 
and incubated for 2-4h (depending on the metabolic capacity of each type of cancer cell 
line), at 37oC. The plates were then centrifuged, and absorbance was recorded at 570 nm 
(using 600 nm as a reference wavelength) by utilizing a Spark 10 M multi-mode plate reader 
(Tecan, Männedorf, Switzerland). The levels of cell viability were estimated and expressed 
as percentage of control cells. Viable cells levels were estimated according to the optical 
density values recorded and cell viability was expressed as percentage of control cells. Five 
replicates (N=5) of each treatment condition were used in each experiment. 
2.2 Flow Cytometry Protocols 
The following experiments were performed by utilizing the FACS Canto II flow cytometer 




Table 2.4: Reagents and kits used for flow cytometry experiments 
Reagent Supplier 
Dihydrorhodamine 123 (DHR123) 
Sigma Aldrich, St. Louis, 
MO, USA 
(D1054) 
CellEvent Caspase 3/7 Green Flow 
Cytometry Assay Kit 
ThermoFisher Scientific Ltd, 
(C10427) 
Intracellular GSG Assay Kit 
Abcam, Cambridge, UK 
(Ab112132) 
FxCycle PI/Rnase Staining Solution 
ThermoFisher Scientific Ltd 
(F10797) 
DAPI 
Sigma Aldrich Ltd 
(10236276001) 
 
2.2.1 Determination of Cell Cycle Phase Distribution 
The FxCycle PI/RNase staining solution was used for the determination of cell population 
distributed among the phases of the cell cycle. The assay is based on the fact that DNA 
content differs in the diverse stages of the cell cycle: the Go/G1 phase contains one set of 
paired chromosomes per cell; the S phase is characterized by variable amount of DNA and 
the G2/M phase contains two sets of paired chromosomes per cell. The FxCycle PI/RNase 
solution contains propidium ioddide (PI), which binds to DNA and upon binding produces 
a fluorescent signal, allowing the determination of DNA content in cells (Excitation and 
Emission maxima at 535/617 nm). 
To assess the DNA content of cells treated with each ITC, we used the FxCycle PI/RNase 
staining solution according to the manufacturer’s instructions. Following exposure to 10 µM 
of each ITC for 24 and 48h (see section 2.1.6 ITCs Exposure Protocols), cells were harvested 
and washed twice with PBS. Approximately, 0.5×106 cells were then fixed in cold 70% 
ethanol and stored at 4oC for at least 1 hr (or longer), until being further processed. Fixed 
cells were then washed twice with PBS to remove ethanol and centrifuged at ~2000 rpm for 
2min. Cell pellet was then re-suspended in FxCycle PI/RNase staining solution (0.5ml/1×106 
cells) and incubated for 30 min at RT and protected from light. Analysis by flow cytometry 
yields frequency histograms showing population of cells distributed among the different cell 
cycle phases. Data from 10,000 events / sample were acquired.  
2.2.2 Determination of Apoptosis 
The CellEvent Caspase 3/7 Green flow cytometry assay kit was utilized for the detection of 
apoptosis through detection of the activated executioner caspases 3 and 7. The CellEvent 




acid binding dye that is dissociated by the activated caspases 3/7, in apoptotic cells. Once 
the dye is free, it binds to the DNA and produces a fluorogenic signal (CellEvent Caspase 
3/7 Detection Reagent; fluorescence excitation and emission maxima: ~511/533 nm). Using 
it together with 4’, 6 – diamidino-2-phenylindole (DAPI), allows us to distinguish necrotic 
from apoptotic cells. DAPI is a fluorescent stain that can be diffused though the membranes 
of the dead cells only. Thus, the fluorescent intensity of Caspase 3/7 Reagent quantifies 
apoptotic cell population, whereas the fluorescent intensity of DAPI (excitation/emission 
364/454) corresponds to the necrotic cell population. 
To determine the extent of the apoptotic induction, under various experimental conditions, 
we used the CellEvent Caspase 3/7 Green flow cytometry assay kit according to the 
manufacturer’s protocol. Post exposure of cells to 10 µM of each ITC, for 24 and 48h (see 
section 2.1.6 ITCs Exposure Protocols), cells were harvested, washed twice with PBS and a 
single cell suspension of 1×106 cells/ml was prepared. Then, 0.5 µl of CellEvent Caspase 3/7 
Green detection reagent was added to 0.5 ml (1µl/1 × 106 cells/ml – final concentration of 
reagent 500 nM) of each cell suspension. Samples were then incubated at 37oC, for 30 min, 
and protected from light. During the final 5 min of incubation, DAPI (1 µM) was added to 
each sample to determine the percent of dead cells in the suspension. Flow cytometric 
analysis results in the identification of Caspase-3/7-positive, DAPI-positive and both 
Caspase-3/7- and DAPI-negative cells. For each experimental condition, we acquired data 
from 20,000 events / sample were acquired.  
2.2.3 Determination of ROS Induction 
Dihydrorhodamine 123 (DHR123) was used for the detection of intracellular ROS levels. 
The assay is based on the fact that in the presence of ROS (or other free intracellular radicals 
inside cells) will bind to DHR123 (an uncharged non-fluorescent dye) which is then oxidized 
and converted into the fluorescent rhodamine 123 (R123) dye that can then be detected 
(excitation/emission 488/530). We used this alongside with 4’, 6 – diamidino-2-
phenylindole (DAPI) in order to exclude the number of dead cells which do not produce 
ROS anyway. 
Cells treated with each ITCs, for 24 and 48h (see section 2.1.6 ITCs Exposure Protocols). 
At the indicated time points, cells were harvested and washed twice with PBS and a single 
cell suspension of 1×106 cells/mL was prepared. DHR 123 (dissolved in PBS at a 
concentration of 200 μΜ; stored at -20oC) was then added in the suspension at a final 




5 min of incubation, DAPI (1 µM) was added to each sample and incubated for further 5 
min. Data from 10,000 events / sample were acquired while DAPI-positive cells were 
excluded from any further analysis. 
2.2.4 Determination of GSH Levels 
For the detection of intracellular levels of GSH, we used the GSH Detection Assay Kit 
according to the manufacturer’s instructions. The kit detects the levels of reduced GSH 
(using a non-fluorescent Green Dye that emits fluorescence when reacts with intracellular 
thiol groups; excitation/emission= 490/520 nm). Specifically, we prepared a 200X Thiol 
Green detection reagent by mixing 500 μl DMSO with the Thiol Green Dye, contained in 
the kit. The reagent was aliquoted and stored at -20oC. 
Cells exposed to each of the ITCs for 24 and 48h (see section 2.1.6 ITCs Exposure Protocols) 
and then were harvested. A single cell suspension of 1×106 cells/ml was prepared. Then, 2.5 
µl of 200X Thiol Green detection reagent was added into 500ml in each cell suspension (5µl 
/ 1 × 106 cells/ml) (containing serum media) and samples were incubated at 37oC for 30 min. 
Then cells were centrifuged at 1000 rpm for 4 mins and cell pellets were re-suspended in 
1ml of Assay Buffer. During the last 5min of incubation, DAPI (1 µM) was added to each 
sample, to determine the percent of dead cells in the suspension. Data of 10,000 events / 
sample were acquired. 
2.3 Molecular Biology Methodologies  
2.3.1 Extraction of RNA  
Total RNA was extracted using the TRIzol Reagent according to the manufacturer’s 
instructions. Following exposure of A375 cells to 10 µM of each ITC for 48h (see section 
2.1.6 ITCs Exposure Protocols), cells were collected via trypsinization, washed twice with 
PBS, suspended in 1ml (per 1-5×106 cells) TRIzol Reagent and stored in micro-centrifuge 
tubes at -20oC, until being further processed.  
Samples were allowed to thaw at RT for a few minutes and then 0.2ml of chloroform per 
1ml of TRIzol was added. The tubes were shaken vigorously by hand for ~15sec, incubated 
for 5 min at RT and next, centrifuged at 12,000 x g for 15 min at 4oC. After this step, the 
mixture was separated into 3 layers: a lower red phenol-chloroform phase, an interphase 
(containing DNA and proteins) and an upper colorless aqueous phase (containing the RNA). 
For RNA extraction, we transferred the aqueous phase of each sample, containing the RNA, 
into a fresh tube by angling the tube at 45° and pipette the solution out. For RNA 




aqueous phase and samples were incubated for 10 min at RT. Then, samples were 
centrifuged at 12,000 x g for 10 min at 4oC. Next, the supernatant was removed from the 
tubes while the RNA precipitate remained at the bottom of the tube. Pellets were then washed 
with 1ml of 75% ethanol per 1ml of TRIzol reagent used, vortexed briefly and centrifuged 
at 7,500 x g for 5 min at 4oC. All remaining ethanol was discarded and pellets were allowed 
to air dry on the bench for ~5-10 min. Then, pellets were re-suspended in RNAase free water 
(~20-50μl, according to pellet size) and stored at -20oC.  
RNA quantity was determined by using the NanoDrop One/OneC (ThermoScientific, 
Waltham, MA, USA) which measures the absorbance at 260 and 280 nm thereby providing 
information on RNA concentration and sample quality respectively. In general, a sample 
with a 260/280 ratio of > 1.8 is considered to contain non-contaminated (pure) RNA.  
RNA integrity and quality, were also assessed by running 2μg of each RNA sample on a 1% 
agarose gel. To prepare 1% agarose gel, we measured 1gr of agarose powder and mixed it 
with 100 ml of 1x Tris acetate EDTA (TAE) [for 1liter of 50X stock of TAE, we added 242 
gr Tris-base, 57.1 ml acetate (100% v/v acetic acid), 100 ml of 0.5M sodium EDTA and 
dH2O up to one liter) in a flask. The mixture was then microwaved for 1-3 min (stopping 
every few seconds and swirling) until the agarose was completely dissolved. After the 
agarose solution was cooled down, for a few minutes, we added ethidium bromide (EtBr) to 
a final concentration of approximately 0.2-0.5 μg/ml (usually about 2-3 μl of stock solution 
per 100 ml gel) which then binds to DNA thus allowing to visualize the DNA under exposure 
to UV light. Then the agarose was poured into a gel tray with the well combs in place and 
left until it was completely solidified. Then, it was placed  into an electrophoresis unit and 
1X TAE was added until the gel was covered. Next, 2μg RNA samples were mixed with 
loading buffer (heated at ~70°C for ~5min) loaded and run the gel at ~100V. The gel was 
then visualized under UV light. Intact total RNA, run on a denaturing gel, showed as sharp 
28S and 18S rRNA bands. 
2.3.2 Synthesis of cDNA 
Complimentary DNA was synthesized by using the SuperScript VILO cDNA synthesis kit 
(Invitrogen) according to the manufacturer’s instructions. Briefly, 2.5μg RNA was diluted 
in RNAase free water to a total volume of 14μl. Then, 4 μl of 5X VILO Reaction Mix 
(random primers, MgCl2, dNTPs) and 2μl of 10X SuperScript Enzyme Mix (SuperScript III 
RT, RNaseOUT recombinant ribonuclease inhibitor and a proprietary helper protein) were 




incubated at 25oC for 10 min. Next, the mixture was heated at 42oC for 60 min to generate 
cDNA and then at 85oC for another 5 min in order to inactivate the enzyme prior to be chilled 
at 4oC. The resulting product was stored at -20oC until further use.     
2.3.3 Real-Time Polymerase Chain Reaction (qPCR)  
The quantitative polymerase chain reaction was carried out by utilizing the TaqMan Array 
Human Apoptosis 96-well plates (Applied Biosystems, Carlsbad, CA, USA, 10480715). The 
predesigned 96-well plates contained a collection of dried-down TaqMan gene expression 
assays, which were composed of gene-specific primers and probe sets, for screening 
candidate genes involved at various stages of the apoptotic pathway. The use of Taqman 
probes significantly increases the specificity of the detection of qPCR and provides accurate 
quantification of the cDNA present. The TaqMan Array Human Apoptosis 96-well plates 
contains 92 assays for genes implicated at various stages of the apoptotic cascade along with 
4 assays for candidate endogenous control genes (18S, GAPDH, GUSB and HPRT1) (Table 
2.6).  
TaqMan Universal master mix (2X) was thawed and 550μl were mixed with an equal amount 
(550 μl) of cDNA (diluted in DNase free water), up to a final volume of 1100μl (all volumes 
contained ~10% excess volume to have enough product to run a 96-well plate). cDNA input 
was 50ng per well. Then, the reaction mixture was gently vortexed and spinned down. Before 
loading the samples, the plate was centrifuged at 1,000 rpm for 1 min. Then 10μl of the 
cDNA-master mix solution into each well of the 96-well plate. The plate was covered with 
a clear adhesive film and was briefly centrifuged (1,000 rpm for 1 min) to ensure that the 
reaction mixture was collected at the bottom of the wells. The plates were run at the StepOne 
Plus Real-Time PCR system (Applied Biosystems, Carlsbad, CA, USA) and the thermal-
cycling conditions was set according to manufacturer guidelines, indicated in the table below 
(Table 2.5).  
Gene expression data were analyzed by the ΔΔCt method and were expressed as fold change 
compared to untreated controls, by using the DataAssist v3.01 software.   
Table 2.5: Thermal cycling conditions for running the TaqMan Array 96-well plates 





 PCR (40 cycles) 




Table 2.5: Thermal cycling conditions for running the TaqMan Array 96-well plates 
(continued) 
50 oC 95oC 95oC 60oC 
2:00 0:20 0:03 0:30 
 
Table 2.6: List of all apoptosis-related genes contained in the TaqMan Array Human 
Apoptosis 96-well plates 
Gene Symbol – Assay ID 
1. 18S-Hs99999901_s1 34. FASLG-Hs00181225_m1 67. PRKCA-Hs00176973_m1 
2. AIFM1-Hs00377585_m1 35. GAPDH-Hs99999905_m1 68. PRKCB-Hs00176998_m1 
3. AKT1-Hs00178289_m1 36. GUSB-Hs99999908_m1 69. PRKCD-Hs01090047_m1 
4. APAF1-Hs00559441_m1 37. HPRT1-Hs99999909_m1 70. PRKCE-Hs00178455_m1 
5. ATM-Hs01112307_m1 38. HTRA2-Hs00234883_m1 71. PRKCZ-Hs00177051_m1 
6. BAD-Hs00188930_m1 39. IGF1-Hs01547656_m1 72. REL-Hs00968436_m1 
7. BAK1-Hs00940249_m1 40. IGF1R-Hs00609566_m1 73. RELA-Hs00153294_m1 
8. BAX-Hs00180269_m1 41. IKBKB-Hs00233287_m1 74. RELB-Hs00232399_m1 
9. BBC3-Hs00248075_m1 42. IKBKE-Hs01063858_m1 75. RIPK1-Hs00169407_m1 
10. BCL2-Hs99999018_m1 43. IKBKG-Hs00415849_m1 76. RPS6KA1-Hs00177257_m1 
11. BCL2L1-Hs00236329_m1 44. IL2-Hs00174114_m1 77. RPS6KA2-Hs00179731_m1 
12. BCL2L11-Hs00197982_m1 45. IL6-Hs00985639_m1 78. RPS6KA3-Hs00177936_m1 
13. BID-Hs00609632_m1 46. KDR-Hs00911700_m1 79. RPS6KA4-Hs00177670_m1 
14. BIRC2-Hs01112284_m1 47. KIT-Hs00174029_m1 80. RPS6KA5-Hs00178054_m1 
15. CASP3-Hs00234387_m1 48. MDM2-Hs99999008_m1 81. SLC25A4-Hs00154037_m1 
16. CASP7-Hs00169152_m1 49. MET-Hs00179845_m1 82. SLC25A5-Hs00854499_g1 
17. CASP8-Hs01018151_m1 50. NFKB1-Hs00765730_m1 83. SLC25A6-Hs00745067_s1 
18. CASP9-Hs00154260_m1 51. NFKB2-Hs00174517_m1 84. TGFB1-Hs00998133_m1 
19. CDKN2A-Hs00923894_m1 52. NFKBIA-Hs00153283_m1 85. TNF-Hs00174128_m1 
20.CFLAR-Hs01116280_m1 53. NFKBIB-Hs00182115_m1 86. TNFRSF10A-
Hs00269492_m1 
21. CHEK2-Hs00200485_m1 54. NFKBIE-Hs00234431_m1 87. TNFRSF1A-
Hs00533560_m1 
22. CHUK-Hs00175141_m1 55. P53AIP1-Hs00223141_m1 88. TNFSF10-Hs00234356_m1 
23. CYCS-Hs01588973_m1 56. PARP1-Hs00242302_m1 89. TNFSF12-Hs00611242_m1 
24. DAPK3-Hs00154676_m1 57. PARP2-Hs00193931_m1 90. TP53-Hs01034249_m1 
25. DAXX-Hs00154692_m1 58. PARP3-Hs00193946_m1 91. TRADD-Hs00182558_m1 
26. DFFA-Hs00189336_m1 59. PARP4-Hs00173105_m1 92. TRAF2-Hs00184192_m1 
27. DFFB-Hs00237077_m1 60. PIK3CA-Hs00180679_m1 93. TSPO-Hs00559362_m1 
28. DIABLO-Hs00219876_m1 61. PIK3CB-Hs00927728_m1 94. VDAC1-Hs01019083_m1 
29. EGFR-Hs01076078_m1 62. PIK3CD-Hs00192399_m1 95. VDAC2-Hs00762994_s1 
30. ENDOG-Hs00172770_m1 63. PIK3R1-Hs00381459_m1 96. VDAC3-Hs00366592_m1 
31. F2RL3-Hs00559732_m1 64. PIK3R2-Hs00178181_m1  
32. FADD-Hs00538709_m1 65. PMAIP1-Hs00560402_m1  





2.4 Protein Methodologies 
2.4.1 Protocols of Protein Extraction and Determination  
2.4.1.1 Nuclear Extraction Protocol 
Cells were trypsinized and washed twice with ice-cold PBS and then pellets were collected 
after centrifugation at 2,000 rpm for 2 min at 4oC. Cell pellets were lysed in 2 volumes of 
lysis buffer (depending on size of pellet) (see Table 2.7) and were left on ice (while 
periodically vortexed) for ~15 min. Next, cell lysates were centrifuged at 3,000 rpm for 10 
min at 4oC. Then the supernatant was transferred into a fresh tube and the nuclei (at the 
bottom of the tube) were washed with lysis buffer by gently pipetting up and down. This 
step was repeated ~5 times while the nuclei were re-suspended in one volume of nuclear 
extraction buffer (see Table 2.7) avoiding clumping to occur. Next, lysates were vortexed in 
low speed and incubated on ice (while vortexed every minute) for ~30 min. Finally, lysates 
were centrifuged at full speed (15,000 rpm/25,200 RCF) for 5 min at 4oC and then were 
transferred back in new tubes.    
The protein content was determined by utilizing the Pierce BCA protein assay kit (Thermo 
Scientific, Waltham, MA, USA) according to the manufacturer’s protocols. To this end, a 
standard curve was created by using Bovine Serum Albumin (BSA) as a standard. To do so, 
a set of BSA standards of known concentrations (0, 0.2, 0.5, 1, 2 μg/ μl) was prepared in a 
96 well plate by mixing the appropriate volumes of dH2O and BSA stock to a final volume 
of 20 μl. Samples were then added at a 1:10 dilution in duplicates. Next, we prepared our 
detection reagent by mixing 50 parts of BCA reagent A with 1 part of BCA reagent B (50:1), 
and then 200 μl of this solution was loaded in each well. The plate was then covered and 
incubated at 37oC, for 30 min, and also protected from light. Finally, the plate was 
centrifuged at 2,000 rpm/448 RCF for ~2 min and the absorbance was then recorded at 
562nm, using a Spark 10 M multi-mode plate reader. The unknown protein concentrations 
of the samples were calculated by generating a standard BSA curve.  
Once protein concentration was determined, the exact volume of lysates was measured and 
was transferred to new micro-centrifuge tubes. Loading buffer (5X) was finally added in a 
ratio of 1 part of loading buffer in 4 parts of sample, which then were either immediately 





Table 2.7: List of constituents of protein extraction buffers 
Lysis buffer Nuclear extraction buffer 
10mM HEPES pH 7.9 20mM HEPES pH 7.9 
10mM KCl 420mM NaCl 
0.1mM EDTA 0.1mM EDTA 
1.5mM MgCl2 1.5mM MgCl2 
0.2% NP40 25% glycerol 
Prior to use, add:  
1. 1mM DTT  
2. Protease Inhibitor Tablets (Thermo Scientific) 
3. Phosphatase Inhibitor Tablets (Thermo Scientific) 
 
2.4.1.2 Total Histone Extraction Protocol 
Total histone extracts were obtained using the EPIXTRACT Total Histone Extraction Kit 
from Enzo Life Sciences, Inc (Farmingdale, NY, USA) according to manufacturer’s 
protocol.  
Following exposure of A375 cells to 10 µM of each ITC, for 48h (see section 2.1.6 ITCs 
Exposure Protocols), cells were trypsinized and washed twice with ice-cold PBS while 
pellets were collected after centrifugation at 2,000 rpm/448 RCF for 2 min at 4oC. Cell 
pellets were then re-suspended in 1X Pre-Lysis Buffer (1:10 dilution of 10X Pre-Lysis 
Buffer with dH2O) at 1×107 cells/ml and incubated on ice for 10 min (while periodically 
vortexed gently). Cell lysates were next centrifuged at 10,000 rpm/ 11,200 RCF for 1 min at 
4oC. The supernatant was discarded and cell pellets were re-suspended in 3 volumes of Lysis 
Buffer (~200μl / 1×107 cells) and left on ice for 30 min. Afterwards lysates were centrifuged 
at 12,000 rpm/16,128 RCF, at 4oC, and the supernatant was transferred into a new tube. 
Finally, 0.3 volumes (0.3ml/1ml of supernatant) of Balance-DTT Buffer were added to the 
supernatants. Balance-DTT Buffer was prepared by adding DTT solution to Balance Buffer 
at a 1:500 ratio. 
Protein content was determined by utilizing the Pierce BCA protein assay kit (Thermo 
Scientific) according to the manufacturer’s instructions [protocol described at section 2.4.1.1 
Nuclear Extraction Protocol)]. In this case, diluted samples (1:5) were added, in duplicates. 
After determining the protein concentration, the exact volume of lysates was measured and 
was transferred to new micro-centrifuge tubes. Loading buffer (5X) was finally added in a 




used or were stored at -20oC (for several days) or -80oC (long term storage), until future 
usage. 
2.4.2 Determination of Total HDAC Activity  
Total HDAC activity levels were determined using the Epigenase HDAC Activity/Inhibition 
Direct Assay kit, Epigentek (Farmingdale, NY, USA) according to the manufacturer’s 
protocol. Briefly, for determination of HDAC activity, nuclear cell lysates were prepared 
(see section 2.4.1.1 Nuclear Extraction Protocol) and 10 μg of extracts were incubated with 
an acetylated substrate for 90 min at 37°C.  
For the enzymatic reaction, we prepared blank and sample wells in triplicates. In each blank 
well, 49 μl of reagent HO1 (HDAC Assay Buffer) was added with 1 μl of HO2 (HDAC 
Substrate). In sample wells, we added 45-48 μl of HO1, 1 μl HO2 and 1-4 μl (10 μg) of 
nuclear extracts (final volume in each well 50 μl). Then, strip-well microplates were tightly 
covered with clear adhesive film to avoid evaporation and incubated at 37°C for 90 min. 
Afterwards the reaction solution was removed and each well was washed three times with 
150 µl of the diluted 1X Wash Buffer (10X Wash Buffer diluted to 1X with dH2O). Next, 
50 µl of the diluted HO4 (1:1000 dilution of HO4 Capture Antibody with 1X Wash Buffer) 
was added into each well, then the strip-slips were covered with Parafilm M and were 
incubated at room temperature for 60 min. Next HO4 solution was discarded, each well was 
then washed three times with 150 µl of the diluted 1X Wash Buffer and 50 μl of the diluted 
HO5 Detection Antibody Solution was added (HO5 diluted with 1X Wash Buffer at a ratio 
of 1:2,000). Strip-wells were then covered with Parafilm M and incubated, for 30min, at RT. 
After 30 min, HO5 solution was removed and each well was washed four times with 150 µl 
of the diluted 1X Wash Buffer. Finally, for signal detection, 100 μl of Developer Solution 
(DS) was added to each well and incubated at room temperature for 1-10min (~ 5 min in our 
case), protected from light. To stop the enzymatic reaction 100 μl of Stop solution (SS) was 
added and the optical density values were detected at 450 nm with an optional reference 
wavelength of 655 nm, using a Spark 10 M multi-mode plate reader (Tecan).  
For a simple calculation of total HDAC activity the following formula was used: 
[𝐇𝐃𝐀𝐂 𝐀𝐜𝐭𝐢𝐯𝐢𝐭𝐲 (𝐎𝐃/𝐦𝐢𝐧/𝐦𝐠)] =  
(𝑺𝒂𝒎𝒑𝒍𝒆 𝑶𝑫 –  𝑩𝒍𝒂𝒏𝒌 𝑶𝑫)
(𝐏𝐫𝐨𝐭𝐞𝐢𝐧 𝐀𝐦𝐨𝐮𝐧𝐭 (µ𝐠) 𝐱 𝐦𝐢𝐧)
𝐱 𝟏𝟎𝟎𝟎 
Where protein amount = the protein amount (μg) added in the reaction (herein 10μg) and 




2.4.3 Determination of Total HAT Activity  
HAT activity levels were determined using the EpiQuik HAT Activity/Inhibition Assay kit, 
Epigentek (Farmingdale, NY, USA) according to the manufacturer’s protocol. Briefly, 
nuclear cell lysates were prepared (see section 2.4.1.1 Nuclear Extraction Protocol) and 5 μg 
of extracts were incubated with a HAT substrate for 60 min at 37°C.  
The first step in the process was the addition of 50 μl of diluted HT2 (HAT Substrate, 20 
μg/ml) in each well. The strip-wells were then covered with Parafilm M and incubated at RT 
for 45 min. HT2 was diluted in 1X HT1 Wash Buffer (1:10 dilution of 10X HT1 with dH2O) 
in a ratio 1:50. Afterwards HT2 was aspirated and each well was washed three times with 
150 µl of the 1X HT1 Wash Buffer. Next, for each blank well, 30 μl of reagent HT5 (HAT 
Assay Buffer) was added, while for sample wells, we added 26 μl of HT5, 2 μl of diluted 
HT4 (1:20 dilution of HT4, Acetyl Co-A with HT5) and 2 μl (5 μg) of nuclear extracts (final 
volume in each well 30 μl). Then, strip-well microplates were tightly covered with clear 
adhesive film to avoid evaporation and incubated at 37°C for 60 min. Afterwards the reaction 
solution was removed and each well was washed three times with 150 µl of the diluted 1X 
HT1 Wash Buffer. Next, 50 µl of the diluted HT6 (1:100 dilution of HT6 Capture Antibody 
with 1X HT1 Wash Buffer) was added into each well, then the strip-slips were covered with 
Parafilm M and were incubated on an orbital shaker (50-100 rpm) at RT for 60 min. Then, 
HT6 solution was discarded, each well was then washed four times with 150 µl of the diluted 
1X HT1 Wash Buffer and 50 μl of the diluted HT7 Detection Antibody was added (HT7 
diluted with 1X HT1 Wash Buffer at a ratio of 1:1000). Strip-wells were then covered with 
Parafilm M and incubated at room temperature for 30min. After the passage of 30min, HT7 
solution was removed and each well was washed four times with 150 µl of the diluted 1X 
HT1 Wash Buffer. Finally, 100 μl of HT8 (Developing Solution) was added to each well 
incubated at RT for ~ 5 min and protected from light. To stop the enzymatic reaction, 50 μl 
of HT9 (Stop Solution) was added and the optical density values were detected at 450 nm 
within 2-15 min, using a Spark 10M multi-mode plate reader (Tecan, Männedorf, 
Switzerland).  
The HAT activity was calculated by utilizing the following formula: 
[𝐇𝐀𝐓 𝐀𝐜𝐭𝐢𝐯𝐢𝐭𝐲 (𝐎𝐃/𝐦𝐢𝐧/𝐦𝐠)] =  
(𝑺𝒂𝒎𝒑𝒍𝒆 𝑶𝑫 –  𝑩𝒍𝒂𝒏𝒌 𝑶𝑫)





Where protein amount = the protein amount (μg) added in the reaction (herein 5μg) and min= 
incubation time with the HT4, Acetyl Co-A (herein 60min). 
2.4.4 Western Immunoblotting 
Western immunoblotting was performed against various antibodies for specific HDAC, 
HAT and HMT enzymes (Histone Deacetylase (HDAC) sampler kit #9928; Lysine 
Acetyltransferase sampler kit #8686 and Lysine Methyltransferase sampler kit #8694) as 
well as acetylated and methylated marks on H3 and H4 (Acetyl-Histone H3 sampler kit 
#9927; Acetyl-Histone H4 sampler kit #8346; Tri-Methyl-Histone H3 sampler kit #9783; 
and Di-methyl-Histone H3 sampler kit #9847). All primary antibodies were obtained from 
Cell Signalling Technology, Danvers, MA, USA (Table 2.8). 
Table 2.8: List of Antibodies used in Western Immunoblotting 
Antibody Dilution Blocking Buffer Isotope 
Catalogue 
Number 
Anti-HDAC1 1:1000 5% nonfat, dry milk in TBS-T* Mouse #5356 
Anti-HDAC2 1:1000 5% nonfat, dry milk in TBS-T Mouse #5113 
Anti-HDAC4 1:2000 5% BSA in TBS-T Rabbit #7628 
Anti-HDAC6 1:1000 5% BSA in TBS-T Rabbit #7558 
Anti-CBP 1:1000 5% BSA in TBS-T Rabbit #7389 
Anti-AcCBP/p300 1:1000 5% BSA in TBS-T Rabbit #4771 
Anti-PCAF 1:1000 5% BSA in TBS-T Rabbit #3378 
Anti-GCN5L2 1:1000 5% BSA in TBS-T Rabbit #3305 
Anti-G9a/EHMT2 1:1000 5% BSA in TBS-T Rabbit #3306 
Anti-ESET 1:1000 5% BSA in TBS-T Rabbit #2196 
Anti-RBBP5 1:1000 5% BSA in TBS-T Rabbit #13171 
Anti-ASH2L 1:2000 5% BSA in TBS-T Rabbit #5019 
Anti-SET 8 1:1000 5% BSA in TBS-T Rabbit #2996 
Anti-SET 7-9 1:1000 5% BSA in TBS-T Rabbit #2813 
Anti-AcH4K5 1:1000 5% BSA in TBS-T Rabbit #8647 
Anti-AcH4K8 1:1000 5% BSA in TBS-T Rabbit #2594 
Anti-AcH4K12 1:1000 5% BSA in TBS-T Rabbit #13944 
Anti-AcH3K9 1:1000 5% BSA in TBS-T Rabbit #9649 
Anti-AcH3K14 1:1000 5% BSA in TBS-T Rabbit #7627 
Anti-AcH3K18 1:1000 5% BSA in TBS-T Rabbit #13998 
Anti-AcH3K27 1:1000 5% BSA in TBS-T Rabbit #8173 




Table 2.8: List of Antibodies used in Western Immunoblotting (continued) 
Anti-H3K4me2 1:1000 5% BSA in TBS-T Rabbit #9725 
Anti-H3K9me2 1:1000 5% BSA in TBS-T Rabbit #4658 
Anti-H3K27me2 1:1000 5% BSA in TBS-T Rabbit #9728 
Anti-H3K36me2 1:1000 5% BSA in TBS-T Rabbit #2901 
Anti-H3K79me2 1:1000 5% BSA in TBS-T Rabbit #5427 
Anti- H3K4me3 1:1000 5% BSA in TBS-T Rabbit #9751 
Anti-H3K9me3 1:1000 5% BSA in TBS-T Rabbit #13969 
Anti- H3K27me3 1:1000 5% BSA in TBS-T Rabbit #9733 
Anti-H3K36me3 1:1000 5% BSA in TBS-T Rabbit #4909 
Anti- H3K79me3 1:1000 5% BSA in TBS-T Rabbit #4260 
Anti-H3 1:2000 5% nonfat, dry milk in TBS-T Rabbit #4499 
H4 1:1000 5% nonfat, dry milk in TBS-T Mouse #2935 








1:2000 5% nonfat, dry milk in TBS-T Horse #7076 
* TBS-T: Tris-buffered saline with 0.1% Tween ® 20 Detergent 
Cell extracts were heated at 95oC for 5 min (to denature proteins and reduce protein-protein 
interactions), were allowed to cool down for a few minutes and then vortexed and spinned 
down briefly. Proteins were then separated by using SDS polyacrylamide gels of different 
acrylamide concentration (10, 12, 10-20%, Novex Tris-Glycine pre-casted Gel, Invitrogen 
), according to the molecular weight of the protein of interest. Twenty (20) μg of nuclear and 
10 μg of total histone protein extracts were then loaded onto a polyacrylamide gel and 
electrophoresis was carried out in SDS running buffer 1X (Table 2.9) at 80-120V for 3-4h, 
using mini gel tank and mini blot module (Invitrogen). A protein ladder (PageRuler plus 
Prestained Protein Ladder, 10-250kDa, ThermoScientific) was also loaded and separated in 
the SDS gel. After being separated, proteins were transferred electrophoretically onto PVDF 
membranes (either 0.45 or 0.2μm, according to the protein’s molecular weight – PVDF 
membranes thickness of 100 µm with pore sizes of  0.25 or 0.45 µm were used. High and 
midium molecular weight proteins were blotted using a 0.45 µm pore size membrane, while 
0.25 µm pore size membrane was used for low molecular weight proteins of  <20k Da), by 




obtained from BioRad (Hercules, CA, USA) at pre-determined running conditions. Next, 
blots were blocked in 5% (w/v) non-fat milk powder in Tris-buffered saline with 0.1% 
Tween ® 20 Detergent (TBS-T) buffer (Table 2.9) for at least 1h at RT, under gentle 
agitation. After blocking, membranes were washed three times with TBS-T (~5min each 
time) and incubated overnight at 4oC, under agitation, with the appropriate primary 
antibodies, diluted in 5% milk or BSA, according to the manufacturer’s instructions (see 
Table 2.8). The following day, membranes were washed three times in TBS-T buffer (~5min 
each time) and were then incubated with the appropriate horseradish peroxidase-conjugated 
secondary antibody for at least 1 hr at RT, under agitation. Then, membranes were washed 
three times in TBS-T and finally, labelled protein bands were visualized using the 
SuperSignal West Pico PLUS Chemiluminescent Substrate kit from Thermo Scientific 
(Waltham, MA, USA), according to the manufacturer’s instructions. Protein bands were 
detected utilizing the G:BOX Chemi XX6/XX9 gel imaging system (Syngene, Cambridge, 
UK). 
Table 2.9: List and composition of Buffers used for Western immunoblotting 
Buffer Components 
SDS running buffer 10X 
250 mM  [Tris Base], 1.92M [Glycine], 1% [SDS], pH 8.3-8.5 
Tris base : 30.3 g 
Glycine : 144 g 
SDS : 10 g 
dH2O : up to 1 L 
SDS running buffer 1X 
25mM [Tris-base], 192mM [Glycine], 0.1% [SDS] 
1:10 dilution of the SDS running buffer 10X with dH2O 
Transfer Buffer 10X 
250 mM [Tris Base], 1.92M [Glycine], pH 8.3-8.5 
Tris base : 30.3 g 
Glycine : 144 g 
dH2O : up to 1 L 
Transfer Buffer 1X 
25mM [Tris-base], 192mM [Glycine], 0.5% [SDS], 20% (v/v) 
[Methanol] 
TB 1X: 100ml (1:10 dilution) 
SDS: 5ml 
MeOH: 200ml 
dH2O : up to 1 L 
Tris Buffered Saline (TBS) 10X 
200 mM [Tris Base], 1.5M [NaCl], pH 7.5-7.6 
Tris Base: 87.66 g 
NaCl: 24.22 g 
Tris Buffered Saline 1X with 
0.1% Tween-20 (TBST) 
20 mM [Tris Base], 150 mM [NaCl], 0.1% [Tween 20] in dH2O 






2.5 Statistical analysis 
In all sets of experiments (apart from viability assays), data were expressed as mean 
values ± standard deviation (SD). For viability assays, data were expressed as 95% 
confidence intervals (CI) . All calculations were performed on Microsoft Office Excel 2016 
software and comparisons and normalizations were made between the untreated control and 
exposure (treated) groups. 
Prior to any statistical analysis, the Shapiro Wilk (small sample sizes) normality test was 
performed to detect whether the sets of data are following the Gaussian (normal) distribution. 
Data passed the normality test [or lognormality test (values transformed into logarithms to 
create a Gaussian distribution)] and parametric tests were utilized accordingly. 
Statistical significance for viability assays was assessed by one-way analysis of variance 
(one-way ANOVA) with Tukey’s test for multiple comparisons (comparison between 
control and treated cells as well as between different treatment groups). CC50 values were 
calculated and expressed as 95% confidence intervals. GraphPad Prism 9.0.2 was used for 
statistical analysis and CC50 value calculations.   
Statistical analysis for flow cytometry data was performed by one-way ANOVA with 
Tukey’s test for multiple comparisons. Student's t-test was also used to compare the mean 
values for HDAC/HAT activity assays and western immunoblotting densitometry data 
(densitometry performed using Image J software V 1.4.3.67). IBM SPSS Statistics v.25 
software was utilized for statistical analysis.  
For all statistical analysis, a value of p < 0.05 was considered statistically significant and 






















Results I – Cytotoxic effects of 














3.1 Profiling of ITCs-mediated Cytotoxic Effects Using an in vitro model of Malignant 
Melanoma  
3.1.1 Cytotoxicity Profile: Determination of Cell Viability 
To investigate the anti-melanoma effect of the five ITCs of interest (SFN, IBN, AITC, BITC 
and PEITC), in an in vitro experimental model of malignant melanoma consisting of human 
i) malignant melanoma (A375), ii) non-tumorigenic immortalized keratinocytes (HaCaT), 
iii) non-melanoma epidermoid carcinoma (A431), iv) melanoma derived from brain 
metastasis (VMM1), v) melanoma derived from lymph node metastasis Hs294T and vi) 
murine malignant melanoma (B16F10) cell lines. As keratinocytes and melanocytes are the 
main cells in the epidermis, this project aimed to determine the cytotoxic effect of these ITCs 
on human malignant melanoma (A375) cells in comparison to normal (HaCaT) keratinocytes 
and non-melanoma skin cancer (A431) cells. In addition, the cytotoxic potential of these 
ITCs not only in primary melanoma (A375) cells but also in metastatic-derived (VMM1 and 
Hs294T) ones was assessed. In order to address these objectives, the optimal experimental 
conditions capable of inducing cytotoxicity determined, in all the above-mentioned cell 
lines, by performing time-course (24 and 48hrs of exposure) and dose-response (2.5-50μM) 
kinetic experiments where cell viability was utilized as an endpoint of cytotoxicity, by using 
the resazurin assay.  
Overall, it was shown that treatment with all 5 ITCs significantly decreased the viability of 
A375 (Figs. 3.1a, 3.2a, 3.3a, 3.4a, 3.5a), Hs294T (Figs. 3.1d, 3.2d, 3.3d, 3.4d, 3.5d) and 
B16F10 (Figs. 3.1f, 3.2f, 3.3f, 3.4f, 3.5f) cells in a concentration- and time-dependent 
manner in comparison to VMM1 (Figs. 3.1e, 3.2e, 3.3e, 3.4e, 3.5e), A431 (Figs. 3.1c, 3.2c, 
3.3c, 3.4c, 3.5c) and HaCaT (Figs. 3.1b, 3.2b, 3.3b, 3.4b, 3.5b) cells. In the latter 3 cell lines, 
a noteworthy inhibition was evident, at concentrations of 25μΜ onwards. Reduced cell 
viability levels were reported, in our experiments, in as early as 24hrs of exposure in all 5 
ITCs in A375, Hs 294T and B16F10 cells although this cytotoxic effect was even more 
profound after 48hrs of exposure. 
In particular, regarding SFN, a reduction on viability levels of A375  (Fig. 3.1a) and B16F10 
(Fig. 3.1f) cells was observed at 10 µM onwards. At this concentration the number of A375 
viable cells was approximately 80% and 70%, at 24 and 48hrs of exposure respectively, 
while in B16F10 cells, 89% (at 24hrs) and 62% (at 48hrs). In Hs294T (Fig 3.1d), SFN 
treatment resulted in a more profound reduction in viability even at 5μM [by reaching 68% 





Figure 3.1: The effect of SFN in cell viability in an in vitro model of human malignant 
melanoma. Our in vitro model consisted of: a) malignant melanoma (A375), b) 
immortalized, normal keratinocyte (HaCaT), c) non-melanoma epidermoid carcinoma 
(A431), d) metastatic melanoma derived from lymph node (Hs294T), e) metastatic 
melanoma derived from brain (VMM1) and f) murine malignant melanoma (B16F10) cells. 
All cells were seeded into 96-well plates and next day they were exposed to a range of 
concentrations (2.5-50μΜ) of SFN for 24 and 48hrs. Cell viability was evaluated using the 
resazurin assay and was expressed as mean percentage of  0.1% v/v DMSO-treated (control) 
cells (as SFN was diluted in DMSO). Data shown are mean percentage of viable cells (n=5) 
expressed as 95%CI and are representative of three independent experiments. Statistical  
analysis performed using one-way ANOVA with Tukey’s test for multiple comparisons and 
significance was set at *, p<0.05, **, p<0.01, ***, p<0.001, relative to corresponding 
(DMSO) controls. 
As far as IBN, our data showed reduced viability levels as early as 24hrs of exposure, in both 
A375 (Fig 3.2a) and Hs294T (Fig 3.2d) cells at 10µM upwards. However, the reduction of 
cell viability was even greater at 48hrs of exposure and even at a concentration as low as 
5μΜ. The viability of B16F10 cells (Fig 3.2f) was greatly reduced (at 10μΜ onwards) to 





Figure 3.2: The effect of IBN in cell viability in an in vitro model of human malignant 
melanoma. Our in vitro model consisted of: a) malignant melanoma (A375), b) 
immortalized, normal keratinocyte (HaCaT), c) non-melanoma epidermoid carcinoma 
(A431), d) metastatic melanoma derived from lymph node (Hs294T), e) metastatic 
melanoma derived from brain (VMM1) and f) murine malignant melanoma (B16F10) cells. 
All cells were seeded into 96-well plates and next day they were exposed to a range of 
concentrations (2.5-50μΜ) of IBN for 24 and 48hrs. Cell viability was evaluated using the 
resazurin assay and was expressed as mean percentage of 0.1% v/v ETHO-treated (control) 
cells (as IBN was diluted in ETOH). Data shown are mean percentage of viable cells (n=5) 
expressed as 95%CI and are representative of three independent experiments. Statistical 
analysis performed using one-way ANOVA with Tukey’s test for multiple comparisons and 
significance was set at *, p<0.05, **, p<0.01, ***, p<0.001, relative to corresponding 
(ETOH) controls. 
Similarly, AITC was also found to reduce cell viability, at 10μM upwards, in A375 (Fig 
3.3a), Hs294T (Fig 3.3d) and B16F10 (Fig 3.3f) cells. Specifically, at this concentration, 
AITC reduced the number of viable A375 cells to 80% and 70% after 24 and 48hrs of 
exposure respectively. Similarly, in Hs294T cells, cell viability was reduced to 85% and 





Figure 3.3: The effect of AITC in cell viability in an in vitro model of human malignant 
melanoma. Our in vitro model consisted of: a) malignant melanoma (A375), b) 
immortalized, normal keratinocyte (HaCaT), c) non-melanoma epidermoid carcinoma 
(A431), d) metastatic melanoma derived from lymph node (Hs294T), e) metastatic 
melanoma derived from brain (VMM1) and f) murine malignant melanoma (B16F10) cells. 
All cells were seeded into 96-well plates and next day they were exposed to a range of 
concentrations (2.5-50μΜ) of AITC for 24h and 48hrs. Cell viability was evaluated using 
the resazurin assay and was expressed as mean percentage of 0.1% v/v DMSO-treated 
(control) cells (as AITC was diluted in DMSO). Data shown are mean percentage of viable 
cells (n=5) expressed as 95%CI and are representative of three independent experiments. 
Statistical analysis performed using one-way ANOVA with Tukey’s test for multiple 
comparisons. and significance was set at *, p<0.05, **, p<0.01, ***, p<0.001, relative to 
corresponding (DMSO) controls. 
As far as BITC, a 30% reduction in cell viability was observed at 2.5 μΜ onwards in A375 
cells at 48hrs of exposure (Fig 3.4a). At this condition, the viability of Hs294T (Fig 3.4d) 
and B16F10 (Fig 3.4f) cells was not significantly affected, while a noteworthy reduction was 






Figure 3.4: The effect of BITC in cell viability in an in vitro model of human malignant 
melanoma. Our in vitro model consisted of: a) malignant melanoma (A375), b) 
immortalized, normal, keratinocyte (HaCaT), c) non-melanoma epidermoid carcinoma 
(A431), d) metastatic melanoma derived from lymph node (Hs294T), e) metastatic 
melanoma derived from brain (VMM1) and f) murine malignant melanoma (B16F10) cells. 
All cells were seeded into 96-well plates and the next day they were exposed to a range of 
concentrations (2.5-50μΜ) of BITC for 24h and 48hrs. Cell viability was evaluated using 
the resazurin assay and was expressed as mean percentage of 0.1% v/v DMSO-treated 
(control) cells (as BITC was diluted in DMSO). Data shown are mean percentage of viable 
cells (n=5) expressed as 95%CI and are representative of three independent experiments. 
Statistical analysis performed using one-way ANOVA with Tukey’s test for multiple 
comparisons  and significance was set at *, p<0.05, **, p<0.01, ***, p<0.001, relative to 
corresponding (DMSO) controls. 
Finally, PEITC reduced cell viability, in A375 (~61%) (Fig 3.5a) and B16F10 (~69%) (Fig 
3.5f) cells at 25μΜ onwards, at 24hrs, whereas a greater reduction was observed at 10μΜ 
and 48hrs of exposure in both A375 (~53%) and B16F10 (~64%) cells. The reduction in cell 
viability levels was even further with Hs294T cells showing a 20% drop even at 5μΜ of 





Figure 3.5: The effect of PEITC in cell viability in an in vitro model of human malignant 
melanoma. Our in vitro model consisted of: a) malignant melanoma (A375), b) 
immortalized, normal, keratinocyte (HaCaT), c) non-melanoma epidermoid carcinoma 
(A431), d) metastatic melanoma derived from lymph node (Hs294T), e) metastatic 
melanoma derived from brain (VMM1) and f) murine malignant melanoma (B16F10) cells. 
All cells were seeded into 96-well plates and the next day they were exposed to a range of 
concentrations (2.5-50μΜ) of PEITC for 24 and 48hrs. Cell viability was evaluated using 
the resazurin assay and was expressed as mean percentage of 0.1% v/v DMSO-treated 
(control) cells (as PEITC was diluted in DMSO). Data shown are mean percentage of viable 
cells (n=5) expressed as 95%CI and are representative of three independent experiments. 
Statistical analysis performed using one-way ANOVA with Tukey’s test for multiple 
comparisons.  and significance was set at *, p<0.05, **, p<0.01, ***, p<0.001, relative to 
corresponding (DMSO) controls. 
On the contrary, no significant effect was observed on cell viability levels of A431 (Fig. 
3.1c, 3.2c, 3.3c, 3.4c, 3.5c), VMM1 (Fig. 3.1e, 3.2e, 3.3e, 3.4e, 3.5e) and HaCaT (Fig. 3.1b, 
3.2b, 3.3b, 3.4b, 3.5b) cells, under the same experimental conditions of ITC exposure, 
indicating a resistance against ITC-induced cytotoxicity. Specifically, the cytotoxic 
concentration, CC50 values (expressed with 95% confidence intervals),for each cell line, at 
24 and 48hrs of ITC exposure, were calculated and summarized in Table 3.1. The overall 
statistical significance regarding the observed differences between the different treatment 




significant reduction in cell viability was observed in all cell lines at concentrations of ITCs 
of 25μΜ upwards suggesting an induction of cytotoxicity exerted by these compounds. 
Taken altogether, our data suggest that A375, Hs294T and B16F10 cell lines are more 
sensitive to the cytotoxicity induced by all ITCs when compared to HaCaT, VMM1 and 
A431 ones. Furthermore, it appears that SFN, PEITC and IBN showed a higher cytotoxic 
potency against Hs294T cells while BITC and AITC were more potent against A375 cells. 
Overall, among all ITCs, BITC was shown to be the most potent whereas AITC the least 
potent one.  
Based on the work described above, it was determined that a concentration of 10μΜ was the 
optimum one, in designing the next set of experiments, for further characterizing the 
cytotoxic profile of ITCs in our experimental in vitro melanoma model. This concentration 
(10μΜ) was chosen, as a significant reduction in viability levels was observed mainly in 
A375 melanoma cells,  reflecting a selective specificity of ITCs towards the primary 
melanoma cell line. In higher concentrations, ITCs anticancer response is increased but 
demonstrated by a pattern of non-specificity towards both tumorigenic and non-tumorigenic 
cells.    
Table 3.1: CC50 values of SFN, IBN, AITC, BITC and PEITC in A375, HaCaT, A431, 
VMM1, Hs294T and B16F10 cells, after 24 and 48hrs of exposure.  






12.49         
[10.45,14.92] 
27.16         
[25.54, 28.92] 
46.02           
[40.71, 53.26] 
53.35        
[50.82, 56.70] 
8.501          
[7.82, 9.238] 






12.77      
[11.71,13.94] 
22.46         
[17.20, 29.55] 
22.92           
[20.47, 28.96 
31.96        
[29.31, 34.92] 
7.114          
[6.73, 7.52] 







10.90          
[9.40, 12.76] 
21.51         
[19.19, 24.11] 
52.96           
[44.11, 67.68] 
42.43        
[40.49, 44.60] 
13.89         
[12.81, 15.07] 






8.65         
[8.08, 9.27] 
21.12          
[16.56, 27.04] 
19.12            
[16.68, 21.91] 
26.44        
[24.87, 28.24] 
8.525          
[7.89, 9.20] 
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Table 3.1: CC50 values of SFN, IBN, AITC, BITC and PEITC in A375, HaCaT, A431, VMM1, Hs294T and 






10.71       
[9.92, 11.56] 
ND 
36.43           
[34.88, 38.05] 
ND 
7.602          
[6.86, 8.44] 




4.37          
[4.04, 4.72] 
26.49         
[20.82, 33.92] 
16.82            
[15.81, 17.89]  
45.37        
[37.18, 58.70] 
6.284          
[5.89, 6.706] 







19.13      
[14.33, 25.3] 
44.40          
[41.23, 44.79] 
26.89        
[25.07, 28.91] 
38.19        
[36.61, 39.94] 
12.76        
[11.99, 13.60] 




10.31     
[8.843,12.18] 
34.23         
[28.03, 41.22] 
19.78            
[17.00, 21.75] 
24.25         
[22.50, 26.04] 
10.24          
[9.208, 11.36] 
15.74          
[14.95, 16.57] 
*CC50 are expressed as 95% CI, calculated using GraphPad Prism. 
Table 3.2: Statistical significance of the differences among SFN, IBN, AITC, BITC 
and PEITC in A375, HaCaT, A431, VMM1, Hs294T and B16F10 cells at 24 and 
48hrs of exposure.  
 24h 48h 
 P value Asterisk P value Asterisk 
A375 0.0318 * <0.0001 *** 
HaCaT 0.2763 ns 0.0029 ** 
A431 0.8251 ns 0.0528 ns 
Hs 294T <0.0001 *** 0.0052 ** 
VMM1 0.1504 ns 0.0057 ** 
B16F-10 0.0053 ** 0.0007 *** 
Statistical significance was assessed by one-way ANOVA with Tukey’s test for multiple 
comparisons. Using GraphPad Prism. Significance was set at *, p<0.05, **, p<0.01, ***, p<0.001. 
 
3.1.2 Cytotoxicity Profile: Determination of Cell Cycle Growth Arrest 
In this set of experiments, we have focused on determining the effect of 10μΜ of all 5 ITCs 
in affecting cell cycle progression in all cell lines at both 24 and 48hrs of exposure. To do 
so, the FxCycle PI/RNase staining solution was utilised in order to quantitate the content of 
DNA under each phase of the cell cycle and thereby analyse the distribution of cells in each 
phase of the cell cycle by flow cytometry (Figure S1 under supplementary material). 
Overall, in A375 cells, an induction of the G2/M phase was observed by all ITCs but to a 
variable degree (Fig. 3.6). Specifically, exposure to BITC (Fig. 3.6d) caused the highest 
increase in the number of cells accumulated at the G2/M phase, which was intensified after 
48hrs of treatment, followed by IBN (Fig. 3.6b) which also exhibited a similar effect. 




the G2/M phase, when compared to untreated cells, but to a lower extent. This pattern was 
followed by a significant reduction in the number of cells at the G1 phase for all ITCs. 
Furthermore, the S phase remained relatively unaffected under treatment with BITC (Fig. 
3.6d), IBN (Fig. 3.6b) and SFN (Fig. 3.6a) but not for PEITC (Fig. 3.6e). Interestingly, 
exposure to AITC although initially showed an induction at the G2/M growth arrest in A375 
cells (alongside with reduced levels of the G1 phase), a shift of cell accumulation back to 
the G1 phase was observed, after 48hrs of exposure, with such levels reaching control ones 
(Fig. 3.6c). No significant differences were observed in the distribution of cells in S phase 
between AITC-treated and untreated (control) cells at both time points of exposure. Finally, 
our data showed a profound elevation in the number of dead cells, observed as an increase 






Figure 3.6: The effect of ITCs in cell cycle progression of A375 cells. Cells were exposed 
to 10μΜ of a) SFN, b) IBN, c) AITC, d) BITC and e) PEITC at 24 and 48hrs of exposure. 
The distribution of cells in sub-G1, G1, S and G2/M phases of the cell cycle were recorded 
by flow cytometry and quantified as percentage of cells (based on cellular DNA content) 
present in each phase of the cell cycle. Results are expressed as mean ± SD of three 
replicates. Data are representatives of three independent experiments. Statistical analysis 
performed by one-way ANOVA with Tukey’s test for multiple comparisons. Asterisks 
indicate statistical significance at *, p<0.05, **, p<0.01, ***, p<0.001 when compared to 
their respective untreated control cells.  
Similarly, in metastatic melanoma derived from lymph node (Hs294T) cells, both BITC (Fig. 




both time points of exposure, although the effect was not as potent as in A375 cells. In 
addition, AITC did not cause any significant effect in the distribution of Hs294T cells in any 
of the cell cycle phases when compared to untreated cells (Fig. 3.7c). Alternatively, BITC 
(Fig. 3.7d) was the most potent in blocking cell cycle progression followed by PEITC (Fig. 
3.7e). Under these conditions, an increased accumulation of cells at the G2/M phase was 
accompanied by a reduced distribution of cells at the G1 phase, a pattern similar with that 
observed also under treatment with SFN and IBN (Figs. 3.7a & 3.7b respectively). It is 
noteworthy that the effect of SFN and IBN in growth arresting cells at the G2/M phase was 
greater at 24hrs of exposure as opposed to 48hrs where the percentage of cellular distribution 
reached control levels. In general, treatment with these two ITCs did not have a significant 
effect on levels of growth arrest as most cells were found at the G1 phase (Figs. 3.7a & 3.7b).  
In addition, our results showed that 24hrs of exposure to BITC (Fig. 3.7d) and PEITC (Fig. 
3.7e) did cause a significant elevation of cells at the sub-G1 and S phases, compared to 





Figure 3.7: The effect of ITCs in cell cycle progression of Hs294T cells. Cells were 
exposed to10μΜ of a) SFN, b) IBN, c) AITC, d) BITC and e) PEITC at 24 and 48hrs of 
exposure. The distribution of cells in sub-G1, G1, S and G2/M phases of the cell cycle were 
recorded by flow cytometry and quantified as percentage of cells (based on cellular DNA 
content) present in each phase of the cell cycle. Results are expressed as mean ± SD of three 
replicates and are representatives of three independent experiments. Statistical analysis 
performed by one-way ANOVA with Tukey’s test for multiple comparisons. Asterisks 
indicate statistical significance at *, p<0.05, **, p<0.01, ***, p<0.001 when compared to 
their respective untreated control cells.  
With respect to metastatic melanoma derived from brain (VMM1) cells, it was shown that 




of cells at the G2/M phase, followed by a reduction of the G1 phase while the S phase 
remained relatively unaffected. On another note, 24hrs exposure to BITC (Fig. 3.8d) and 
PEITC (Fig. 3.8e) induced growth arrest at the S phase while at 48hrs of exposure, a shift 
towards the G2/M phase was reported (alongside with a further reduction of cells at the G1 
phase). In addition, both BITC and PEITC significantly increased the number of cells at the 
sub-G1 phase, after 48hrs of exposure. Interestingly, a marked reduction of the G1 alongside 
with an increase in S phase were observed when VMM1 cells were exposed to AITC in both 
at both time points (Fig. 3.8c).   
 
Figure 3.8: The effect of ITCs in cell cycle progression of VMM1 cells. Cells were 
exposed to10μΜ of a) SFN, b) IBN, c) AITC, d) BITC and e) PEITC at 24 and 48hrs of 




recorded by flow cytometry and quantified as percentage of cells (based on cellular DNA 
content) present in each phase of the cell cycle. Results are expressed as mean ± SD of three 
replicates and are representatives of three independent experiments. Statistical analysis 
performed by one-way ANOVA with Tukey’s test for multiple comparisons. Asterisks 
indicate statistical significance at *, p<0.05, **, p<0.01, ***, p<0.001 when compared to 
their respective untreated control cells.  
In non-melanoma epidermoid carcinoma (A431) cells, an elevation in G2/M phase was 
observed accompanied by a reduction in G1 phase after 24hrs of exposure to BITC and 
PEITC respectively (Figs. 3.9d & 3.9e), an effect which was maintained even at 48hrs of 
exposure to BITC, PEITC and SFN as well (although not as profound) (Fig. 3.9a). Moreover, 
PEITC (Fig. 3.9e) and IBN (Fig. 3.9b) reduced the number of cells accumulated in S phase, 
a pattern which was more profound at 24hrs of exposure while at 48hrs the number of cells 
was reported to be comparable to control levels. Interestingly, exposure to AITC caused no 
significant differences in the distribution of cells at all phases of cell cycle (Fig. 3.9c). 
Finally, the population of dead cells (showed as cellular distribution at the sub-G1 phase) 
was significantly enhanced after exposure to BITC, PEITC and slightly to IBN but not with 





Figure 3.9: The effect of ITCs in cell cycle progression of A431 cells. Cells were exposed 
to10μΜ of a) SFN, b) IBN, c) AITC, d) BITC and e) PEITC at 24 and 48hrs of exposure. 
The distribution of cells in sub-G1, G1, S and G2/M phases of the cell cycle were recorded 
by flow cytometry and quantified as percentage of cells (based on cellular DNA content) 
present in each phase of the cell cycle. Results are expressed as mean ± SD of three replicates 
and are representatives of three independent experiments. Statistical analysis performed by 
one-way ANOVA with Tukey’s test for multiple comparisons.  Asterisks indicate statistical 
significance at *, p<0.05, **, p<0.01, ***, p<0.001 when compared to their respective 
untreated control cells.  
In transformed, normal, keratinocyte (HaCaT) cells, exposure to SFN (Fig. 3.10a) and IBN 




phase at 24hrs of exposure, an effect which was not persistent at 48hrs of similar exposure. 
In addition, our results showed that BITC growth arrested cells at the G2/M phase which 
was further accompanied with a reduction of cells in S phase, during 24hrs of exposure (Fig. 
3.10d). However, at 48hrs of exposure, the cellular distribution at G2/M and S phases was 
reduced to control levels together with that of the G1 phase. Moreover, exposure to AITC 
and PEITC exerted a similar effect (Figs. 3.10c & 3.10e, respectively) indicated as a decrease 
of cells at the G1 phase along with a slight increase in G2/M and S phases. In addition, a 
decrease in S phase was observed at 24hrs of exposure (but not at 48hrs) in cells exposed to 
AITC (Fig. 3.10c). Finally, the number of dead cells (sub-G1 phase) remained quite low 





Figure 3.10: The effect of ITCs in cell cycle progression of HaCaT cells. Cells were 
exposed to10μΜ of a) SFN, b) IBN, c) AITC, d) BITC and e) PEITC at 24 and 48hrs of 
exposure. The distribution of cells in sub-G1, G1, S and G2/M phases of the cell cycle were 
recorded by flow cytometry and quantified as percentage of cells (based on cellular DNA 
content) present in each phase of the cell cycle. Results are expressed as mean ± SD of three 
replicates and are representatives of three independent experiments. Statistical analysis 
performed by one-way ANOVA with Tukey’s test for multiple comparisons. Asterisks 
indicate statistical significance at *, p<0.05, **, p<0.01, ***, p<0.001 when compared to 
their respective untreated control cells.  
On the other hand, the kinetics of cell cycle growth arrest in B16F10 cells remained relatively 




observed a slight increase of cells at the G2/M phase, whereas those at the G1 phase were 
slightly decreased under BITC and PEITC exposure in both time points (Figs 3.11d & 3.11e). 
Furthermore, PEITC showed an increased accumulation of cells at the S phase and 
subsequently a diminished G2/M, after 48hrs of exposure (Fig. 3.11e). Overall, our data 
suggest that exposure to all 5 ITCs exerted a potent effect in growth arresting cells at various 
phases of the cell cycle when compared to unexposed (control) cells.  
 
Figure 3.11: The effect of ITCs in cell cycle progression of B16F10 cells. Cells were 
exposed to10μΜ of a) SFN, b) IBN, c) AITC, d) BITC and e) PEITC at 24 and 48hrs of 
exposure. The distribution of cells in sub-G1, G1, S and G2/M phases of the cell cycle were 
recorded by flow cytometry and quantified as percentage of cells (based on cellular DNA 




replicates and are representatives of three independent experiments. Statistical analysis 
performed by one-way ANOVA with Tukey’s test for multiple comparisons. Asterisks 
indicate statistical significance at *, p<0.05, **, p<0.01, ***, p<0.001 when compared to 
their respective untreated control cells.  
3.1.3: Cytotoxicity Profile: Determination of Cell Death Induction 
In this set of experiments, we used flow cytometry to distinguish between populations of 
apoptotic and necrotic cells. All cell lines were subjected to 10μΜ of each one of the 5 ITCs 
for 24 and 48hrs of exposure. To distinguish between these two modes of cell death, the Cell 
Event Caspase 3/7 Green detection reagent was utilized as a detector of activated caspase 3 
and caspase 7 in apoptotic cells while DAPI was utilized as an indicator of necrosis. Flow 
cytometry histograms for all experiments are represented in Figure S2 (under supplementary 
material). 
In particular, in A375 cells, our data showed that SFN, IBN, BITC and PEITC were able to 
induce cell death, during the first 24h, an effect which was intensified over time, in a manner 
where live cells were reduced, while necro-apoptotic cells increased markedly (Fig. 3.12). 
Apoptotic induction in these cells was indicated by the increased levels of cells stained 
positive for activated caspase 3/7 compared to untreated ones. BITC (Fig. 3.12d) was the 
most potent one in triggering cell death followed by PEITC (Fig. 3.12e). The population of 
cells that had undergone apoptosis, during 24hrs of exposure to BITC and PEITC, was higher 
compared to the necrotic one while at 48hrs, a significant elevation of necrosis was noted. 
Moreover, SFN (Fig. 3.12a) and IBN (Fig. 3.12b) showed similar levels of necrosis and 





Figure 3.12: ITCs-induced cell death in A375 cells. Cells were exposed to 10μΜ of a) 
SFN, b) IBN, c) AITC, d) BITC and e) PEITC for 24 and 48hrs and the percentage of live, 
apoptotic and necrotic cells was recorded by flow cytometry.  Results are expressed as mean 
± SD of three replicates and are representatives of three independent experiments. Statistical 
analysis performed by one-way ANOVA  with Tukey’s test for multiple comparisons. 
Asterisks denote statistical significance at *, p<0.05, **, p<0.01, ***, p<0.001 when 
compared to their respective untreated control cells.  
Next, in Hs294T cells, a slight increase in the percentage of dead cells after 24hrs of exposure 
to SFN (~18%) and IBN (~16%) was observed as compared to control (~13%) with similar 
levels being recorded at 48hrs as well (Figs. 3.13a & 3.13b). However, excessive cell death 




particular, a dramatic reduction in the number of viable cells followed by a marked increase 
in the number of caspase 3/7 positive-stained (apoptotic) and to a greater extent of DAPI-
positive (necrotic) cells was observed at 24hrs post-exposure to BITC and PEITC. 
Interestingly, at 48hrs of exposure to these two ITCs, the number of apoptotic cells was 
decreased while the necrotic one increased significantly, reaching approximately 48% and 
46% under BITC and PEITC exposure respectively.  
 
Figure 3.13: ITCs-induced cell death in Hs294T cells. Cells were exposed to 10μΜ of a) 
SFN, b) IBN, c) AITC, d) BITC and e) PEITC for 24 and 48hrs and the percentage of live, 
apoptotic and necrotic cells was recorded by flow cytometry. Results are expressed as mean 
± SD of three replicates and are representatives of three independent experiments. Statistical 




Asterisks denote statistical significance at *, p<0.05, **, p<0.01, ***, p<0.001 when 
compared to their respective untreated control cells.  
Furthermore, when VMM1 cells were exposed to all 5 ITCs, an increase in dead cells was 
observed, especially under exposure to SFN, IBN, BITC and PEITC. However, such effect 
was not as significant in A375 and Hs294T cells (Fig. 3.14). In contrast, exposure to AITC 
did not alter the levels of dead cells (Fig. 3.14c). More specifically, at 24hrs of exposure, an 
elevation in the number of DAPI-positive cells was noted by SFN (Fig. 3.14a), IBN (Fig. 
3.14b), BITC (Fig. 3.14d) and PEITC (Fig. 3.14e) while BITC and PEITC also induced 
apoptosis at this time point. However, at 48hrs, PEITC exposure reduced the number of 
apoptotic cells whereas BITC and IBN exposure increased the number of apoptotic cells 





Figure 3.14: ITCs-induced cell death in VMM1 cells. Cells were exposed to 10μΜ of a) 
SFN, b) IBN, c) AITC, d) BITC and e) PEITC for 24 and 48hrs and the percentage of live, 
apoptotic and necrotic cells was recorded by flow cytometry. Results are expressed as mean 
± SD of three replicates and are representatives of three independent experiments. Statistical 
analysis performd by one-way ANOVA  with Tukey’s test for multiple comparisons. 
Asterisks denote statistical significance at *, p<0.05, **, p<0.01, ***, p<0.001 when 
compared to their respective untreated control cells.  
In non-melanoma epidermoid carcinoma (A431) cells, increased levels of cell death were 
observed after exposure to BITC and PEITC but not with SFN, IBN and AITC (Fig. 3.15). 
In particular, BITC induced caspase 3/7 activation at 24hrs of exposure (Fig. 3.15d), an 




exposure to PEITC resulted in elevated levels of both caspase3/7-positive and DAPI-positive 
cells but only 48hrs post exposure (Fig. 3.15e).  
 
Figure 3.15: ITCs-induced cell death in A431 cells. Cells were exposed to 10μΜ of a) 
SFN, b) IBN, c) AITC, d) BITC and e) PEITC for 24 and 48hrs and the percentage of live, 
apoptotic and necrotic cells was recorded by flow. Results are expressed as mean ± SD of 
three replicates and are representatives of three independent experiments. Statistical analysis 
performd by one-way ANOVA  with Tukey’s test for multiple comparisons. Asterisks 
denote statistical significance at *, p<0.05, **, p<0.01, ***, p<0.001 when compared to their 
respective untreated control cells.  
Similarly, in HaCaT cells, no significant induction of cell death was reported under exposure 
to all 5 ITCs during the initial 24hrs (Fig. 3.16). However, after 48hrs, our data showed an 




PEITC (Fig. 3.16e) and AITC (Fig. 3.16c). In contrast, PEITC showed increased caspase 3/7 
activity at this particular time point.  
 
Figure 3.16: ITCs-induced cell death in HaCaT cells. Cells were exposed to 10μΜ of a) 
SFN, b) IBN, c) AITC, d) BITC and e) PEITC for 24 and 48hrs and the percentage of live, 
apoptotic and necrotic cells was recorded by flow. Results are expressed as mean ± SD of 
three replicates and are representatives of three independent experiments. Statistical analysis 
performd by one-way ANOVA  with Tukey’s test for multiple comparisons. Asterisks 
denote statistical significance at *, p<0.05, **, p<0.01, ***, p<0.001 when compared to their 




Finally, when B16F10 cells were incubated with each one of the ITCs, the levels of dead 
cell were shown to be similar to those of the control ones, at both time points  of exposure, 
suggesting that neither apoptosis nor necrosis was induced in this cell line (Fig. 3.17).  
 
Figure 3.17: ITCs-induced cell death in B16F10 cells. Cells were exposed to 10μΜ of a) 
SFN, b) IBN, c) AITC, d) BITC and e) PEITC for 24 and 48hrs and the percentage of live, 
apoptotic and necrotic cells was recorded by flow. Results are expressed as mean ± SD of 
three replicates and are representatives of three independent experiments. Statistical analysis 
performd by one-way ANOVA  with Tukey’s test for multiple comparisons. Asterisks 
denote statistical significance at *, p<0.05, **, p<0.01, ***, p<0.001 when compared to their 




3.1.4 Cytotoxicity Profile: Determination of ROS Induction 
Another important aspect in ITC-induced cytotoxicity is the generation of oxidative stress 
(measured as levels of reactive oxygen species; ROS) and so the capacity of all 5 ITCs to 
induce ROS production, in our in vitro melanoma model, was investigated. For this reason, 
we evaluated the levels of intracellular ROS generation post-exposure to 10μΜ of each ITC, 
using flow cytometry and utilizing a fluorescent DHR 123 probe as a ROS detector. Flow 
cytometry histograms for all experiments are represented in Figure S3 (under supplementary 
material). 
More specifically, treatment of A375 cells with SFN, IBN, BITC and PEITC induced an 
increase in intracellular ROS levels, at 24hrs of exposure, which became 2-fold higher after 
48hrs when compared to control cells (Fig. 3.18a). ROS generation was also observed in 
Hs294T cells exposed to the same ITCs at 24hrs, which was sustained even at 48hrs post-
exposure (Fig. 3.18c). In contrast, no significant induction of oxidative response was 
observed in AITC-exposed A375 and Hs294T cells, conditions where ROS levels were close 
to control ones at both time points (Figs. 3.18a & 3.17c). Regarding B16F10 cells, our data 
showed that there were no statistically significant differences in ROS levels under SFN, IBN 
and AITC exposure conditions, at 24 and 48hrs. However, BITC and PEITC showed a 
capacity to induce ROS production after 48hrs in of exposure (Fig. 3.18f). Interestingly, we 
observed a decline in intracellular ROS levels at 24hrs of exposure, in VMM1 cells, that 
reached control levels at 48hrs under all ITCs examined (Fig. 3.18b). In addition, 
intracellular ROS levels in HaCaT (Fig. 3.18d) and A431 (Fig. 3.18e) were similar to control 
levels under 24hrs of exposure to all ITCs. At 48hrs of exposure to BITC and PEITC, a 1.5 
fold increase in ROS production was observed in HaCaT cells only. Finally, PEITC was 
shown to exert the capacity to trigger generation of oxidative stress in A431 cells at 48hrs 





Figure 3.18: ITCs-induce generation of oxidative stress in an in vitro model of 
malignant melanoma. Our in vitro model consisted of: a) malignant melanoma (A375), b) 
metastatic melanoma derived from brain (VMM1), c) metastatic melanoma derived from 
lymph node (Hs294T), d) transformed, normal, keratinocyte (HaCaT), e) non-melanoma 
epidermoid carcinoma (A431) and f) murine malignant melanoma (B16F10) cells. All cell 
lines were treated with 10μΜ of each of the 5 ITCs for 24 and 48hrs and ROS production 
was examined by flow cytometry. Data quantitated as fold induction relative to untreated 
control cells. Results are expressed as mean ± SD of three replicates and are representatives 
of three independent experiments. Statistical analysis performed by one-way ANOVA with 
Tukey’s test for multiple comparisons. Statistical significance was set at *, p<0.05, **, 
p<0.01, ***, p<0.001, relative to corresponding untreated controls. 
Overall, our data showed that among all cell lines, the FITC spectrum increased dramatically 




effect in all cell lines tested. A similar effect was observed in Hs294T cells but not as 
significant as in A375 cells. Also, our results suggest that most of the cell lines (e.g. B16F10, 
VMM1, A431 and HaCaT) were resistant to ITC-induced production of oxidative stress 
suggesting that perhaps such production does not modulate the ITC-induced cytotoxicity 
observed in these cells. In addition, BITC and PEITC were shown to be the most potent ones 
in triggering an oxidative stress response in all cells.  
3.1.5: Cytotoxicity Profile: Determination of GSH Levels 
In this experimental setting, our in vitro model was exposed to 10μΜ of each of the ITCs 
and the levels of total reduced glutathione (GSH) were evaluated 24 and 48hrs post exposure 
by using flow cytometry with the utilization of a Thiol Green Dye as reduced GSH detector. 
Flow cytometry histograms for all experiments are represented in Figure S4 (under 
supplementary material). 
In A375 cells, a marked decrease in GSH levels was observed 24hrs post exposure to all 5 
ITCs. However, at 48hrs of exposure, GSH levels were increased significantly when the cells 
were exposed to SFN, IBN, BITC and PEITC. Under exposure to AITC, these levels were 
recovered back to control ones (Fig. 3.19a).  Similarly, in Hs294T cells, 24hrs after exposure 
to all 5 ITCs, the total cellular concentration of GSH declined whiles after 48hrs of exposure 
a significant elevation was observed. However, in SFN-, IBN-, AITC- and PEITC-exposed 
cells, GSH levels still remained declined and there was no period for recovery of cellular 
GSH concentration levels. On the contrary, in BITC-exposed Hs294T cells, GSH levels were 
elevated (Fig. 3.19c). Alternatively, when B16F10 cells were exposed to SFN and IBN, for 
24hrs, the GSH levels were increased, an observation that was further enhanced after 48hrs 
of exposure. In line with these observations, in PEITC-exposed cells, a slight elevation in 
intracellular GSH levels was observed, at 24hrs, which was persistent all the way through 
the 48hrs time point of exposure. On the other hand exposure of these cells to BITC resulted 
in a slight increase of GSH levels only after 48hrs. Interestingly, GSH concentration 
remained at control levels at both time points of AITC exposure (Fig. 3.19f). In the case of 
the VMM1 cells, our results showed that BITC induced a significant elevation in GSH, at 
24hrs but not at 48hrs of exposure. In contrast, PEITC caused a significant decline in GSH 
at 24hrs but also not at 48hrs of exposure. On the other hand, exposure to SFN and IBN had 
no significant effect on cellular GSH levels (Fig. 3.19b). In A431 cells, at 24hrs of exposure, 
PEITC markedly increased the GSH concentration, an effect that was even further 




after 48hrs of exposure whereas AITC diminished those levels at both time points. In 
addition, in SFN-exposed A431 cells, GSH decreased at  24hrs, followed by a slight increase 
over 48hrs while during IBN exposure, an increase in GSH levels occurred mainly at 48hrs 
(Fig. 3.19e). Finally, in HaCaT cells, the GSH concentration declined at 24hrs of exposure 
to SFN, IBN, AITC and PEITC. However, at 48hrs of exposure, the GSH levels were 
recovered (to control values) for both IBN and PEITC while increased with Furthermore, 
exposure to AITC induced a decline in GSH levels at both time points. Finally, BITC 
exposure did not change significantly the GSH levels, at 24hrs, but increased over 48hrs 
(Fig. 3.19d). 
 
Figure 3.19: The effect of ITCs on total intracellular levels of GSH in an in vitro model 
of malignant melanoma. Our in vitro model consisted of: a) malignant melanoma (A375), 
b) metastatic melanoma derived from brain (VMM1), c) metastatic melanoma derived from 




epidermoid carcinoma (A431) and f) murine malignant melanoma (B16F10) cells. All cells 
were exposed to 10μΜ of each of the 5 ITCs for 24 and 48hrs. Total intracellular GSH levels 
were recorded by flow cytometry. Data quantitated as fold induction relative to GSH levels 
of untreated control cells. Results are expressed as mean ± SD of three replicates and are 
representatives of three independent experiments. Statistical analysis performed by one-way 
ANOVA with Tukey’s test for multiple comparisons. Asterisks denote statistical 
significance at *, p<0.05, **, p<0.01, ***, p<0.001, relative to corresponding untreated 
controls. 
Based on the detailed characterization of the cytotoxicity profile of each ITC, a concentration 
of 10μM over 48hrs of exposure were chosen as optimum experimental conditions in order 
to demonstrate the anti-melanoma effect of all 5ITCs on human malignant melanoma (A375) 
as well as in melanoma metastatic Hs294T cells. On the other hand, the brain metastatic cell 
line (VMM1), the non-tumorigenic keratinocyte (HaCaT), non-melanoma epidermoid 
carcinoma  (A431)  and  murine malignant melanoma (B16F10) cell lines remained 
relatively unaffected, reflecting a specificity of these ITCs towards human primary and 

























Results II – Assessment of 
apoptotic induction in response to 












3.2 ITCs modulate the Expression Profile of Key Apoptotic Genes in Human Malignant 
Melanoma (A375) Cells  
In order to further investigate the ITC-induced apoptotic response in malignant melanoma 
cells, a transcriptomic approach for screening multiple critical gene targets involved in 
various stages of the apoptotic process was used. To do so, we utilized a TaqMan real-time 
PCR microarray-based gene expression profiling system containing 92 candidate apoptosis-
associated genes involved in the initiation of apoptosis, death receptor regulated pathways, 
the BCL-2 family of pro- and anti-apoptotic molecules, and various caspases in addition to 
4 endogenous housekeeping (control) genes. This system allows the profiling of the 
differential expression pattern of these 92 genes, in response to 10μΜ of each of the 5 ITCs, 
48h post exposure, in A375 cells compared to untreated (control) ones. Apoptotic gene 
expression was assessed 48h post exposure to the five ITCs, as at this time point a significant 
increase in cell death induction was observed accompanied with increased levels of cells 
stained positive for activated caspase 3/7, compared to 24h (as observed from the cell death 
induction experiments). Our data showed that several genes were differentially expressed 
(by being either up- or down-regulated) after exposure to each ITC. It should be highlighted 
that gene expression experiments are still in the early discovery phase and the reported data 
demonstate prelminary observations requiring futher validation experiments in the future. 
In particular, in SFN-exposed A375 cells, we observed  29 genes being differentially 
expressed in comparison to untreated cells of which 19 were  up-regulated (by at least 2-
fold). Among them, 5 genes (e.g. FAS, FASLG, IGF1, IL6 and MDM2) were highly 
expressed (e.g. 4- to 8-fold) while the expression levels of 10 genes were down-regulated 
(by 2-fold) (Table 3.3):  
Table 3.3: List of differentially regulated apoptosis-associated genes as a response to 









Apoptosis Inducing Factor Mitochondria Associated 1 
Acts as a pro-apoptotic factor promoting disassembly in apoptotic cells 






BCL2 Binding Component 3 
Member of the BCL-2 family of proteins - Binds to anti-apoptotic Bcl-
2 family members to induce mitochondrial dysfunction, caspase 







Table 3.3: List of differentially regulated apoptosis-associated genes as a response to 




Bcl-2-Like Protein 1 
Member of the BCL-2 protein family - Acts as anti- or pro-apoptotic 
regulators and regulate mitochondrial membrane potential, the 






BH3 Interacting Domain Death Agonist Interacts with either agonist 
BAX or antagonist BCL2 and regulate apoptosis, mediating 
mitochondrial damage induced by caspase-8 and triggering 







Member of the cysteine-aspartic acid protease family - Play a central 
role in apoptosis and acts as a tumor suppressor, activated by the 
apoptosome -  Induces cleavage and activation of caspase-3 and 7 - 






DNA Fragmentation Factor Subunit Beta 







Solute Carrier Family 25 Member 6 
Member of the mitochondrial carrier subfamily of solute carrier 
protein genes - Catalyzes the exchange of cytoplasmic ADP with 
mitochondrial ATP across the mitochondrial inner membrane and is 
implicated in the function of the permeability transition pore complex 








BCL2 Associated X Protein 
Act as an apoptotic activator triggering  loss in mitochondria 
membrane potential and release of cytochrome c and promotes 







Is an E3 ubiquitin ligase that mediate p53/TP53 inhibition via 
proteasome degradation and blocks p73/TP73-mediated cell cycle 
arrest and apoptosis. It is also involved in p53/TP53 stabilization as 




ER-stress mediated apoptosis 
 
BBC3 
BCL2 Binding Component 3 
Member of the BCL-2 family of proteins - Binds to anti-apoptotic Bcl-
2 family members to induce mitochondrial dysfunction, caspase 








Fas Cell Surface Death Receptor 
Member of the TNF-receptor superfamily - Initiates the subsequent 
cascade of caspases mediating apoptosis promoting the formation of 
death-inducing signaling complex that includes Fas-associated death 






Fas Ligand (TNF Superfamily, Member 6) 
Member of the tumor necrosis factor superfamily - Transmembrane 






TNF Superfamily Member 10 
Member of the tumor necrosis factor (TNF) ligand family – It induces 
apoptosis preferentially in transformed and tumor cells and has been reported 







Table 3.3: List of differentially regulated apoptosis-associated genes as a response to 
SFN exposure in malignant melanoma (A375) cells (continued) 
 
TRADD 
TNF Receptor Type 1-Associated DEATH Domain Protein 
Interacts with TNFRSF1A/TNFR1 and mediates programmed cell 






DNA Fragmentation Factor Subunit Beta 







TNF Receptor Associated Factor 2 
Member of the TNF receptor associated factor protein family, required 
for TNF-alpha-mediated activation of MAPK8/JNK and NF-kappa-B 








Insulin Like Growth Factor 1 
Member of a family of proteins, structurally and functionally related 
to insulin, involved in mediating growth and development – Regulate 







Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta 
Plays an essential role in the NFkB signaling pathway – Activates 
NFkB and thus induces genes involved in immune response, growth 





Inhibitor of Nuclear Factor Kappa B Kinase Subunit Gamma 
Acts as a regulator of the IKK complex, which once activated, promote 






Is a cytokine involved in inflammation and maturation of B cells as 






Kinase Insert Domain Receptor or Vascular Endothelial Growth 
Factor Receptor 2 
Plays a key role in the regulation of angiogenesis, vascular 
development and permeability and promotes proliferation, survival, 








Nuclear Factor Kappa B Subunit 2 
Encodes a subunit of the transcription factor complex NFkB which 
functions as a central activator of genes involved in biological 
processes such as inflammation, immunity, differentiation, cell 






NF-Kappa-B Inhibitor Alpha 
Encodes a member of the NFkB inhibitor family and interacts with 







Transforming Growth Factor Beta 1 
Encodes a secreted ligand of the TGF-beta superfamily of proteins and 
regulates cell proliferation, differentiation and growth, immune 
function, and can regulate the activation of other growth factors 







Checkpoint Kinase 2 
It is a cell cycle checkpoint regulator and tumor suppressor, required 
for checkpoint-mediated growth arrest, activation of DNA repair and 







Table 3.3: List of differentially regulated apoptosis-associated genes as a response to 




Epidermal Growth Factor Receptor 
Member of the protein kinase superfamily that interact with members 
of the epidermal growth factor family and activates complex 







Poly(ADP-Ribose) Polymerase 1 
Encodes the poly(ADP-ribosyl)transferase which is involved in the 
regulation of various crucial cellular processes such as differentiation, 







Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit 
Beta 
Is an isoform of the catalytic subunit of phosphoinositide 3-kinase 
PI3Kbeta (PI3KB) and is implicated in signaling pathways involved in 







Protein Kinase C Alpha 
Member of serine- and threonine-specific protein kinase family 
involved in diverse cellular processes, including cell proliferation, 
apoptosis, differentiation, migration, adhesion, transformation, 







Ribosomal Protein S6 Kinase A2 
Member of the ribosomal S6 kinase family of serine/threonine kinases 
that functions downstream the MAPK signaling pathway and thus 







Ribosomal Protein S6 Kinase A5 
Serine/threonine-protein kinase, required for the regulation of 
inflammatory genes, while mediate activation of several immediate 





In IBN-exposed A375 cells, a diverse expression pattern regarding 35 genes was noted. Most 
of these genes showed reduced relative expression levels among which BCL2 was the one 
with the lowest fold induction compared to control cells. In contrast, the expression of 12 
genes was found to be up-regulated among which FAS, IL6 and KDR were shown to be the 
ones with the highest induction of expression (e.g. 4-fold) (Table 3.4):   
Table 3.4: List of differentially regulated apoptosis-associated genes as a response to 









BCL2 Associated Agonist Of Cell Death 
Member of the BCL-2 family with pro-apoptotic activity - Promotes 







BH3 Interacting Domain Death Agonist 
Member of the BCL-2 family - Encodes a death agonist and regulate 






Table 3.4: List of differentially regulated apoptosis-associated genes as a response to 
IBN exposure in malignant melanoma (A375) cells (continued) 
APAF1 
Apoptotic Peptidase Activating Factor 1 
Initiator of apoptosis by promoting cytochrome c-induced activation 
of caspase 9, which then induce the subsequent caspase cascade and 





BCL2 Apoptosis Regulator 
Encodes an integral outer mitochondrial membrane protein that reverse 
the apoptotic death regulating mitochondrial permeability, inhibits 





BCL2 Like 11 
Member of the BCL-2 protein family - Interacts with other members 




Member of the cysteine-aspartic acid protease family – It is an effector 
caspase having a crucial role in the execution-phase of cell apoptosis. 




Member of the cysteine-aspartic acid protease family – It is an effector 
caspase having a crucial role in the execution-phase of cell apoptosis 
0.5 
CYCS 
Cytochrome C, Somatic 
It is a central component of the electron transport chain in 
mitochondria and plays an important role in apoptosis initiation. 
Modulate both anti-apoptotic and pro-apoptotic members of the Bcl-2 
family, altering mitochondrial membrane permeability, which leads to 
cytochrome c release 
0.5 
SLC25A5 
Solute Carrier Family 25 Member 5 
Member of the mitochondrial carrier subfamily of solute carrier protein 
genes - Catalyzes the exchange of cytoplasmic ADP with 
mitochondrial ATP across the mitochondrial inner membrane. 
Repression of SLC25A5 reported to be associated with apoptosis 





BCL2 Associated X Protein 
Act as an apoptotic activator triggering  loss in mitochondria 
membrane potential and release of cytochrome c and promotes 







Is an E3 ubiquitin ligase that mediate p53/TP53 inhibition via 
proteasome degradation and blocks p73/TP73-mediated cell cycle 
arrest and apoptosis. It is also involved in p53/TP53 stabilization as 





ATM Serine/Threonine Kinase 
Member of the PI3/PI4-kinase family – Acts as a DNA damage sensor 
and thus induce several genes such as the ones involved in cell cycle 
checkpoint signaling pathways and the tumor suppressor proteins p53 







Fas Cell Surface Death Receptor 
Member of the TNF-receptor superfamily - Initiates the subsequent 
cascade of caspases mediating apoptosis promoting the formation of 
death-inducing signaling complex that includes Fas-associated death 








Table 3.4: List of differentially regulated apoptosis-associated genes as a response to 
IBN exposure in malignant melanoma (A375) cells (continued) 
 
TRADD 
TNF Receptor Type 1-Associated DEATH Domain Protein 
Interacts with TNFRSF1A/TNFR1 and mediates programmed cell 






Member of the cysteine-aspartic acid protease family – It is an effector 
caspase having a crucial role in the execution-phase of cell apoptosis. 




Member of the cysteine-aspartic acid protease family – It is an effector 
caspase having a crucial role in the execution-phase of cell apoptosis 
0.5 
CFLAR 
CASP8 and FADD Like Apoptosis Regulator 
It is an apoptotic regulator, structurally similar to caspase-8 that acts 
as an important link between cell survival and cell death pathways. It 
has a dual role acting either as an apoptotic inducer or an anti-apoptotic 
factor inhibiting TNFRSF-mediated apoptosis 
0.5 
DAXX 
Death Domain Associated Protein 
It’s a multifunctional protein located both in the nucleus and in the 
cytoplasm. It interacts with various proteins, such as apoptosis antigen 
Fas. It’s also implicated in apoptosis regulation, by inducing JNK 
pathway activation and thus TNFRSF6-dependent apoptosis. Also 




TNF Receptor Associated Factor 2 
Member of the TNF receptor associated factor protein family, required 
for TNF-alpha-mediated activation of MAPK8/JNK and NF-kappa-B 
and plays a key role in controlling cell survival and apoptosis 
0.5 
Other cellular processes: Cell growth, Proliferation, Immune responses and Inflammation 
 
IKBKB 
Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta 
Plays an essential role in the NFkB signaling pathway – Activates 
NFkB and thus induces genes involved in immune response, growth 






Is a cytokine involved in inflammation and maturation of B cells as 






Kinase Insert Domain Receptor or Vascular Endothelial Growth Factor 
Receptor 2 
Plays a key role in the regulation of angiogenesis, vascular 
development and permeability and promotes proliferation, survival, 







NF-Kappa-B Inhibitor Alpha 
Encodes a member of the NFkB inhibitor family and interacts with 






Phosphoinositide-3-Kinase Regulatory Subunit 1 
Plays a crucial role in insulin-related metabolic actions and regulates 




AKT Serine/Threonine Kinase 1 
Regulate a range of functions including metabolism, proliferation, cell 
survival, apoptosis, growth and angiogenesis as well as NFkB-





Table 3.4: List of differentially regulated apoptosis-associated genes as a response to 
IBN exposure in malignant melanoma (A375) cells (continued) 
 
ATM 
ATM Serine/Threonine Kinase 
Member of the PI3/PI4-kinase family – Acts as a DNA damage sensor 
and thus induce several genes such as the ones involved in cell cycle 
checkpoint signaling pathways and the tumor suppressor proteins p53 
and BRCA1 maintaining genome stability 
0.5 
CHEK2 
Checkpoint Kinase 2 
It is a cell cycle checkpoint regulator and tumor suppressor, required 
for checkpoint-mediated growth arrest, activation of DNA repair and 
regulates pro-apoptotic genes and apoptosis through p53 
0.5 
CHUK 
Component Of Inhibitor Of Nuclear Factor Kappa B Kinase Complex 
Member of the serine/threonine protein kinase family – It is an 
important regulator of the NF-kappa-B signaling pathway, thus 
modulating genes involved in immune response, growth control, or 
protection against apoptosis 
0.5 
PARP1 
Poly(ADP-Ribose) Polymerase 1 
Encodes the poly(ADP-ribosyl)transferase which is involved in the 
regulation of various crucial cellular processes such as differentiation, 
proliferation, tumor transformation and DNA repair 
0.5 
PARP2 
Poly(ADP-Ribose) Polymerase 2 
Encodes the poly(ADP-ribosyl)transferase -like 2 protein plays a key 
role in DNA repair 
0.5 
REL 
REL Proto-Oncogene, NF-KB Subunit 
Member of the Rel homology domain/immunoglobulin-like fold, 
plexin, transcription factor (RHD/IPT) family. Interacts with NFkB 
and regulate processes such as apoptosis, inflammation, immune 




Ribosomal Protein S6 Kinase A1 
Member of the ribosomal S6 kinase family of serine/threonine kinases 
that functions downstream the MAPK signaling pathway and thus 
control cell growth, proliferation, survival and differentiation. It is also 




Ribosomal Protein S6 Kinase A2 
Member of the ribosomal S6 kinase family of serine/threonine kinases 
that functions downstream the MAPK signaling pathway and thus 
control cell growth, proliferation, survival, differentiation and motility 
0.5 
RPS6KA4 
Ribosomal Protein S6 Kinase A4 
Member of the ribosomal S6 kinase family of serine/threonine kinases 
- Functions in the regulation of inflammatory genes, in the control of 
RELA transcriptional activity in response to TNF as well as of cell 
growth, proliferation, survival, differentiation and motility 
0.5 
RPS6KA5 
Ribosomal Protein S6 Kinase A5 
Serine/threonine-protein kinase, required for the regulation of 
inflammatory genes, while mediate activation of several immediate 
early genes, including proto-oncogenes 
0.5 
 
In AITC-exposed A375 cells, a diverse expression profile of 17 genes was identified. Most 
of these genes were down-regulated whereas 6 of them were upregulated to a variable degree 




inflammation responses) was shown to be markedly up-regulated (e.g.30-fold induction) 
suggesting a role of inflammation in AITC-induced cytotoxicity of A375 cells (Table 3.5): 
Table 3.5: List of differentially regulated apoptosis-associated genes as a response to 













Member of the cysteine-aspartic acid protease family - Play a central 
role in apoptosis and acts as a tumor suppressor, activated by the 
apoptosome -  Induces cleavage and activation of caspase-3 and 7 - 







Apoptotic Peptidase Activating Factor 1 
Initiator of apoptosis by promoting cytochrome c-induced activation 
of caspase 9, which then induce the subsequent caspase cascade and 






DNA Fragmentation Factor Subunit Beta 









Is an E3 ubiquitin ligase that mediate p53/TP53 inhibition via 
proteasome degradation and blocks p73/TP73-mediated cell cycle 
arrest and apoptosis. It is also involved in p53/TP53 stabilization as 







Fas Ligand (TNF Superfamily, Member 6) 
Member of the tumor necrosis factor superfamily - Transmembrane 







Tumor Necrosis Factor 
Member of the tumor necrosis factor (TNF) superfamily – It binds to 
TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR receptors and thus 
regulate various biological processes including cell proliferation, 







DNA Fragmentation Factor Subunit Beta 







Baculoviral IAP Repeat Containing 2 
Member of a family of proteins that inhibits apoptosis – It’s a 
multifactorial protein that binds to tumor necrosis factor receptor-
associated factors, TRAF1 and TRAF2 and regulates caspases and 
apoptosis and modulates inflammatory signaling, immunity, 









TNF Receptor Superfamily Member 10a 
Member of the TNF-receptor superfamily – interacts with TNF-
related ligand, TNFSF10/TRAIL, and mediates downstream cell 
death signaling and induces apoptosis and NFkB activation. FADD 
adaptor protein is required for TNFRSF10A-induced apoptosis, 








Table 3.5: List of differentially regulated apoptosis-associated genes as a response to 




TNF Receptor Superfamily Member 1A 
Member of the TNF receptor superfamily – Binding of TNFa in this 
receptor results in its activation and transduces signals for the 
regulation of cell functions including cell survival, FADD-mediated 








TNF Superfamily Member 12 
Member of the tumor necrosis factor (TNF) ligand family – Interacts 
with the FN14/TWEAKR receptor and is involved in apoptotic 
induction in a cell type-specific manner and also mediates NFkB 









TNF Receptor Associated Factor 2 
Member of the TNF receptor associated factor protein family, 
required for TNF-alpha-mediated activation of MAPK8/JNK and 









Ribosomal Protein S6 Kinase A3 
Member of the ribosomal S6 kinase family of serine/threonine 
kinases that functions downstream the MAPK signaling pathway and 
thus control cell growth, proliferation, survival, differentiation and 
motility. It is also associated with repression of pro-apoptotic 








Baculoviral IAP Repeat Containing 2 
Member of a family of proteins that inhibits apoptosis – It’s a 
multifactorial protein that binds to tumor necrosis factor receptor-
associated factors, TRAF1 and TRAF2 and regulates caspases and 
apoptosis and modulates inflammatory signaling, immunity, 







F2R Like Thrombin Or Trypsin Receptor 3 
Member of the protease-activated receptor subfamily - Plays a role 







Tumor Necrosis Factor 
Member of the tumor necrosis factor (TNF) superfamily – It binds to 
TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR receptors and thus 
regulate various biological processes including cell proliferation, 








Epidermal Growth Factor Receptor 
Member of the protein kinase superfamily that interact with members 
of the epidermal growth factor family and activates complex 








KIT Proto-Oncogene, Receptor Tyrosine Kinase 
Human homolog of the proto-oncogene c-kit – It’s a tyrosine-protein 
kinase involved in the regulation of cell survival and proliferation, 
hematopoiesis, stem cell maintenance, gametogenesis, mast cell 








Protein Kinase C Alpha 
Member of serine- and threonine-specific protein kinase family 
involved in diverse cellular processes, including cell proliferation, 
apoptosis, differentiation, migration, adhesion, transformation, 







Table 3.5: List of differentially regulated apoptosis-associated genes as a response to 




Protein Kinase C Beta 
Member of serine- and threonine-specific protein kinase family 
involved in diverse cellular processes, including B cell activation, 
intestinal sugar absorption, cell proliferation, oxidative stress-








Ribosomal Protein S6 Kinase A1 
Member of the ribosomal S6 kinase family of serine/threonine 
kinases that functions downstream the MAPK signaling pathway and 
thus control cell growth, proliferation, survival and differentiation. It 










Ribosomal Protein S6 Kinase A4 
Member of the ribosomal S6 kinase family of serine/threonine 
kinases - Functions in the regulation of inflammatory genes, in the 
control of RELA transcriptional activity in response to TNF as well 








TNF Receptor Superfamily Member 1A 
Member of the TNF receptor superfamily – Binding of TNFa in this 
receptor results in its activation and transduces signals for the 
regulation of cell functions including cell survival, FADD-mediated 








TNF Superfamily Member 12 
Member of the tumor necrosis factor (TNF) ligand family – Interacts 
with the FN14/TWEAKR receptor and is involved in apoptotic 
induction in a cell type-specific manner and also mediates NFkB 







In BITC-exposed A375 cells, we reported an increased number of differentially expressed 
genes compared to the other ITC exposures. Overall, BITC influenced the expression pattern 
of 42 genes in a manner where 20 of them were down-regulated with BCL2 and EGFR 
showing the highest degree of reduction while 22 genes of them were up-regulated and being 
involved in diverse apoptotic stages [e.g. the BCL2-family (BBC3, BAK1 and BAX), death 
receptors (FAS and FASLG) and p53-related (MDM2), among others] (Table 3.6).  
Table 3.6: List of differentially regulated apoptosis-associated genes as a response to 







BCL2 Antagonist/Killer 1 
Member of the BCL2 protein family – It promotes apoptotic 
induction via loss of membrane potential resulting in the release of 
apoptogenic factors such as cytochrome c, promoting the activation 
of caspase 9. IT also interacts with the p53 tumor suppressor gene 





Table 3.6: List of differentially regulated apoptosis-associated genes as a response to 
BITC exposure in malignant melanoma (A375) cells (continued) 
BBC3 
BCL2 Binding Component 3 
Member of the BCL-2 family of proteins - Binds to anti-apoptotic 
Bcl-2 family members to induce mitochondrial dysfunction, caspase 




Phorbol-12-Myristate-13-Acetate-Induced Protein 1 
Promotes loss of mitochondrial membrane potential and efflux of 




Apoptotic Peptidase Activating Factor 1 
Initiator of apoptosis by promoting cytochrome c-induced activation 
of caspase 9, which then induce the subsequent caspase cascade and 
commits the cell to apoptosis 
0.5 
BCL2 
BCL2 Apoptosis Regulator 
Encodes an integral outer mitochondrial membrane protein that 
reverse the apoptotic death regulating mitochondrial permeability, 
inhibits caspase activity and may also attenuate inflammation 
0.2 
BCL2L1 
Bcl-2-Like Protein 1 
Member of the BCL-2 protein family - Acts as anti- or pro-apoptotic 
regulators and regulate mitochondrial membrane potential, the 




Member of the cysteine-aspartic acid protease family – It is an 
effector caspase having a crucial role in the execution-phase of cell 
apoptosis. Activates caspases 6, 7, and 9 
0.5 
CYCS 
Cytochrome C, Somatic 
It is a central component of the electron transport chain in 
mitochondria and plays an important role in apoptosis initiation. 
Modulate both anti-apoptotic and pro-apoptotic members of the Bcl-
2 family, altering mitochondrial membrane permeability, which 
leads to cytochrome c release 
0.5 
DFFA 
DNA Fragmentation Factor Subunit Alpha 
It’s the substrate for caspase-3 and triggers DNA fragmentation 





BCL2 Associated X Protein 
Act as an apoptotic activator triggering  loss in mitochondria 
membrane potential and release of cytochrome c and promotes 




Is an E3 ubiquitin ligase that mediate p53/TP53 inhibition via 
proteasome degradation and blocks p73/TP73-mediated cell cycle 
arrest and apoptosis. It is also involved in p53/TP53 stabilization as 
well as growth and DNA damage response pathways 
4.0 
ER-stress mediated apoptosis 
BBC3 
BCL2 Binding Component 3 
Member of the BCL-2 family of proteins - Binds to anti-apoptotic 
Bcl-2 family members to induce mitochondrial dysfunction, caspase 







Table 3.6: List of differentially regulated apoptosis-associated genes as a response to 
BITC exposure in malignant melanoma (A375) cells (continued) 
FAS 
Fas Cell Surface Death Receptor 
Member of the TNF-receptor superfamily - Initiates the subsequent 
cascade of caspases mediating apoptosis promoting the formation of 
death-inducing signaling complex that includes Fas-associated death 
domain protein (FADD), caspase 8, and caspase 10 
4.0 
FASLG 
Fas Ligand (TNF Superfamily, Member 6) 
Member of the tumor necrosis factor superfamily - Transmembrane 
protein that primarily induce apoptosis triggered by binding to FAS 
2.1 
TNF 
Tumor Necrosis Factor 
Member of the tumor necrosis factor (TNF) superfamily – It binds to 
TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR receptors and thus 
regulate various biological processes including cell proliferation, 
differentiation, apoptosis, lipid metabolism, and coagulation 
2.0 
TNFSF12 
TNF Superfamily Member 12 
Member of the tumor necrosis factor (TNF) ligand family – Interacts 
with the FN14/TWEAKR receptor and is involved in apoptotic 
induction in a cell type-specific manner and also mediates NFkB 





Member of the cysteine-aspartic acid protease family – It is an 
effector caspase having a crucial role in the execution-phase of cell 
apoptosis. Activates caspases 6, 7, and 9 
0.5 
DAXX 
Death Domain Associated Protein 
It’s a multifunctional protein located both in the nucleus and in the 
cytoplasm. It interacts with various proteins, such as apoptosis 
antigen Fas. It’s also implicated in apoptosis regulation, by inducing 
JNK pathway activation and thus TNFRSF6-dependent apoptosis. 
Also mediate p53 stabilization by promoting MDM2 degradation, 
upon DNA damage 
0.5 
DFFA 
DNA Fragmentation Factor Subunit Alpha 
It’s the substrate for caspase-3 and triggers DNA fragmentation 




TNF Receptor Associated Factor 2 
Member of the TNF receptor associated factor protein family, 
required for TNF-alpha-mediated activation of MAPK8/JNK and 
NF-kappa-B and plays a key role in controlling cell survival and 
apoptosis 
0.5 
Other cellular processes: Cell growth, Proliferation, Immune responses and Inflammation 
CDKN2A 
Cyclin Dependent Kinase Inhibitor 2A 
It is a CDK4 kinase inhibitor that regulate cell proliferation by 
promoting cell cycle arrest in G1 and G2 phases and also acts as a 
tumor suppressor inducing apoptosis. In addition, acts as a p53 




Is a cytokine involved in inflammation and maturation of B cells as 





Table 3.6: List of differentially regulated apoptosis-associated genes as a response to 
BITC exposure in malignant melanoma (A375) cells  (continued) 
 
KDR 
Kinase Insert Domain Receptor or Vascular Endothelial Growth 
Factor Receptor 2 
Plays a key role in the regulation of angiogenesis, vascular 
development and permeability and promotes proliferation, survival, 




Nuclear Factor Kappa B Subunit 1 
This gene produces two transcripts: A 105 kD protein acting as Rel 
protein-specific transcription inhibitor and a 50 kD protein which is 
a DNA binding subunit of the NFkB protein complex, thus it is 
involved in processes including inflammation, immunity, 
differentiation, cell growth, tumorigenesis and apoptosis 
2.0 
NFKB2 
Nuclear Factor Kappa B Subunit 2 
Encodes a subunit of the transcription factor complex NFkB which 
functions as a central activator of genes involved in biological 
processes such as inflammation, immunity, differentiation, cell 
growth, tumorigenesis and apoptosis 
4.1 
NFKBIA 
NF-Kappa-B Inhibitor Alpha 
Encodes a member of the NFkB inhibitor family and interacts with 




NFKB Inhibitor Beta 
Member of the  NFkB inhibitor family – It inhibits NFkB activation 
by complexing and trapping it to the cytoplasm 
2.0 
NFKBIE 
NFKB Inhibitor Epsilon 
Member of the  NFkB inhibitor family – It inhibits NFkB activation 
by complexing and trapping it to the cytoplasm as well as DNA-
binding of NFkB subunit complexes 
2.0 
PRKCB 
Protein Kinase C Beta 
Member of PKC family belonging to serine- and threonine-specific 
protein kinases - regulate diverse cellular signaling pathways such as 
the B cell activation, oxidative stress-induced apoptosis, androgen 




REL Proto-Oncogene, NF-KB Subunit 
Member of the Rel homology domain/immunoglobulin-like fold, 
plexin, transcription factor (RHD/IPT) family - Interacts with NFkB 
and regulate processes such as apoptosis, inflammation, immune 




RELB Proto-Oncogene, NF-KB Subunit 
Member of the Rel homology domain/immunoglobulin-like fold, 
plexin, transcription factor (RHD/IPT) family - Interacts with NFkB2 
and NFkB1 and regulates processes including inflammation, 
immunity, differentiation, cell growth, tumorigenesis and apoptosis. 
4.0 
TNF 
Tumor Necrosis Factor 
Member of the tumor necrosis factor (TNF) superfamily – It binds to 
TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR receptors and thus 
regulate various biological processes including cell proliferation, 





Table 3.6: List of differentially regulated apoptosis-associated genes as a response to 
BITC exposure in malignant melanoma (A375) cells (continued) 
TNFSF12 
TNF Superfamily Member 12 
Member of the tumor necrosis factor (TNF) ligand family – Interacts 
with the FN14/TWEAKR receptor and is involved in apoptotic 
induction in a cell type-specific manner and also mediates NFkB 




AKT Serine/Threonine Kinase 1 
Regulate a range of functions including metabolism, proliferation, 
cell survival, apoptosis, growth and angiogenesis as well as NFkB-
dependent gene transcription 
0.5 
CHEK2 
Checkpoint Kinase 2 
It is a cell cycle checkpoint regulator and tumor suppressor, required 
for checkpoint-mediated growth arrest, activation of DNA repair and 
regulates pro-apoptotic genes and apoptosis through p53 
0.5 
EGFR 
Epidermal Growth Factor Receptor 
Member of the protein kinase superfamily that interact with members 
of the epidermal growth factor family and activates complex 
downstream signaling cascades that regulate cell proliferation 
0.2 
IGF1R 
Insulin Like Growth Factor 1 Receptor 
Interacts with the insulin-like growth factor and plays a role in cell 
growth, proliferation and survival, tumor transformation and also 




It’s a cytokine, important for the proliferation of T and B 
lymphocytes. Primarily plays a crucial role in the regulation of 




MET Proto-Oncogene, Receptor Tyrosine Kinase 
Member of the receptor tyrosine kinase family – It’s a proto-
oncogenic receptor that binds to hepatocyte growth factor/HGF 
ligand and regulates cellular survival, embryogenesis, and cellular 
migration and invasion 
0.5 
PARP1 
Poly(ADP-Ribose) Polymerase 1 
Encodes the poly(ADP-ribosyl)transferase which is involved in the 
regulation of various crucial cellular processes such as 
differentiation, proliferation, tumor transformation and DNA repair 
0.5 
PIK3CB 
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit 
Beta 
Is an isoform of the catalytic subunit of phosphoinositide 3-kinase 
PI3Kbeta (PI3KB) and is implicated in signaling pathways involved 
in cell growth, survival, proliferation, motility and morphology 
0.5 
PRKCA 
Protein Kinase C Alpha 
Member of serine- and threonine-specific protein kinase family 
involved in diverse cellular processes, including cell proliferation, 
apoptosis, differentiation, migration, adhesion, transformation, 
angiogenesis, platelet function and inflammation 
0.5 
RPS6KA1 
Ribosomal Protein S6 Kinase A1 
Member of the ribosomal S6 kinase family of serine/threonine 
kinases that functions downstream the MAPK signaling pathway and 
thus control cell growth, proliferation, survival and differentiation. It 






Table 3.6: List of differentially regulated apoptosis-associated genes as a response to 
BITC exposure in malignant melanoma (A375) cells (continued) 
RPS6KA5 
Ribosomal Protein S6 Kinase A5 
Serine/threonine-protein kinase, required for the regulation of 
inflammatory genes, while mediate activation of several immediate 




It is located in the mitochondrial compartment of peripheral tissues 
and promotes the transport of cholesterol across mitochondrial 
membranes and may also be involved in lipid metabolism. It is 




Finally, the expression profile of 39 genes was found to be differentially regulated after 
exposure of A375 cells to PEITC. Overall, a number of genes showed an important increase 
(e.g. 4- to 8-fold induction) in their expression levels, including FASLG, MDM2, IGF1, 
CASP9 and FAS (Table 3.7):  
Table 3.7: List of differentially regulated apoptosis-associated genes as a response to 







BCL2 Antagonist/Killer 1 
Member of the BCL2 protein family – It promotes apoptotic 
induction via loss of membrane potential resulting in the release of 
apoptogenic factors such as cytochrome c, promoting the activation 
of caspase 9. IT also interacts with the p53 tumor suppressor gene 
under stress stimuli 
2.0 
BBC3 
BCL2 Binding Component 3 
Member of the BCL-2 family of proteins - Binds to anti-apoptotic 
Bcl-2 family members to induce mitochondrial dysfunction, caspase 




Bcl-2-Like Protein 1 
Member of the BCL-2 protein family - Acts as anti- or pro-apoptotic 
regulators and regulate mitochondrial membrane potential, the 




Member of the cysteine-aspartic acid protease family – It is an 
effector caspase having a crucial role in the execution-phase of cell 




Member of the cysteine-aspartic acid protease family – It is an effector 




Member of the cysteine-aspartic acid protease family - Play a central 
role in apoptosis and acts as a tumor suppressor, activated by the 
apoptosome -  Induces cleavage and activation of caspase-3 and 7 - 





Table 3.7: List of differentially regulated apoptosis-associated genes as a response to 
PEITC exposure  in malignant melanoma (A375) cells (continued) 
CYCS 
Cytochrome C, Somatic 
It is a central component of the electron transport chain in 
mitochondria and plays an important role in apoptosis initiation. 
Modulate both anti-apoptotic and pro-apoptotic members of the Bcl-
2 family, altering mitochondrial membrane permeability, which leads 
to cytochrome c release 
2.0 
PMAIP1 
Phorbol-12-Myristate-13-Acetate-Induced Protein 1 
Promotes loss of mitochondrial membrane potential and efflux of 




Solute Carrier Family 25 Member 6 
Member of the mitochondrial carrier subfamily of solute carrier 
protein genes - Catalyzes the exchange of cytoplasmic ADP with 
mitochondrial ATP across the mitochondrial inner membrane and is 
implicated in the function of the permeability transition pore complex 
(PTPC), which controls the release of mitochondrial products that 
induce apoptosis 
0.5 
ER-stress mediated apoptosis 
BBC3 
BCL2 Binding Component 3 
Member of the BCL-2 family of proteins - Binds to anti-apoptotic 
Bcl-2 family members to induce mitochondrial dysfunction, caspase 






Is an E3 ubiquitin ligase that mediate p53/TP53 inhibition via 
proteasome degradation and blocks p73/TP73-mediated cell cycle 
arrest and apoptosis. It is also involved in p53/TP53 stabilization as 




Fas Ligand (TNF Superfamily, Member 6) 
Member of the tumor necrosis factor superfamily - Transmembrane 
protein that primarily induce apoptosis triggered by binding to FAS 
8.3 
FAS 
Fas Cell Surface Death Receptor 
Member of the TNF-receptor superfamily - Initiates the subsequent 
cascade of caspases mediating apoptosis promoting the formation of 
death-inducing signaling complex that includes Fas-associated death 
domain protein (FADD), caspase 8, and caspase 10 
4.0 
DAXX 
Death Domain Associated Protein 
It’s a multifunctional protein located both in the nucleus and in the 
cytoplasm. It interacts with various proteins, such as apoptosis 
antigen Fas. It’s also implicated in apoptosis regulation, by inducing 
JNK pathway activation and thus TNFRSF6-dependent apoptosis. 
Also mediate p53 stabilization by promoting MDM2 degradation, 




Member of the cysteine-aspartic acid protease family – It is an 
effector caspase having a crucial role in the execution-phase of cell 





Table 3.7: List of differentially regulated apoptosis-associated genes as a response to 
PEITC exposure  in malignant melanoma (A375) cells (continued) 
CASP7 
Caspase 7 
Member of the cysteine-aspartic acid protease family – It is an 




Tumor Necrosis Factor 
Member of the tumor necrosis factor (TNF) superfamily – It binds to 
TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR receptors and thus 
regulate various biological processes including cell proliferation, 
differentiation, apoptosis, lipid metabolism, and coagulation 
2.0 
FADD 
Fas Associated Via Death Domain 
It’s an apoptotic adaptor molecule that binds to several cell surface 
receptors, Fas- or TNFR- receptors, and induces cell apoptotic death 
via activation of caspase-8 that subsequently induce the downstream 




TNF Receptor Superfamily Member 1A 
Member of the TNF receptor superfamily – Binding of TNFa in this 
receptor results in its activation and transduces signals for the 
regulation of cell functions including cell survival, FADD-mediated 
apoptosis, and inflammation 
0.5 
TRAF2 
TNF Receptor Associated Factor 2 
Member of the TNF receptor associated factor protein family, 
required for TNF-alpha-mediated activation of MAPK8/JNK and 
NF-kappa-B and plays a key role in controlling cell survival and 
apoptosis 
0.5 
Other cellular processes: Cell growth, Proliferation, Immune responses and Inflammation 
CDKN2A 
Cyclin Dependent Kinase Inhibitor 2A 
It is a CDK4 kinase inhibitor that regulate cell proliferation by 
promoting cell cycle arrest in G1 and G2 phases and also acts as a 
tumor suppressor inducing apoptosis. In addition, acts as a p53 
stabilizer via interaction with MDM2. 
2.0 
F2RL3 
F2R Like Thrombin Or Trypsin Receptor 3 
Member of the protease-activated receptor subfamily - Plays a role in 
blood coagulation, inflammation and response to pain 
16.2 
IGF1 
Insulin Like Growth Factor 1 
Member of a family of proteins, structurally and functionally related 
to insulin, involved in mediating growth and development – Regulate 
activation of the PI3K-AKT/PKB and the Ras-MAPK pathways 
7.2 
IKBKG 
Inhibitor of Nuclear Factor Kappa B Kinase Subunit Gamma 
Acts as a regulator of the IKK complex, which once activated, 




It’s a cytokine, important for the proliferation of T and B 
lymphocytes. Primarily plays a crucial role in the regulation of 





Is a cytokine involved in inflammation and maturation of B cells as 





Table 3.7: List of differentially regulated apoptosis-associated genes as a response to 
PEITC exposure  in malignant melanoma (A375) cells (continued) 
KDR 
Kinase Insert Domain Receptor or Vascular Endothelial Growth 
Factor Receptor 2 
Plays a key role in the regulation of angiogenesis, vascular 
development and permeability and promotes proliferation, survival, 




NF-Kappa-B Inhibitor Alpha 
Encodes a member of the NFkB inhibitor family and interacts with 




Phosphoinositide-3-Kinase Regulatory Subunit 1 
Plays a crucial role in insulin-related metabolic actions and regulates 
various cell functions such as proliferation and survival 
2.0 
REL 
REL Proto-Oncogene, NF-KB Subunit 
Member of the Rel homology domain/immunoglobulin-like fold, 
plexin, transcription factor (RHD/IPT) family. Interacts with NFkB 
and regulate processes such as apoptosis, inflammation, immune 




Tumor Necrosis Factor 
Member of the tumor necrosis factor (TNF) superfamily – It binds to 
TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR receptors and thus 
regulate various biological processes including cell proliferation, 
differentiation, apoptosis, lipid metabolism, and coagulation 
2.0 
AKT1 
AKT Serine/Threonine Kinase 1 
Regulate a range of functions including metabolism, proliferation, 
cell survival, apoptosis, growth and angiogenesis as well as NFkB-
dependent gene transcription 
0.5 
CHEK2 
Checkpoint Kinase 2 
It is a cell cycle checkpoint regulator and tumor suppressor, required 
for checkpoint-mediated growth arrest, activation of DNA repair and 
regulates pro-apoptotic genes and apoptosis through p53 
0.5 
DAPK3 
Death Associated Protein Kinase 3 
Member of serine/threonine kinase family – It is involved in the 
regulation of cell cycle progression and proliferation, autophagy, 
transcription, translation, actin cytoskeleton reorganization and 
induces morphological changes in apoptosis 
0.5 
EGFR 
Epidermal Growth Factor Receptor 
Member of the protein kinase superfamily that interact with members 
of the epidermal growth factor family and activates complex 
downstream signaling cascades that regulate cell proliferation 
0.5 
FADD 
Fas Associated Via Death Domain 
It’s an apoptotic adaptor molecule that binds to several cell surface 
receptors, Fas- or TNFR- receptors, and induces cell apoptotic death 
via activation of caspase-8 that subsequently induce the downstream 




Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta 
Plays an essential role in the NFkB signaling pathway – Activates 
NFkB and thus induces genes involved in immune response, growth 





Table 3.7: List of differentially regulated apoptosis-associated genes as a response to 
PEITC exposure  in malignant melanoma (A375) cells (continued) 
 
PARP1 
Poly(ADP-Ribose) Polymerase 1 
Encodes the poly(ADP-ribosyl)transferase which is involved in the 
regulation of various crucial cellular processes such as 
differentiation, proliferation, tumor transformation and DNA repair 
0.5 
PIK3CB 
Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit 
Beta 
Is an isoform of the catalytic subunit of phosphoinositide 3-kinase 
PI3Kbeta (PI3KB) and is implicated in signaling pathways involved 
in cell growth, survival, proliferation, motility and morphology 
0.5 
RPS6KA1 
Ribosomal Protein S6 Kinase A1 
Member of the ribosomal S6 kinase family of serine/threonine 
kinases that functions downstream the MAPK signaling pathway and 
thus control cell growth, proliferation, survival and differentiation. It 




Ribosomal Protein S6 Kinase A4 
Member of the ribosomal S6 kinase family of serine/threonine 
kinases - Functions in the regulation of inflammatory genes, in the 
control of RELA transcriptional activity in response to TNF as well 
as of cell growth, proliferation, survival, differentiation and motility 
0.5 
RPS6KA5 
Ribosomal Protein S6 Kinase A5 
Serine/threonine-protein kinase, required for the regulation of 
inflammatory genes, while mediate activation of several immediate 
early genes, including proto-oncogenes 
0.5 
TNFRSF1A 
TNF Receptor Superfamily Member 1A 
Member of the TNF receptor superfamily – Binding of TNFa in this 
receptor results in its activation and transduces signals for the 
regulation of cell functions including cell survival, FADD-mediated 




It is located in the mitochondrial compartment of peripheral tissues 
and promotes the transport of cholesterol across mitochondrial 
membranes and may also be involved in lipid metabolism. It is 




Taken together, the gene expression data indicated an altered expression pattern of several 
genes implicated at various stages of the apoptotic process as well as processes important 
for cell growth and survival based on each ITC exposure. Among them, about 20 genes 
(summarized in Fig. 3.20 and Table 3.8) were shown to have a common profile among all 
ITC exposures. More specifically, we reported 19 genes that show a common expression 
pattern (being either up- or down- regulated) in at least three of the ITCs used, while two 
genes, MDM2 (p53-related pathway) and TRAF2 (extrinsic pathway) were shown  to be 
highly up- or down-regulated respectively, under exposure to all 5 ITCs. These common 




APAF1, BAX, BBC3, CASP9 and SLC25A6), ii) extrinsic (e.g. FAS, FASLG and TRAF2), iii) 
ER stress-mediated (e.g. BBC3) and iv) p53-related (e.g. BAX, CHEK2 and MDM2) ones. In 
addition, we have reported a differential expression pattern of genes involved in other 
important cellular processes, that promote apoptosis, including inflammatory and immune 
responses (e.g. IL6, NFKBIA, RPS6KA4, RPS6KA5 and TNF) as well as cell growth, 
survival, differentiation, cell adhesion and migration (e.g. AKT1, EGFR, KDR, PIK3CB, 
PRKCA). Overall, our data support the involvement of ITCs in regulating the apoptotic 
response, as part of their cytotoxic potential, by modulating the expression of various 
apoptosis-related genes implicated in diverse pathways and cellular functions thereby 
reflecting their plurality  of functions and activities.  
 
Figure 3.20: Commonly expressed apoptosis-associated genes upon exposure to all 5 
ITCs in malignant melanoma (A375) cells. A375 melanoma cells were exposed to 10μΜ 
of each of the 5 ITCs for 48hrs and the expression of 92 candidate apoptosis-associated genes 
was evaluated utilizing a TaqMan real-time PCR array-based gene expression profiling 
system. Several genes, involved in various stages of the apoptotic process, found to be 
differentially expressed post exposure to each ITC. Among them, 22 genes found to follow 




ITCs used, which are summarized in this figure. Genes in red refers to upregulated ones, 
while blue to downregulated, whereas the two genes in bold (MDM2 and TRAF2) found to 
be regulated, under exposure to all 5 ITCs. 
Table 3.8: List of common differentially expressed apoptosis-associated genes upon 
exposure to all 5 ITCs in malignant melanoma (A375) cells  
GENE DESCRIPTION SFN IBN AITC BITC PEITC 
Intrinsic pathway 
BBC3 
BCL2 Binding Component 3   
Member of the BCL-2 family of proteins - 
Binds to anti-apoptotic Bcl-2 family 
members to induce mitochondrial 
dysfunction, caspase activation and 
apoptosis. Regulates ER stress-induced 
neuronal apoptosis 
2.0 2.0 - 2.0 2.0 
CASP9 
Caspase 9 
Member of the cysteine-aspartic acid 
protease family - Play a central role in 
apoptosis and acts as a tumor suppressor, 
activated by the apoptosome -  Induces 
cleavage and activation of caspase-3 and 7 - 
Promotes DNA damage-induced apoptosis 
2.0 - 2.0 - 4.0 
APAF1 
Apoptotic Peptidase Activating Factor 1 
Initiator of apoptosis by promoting 
cytochrome c-induced activation of caspase 
9, which then induce the subsequent caspase 
cascade and commits the cell to apoptosis 
- 0.5 0.5 0.5 - 
SLC25A6 
Solute Carrier Family 25 Member 6   
Member of the mitochondrial carrier 
subfamily of solute carrier protein genes - 
Catalyzes the exchange of cytoplasmic ADP 
with mitochondrial ATP across the 
mitochondrial inner membrane and is 
implicated in the function of the permeability 
transition pore complex (PTPC), which 
controls the release of mitochondrial 
products that induce apoptosis 
0.5 0.5 - - 0.5 
ER-stress mediated apoptosis 
BBC3 
BCL2 Binding Component 3   
Member of the BCL-2 family of proteins - 
Binds to anti-apoptotic Bcl-2 family 
members to induce mitochondrial 
dysfunction, caspase activation and 
apoptosis. Regulates ER stress-induced 
neuronal apoptosis 
2.0 2.0 - 2.0 2.0 
p53-mediated apoptosis 
BAX 
BCL2 Associated X Protein 
Act as an apoptotic activator triggering  loss 
in mitochondria membrane potential and 
release of cytochrome c and promotes 
activation of CASP3 




Table 3.8: List of common differentially expressed apoptosis-associated genes upon 
exposure to all 5 ITCs  in malignant melanoma (A375) cells (continued) 
MDM2 
MDM2 proto-oncogene  
Is an E3 ubiquitin ligase that mediate 
p53/TP53 inhibition via proteasome 
degradation and blocks p73/TP73-mediated 
cell cycle arrest and apoptosis. It is also 
involved in p53/TP53 stabilization as well as 
growth and DNA damage response pathways  
8.1 2.0 2.0 4.0 8.2 
Extrinsic pathway 
FAS 
Fas Cell Surface Death Receptor  
Member of the TNF-receptor superfamily - 
Initiates the subsequent cascade of caspases 
mediating apoptosis promoting the 
formation of death-inducing signaling 
complex that includes Fas-associated death 
domain protein (FADD), caspase 8, and 
caspase 10 
4.0 4.0 - 4.0 4.0 
FASLG 
Fas Ligand (TNF Superfamily, Member 6) 
Member of the tumor necrosis factor 
superfamily - Transmembrane protein that 
primarily induce apoptosis triggered by 
binding to FAS 
8.3 - 8.0 2.1 8.3 
TNF 
Tumor Necrosis Factor  
Member of the tumor necrosis factor (TNF) 
superfamily – It binds to 
TNFRSF1A/TNFR1 and 
TNFRSF1B/TNFBR receptors and thus 
regulate various biological processes 
including cell proliferation, differentiation, 
apoptosis, lipid metabolism, and coagulation 
- - 2.0 2.0 2.0 
TRAF2 
TNF Receptor Associated Factor 2 
Member of the TNF receptor associated 
factor protein family, required for TNF-
alpha-mediated activation of MAPK8/JNK 
and NF-kappa-B and plays a key role in 
controlling cell survival and apoptosis 
0.5 0.5 0.5 0.5 0.5 
Other cellular processes: Cell growth, Proliferation, Immune responses and Inflammation 
IL6 
Interleukin 6  
Is a cytokine involved in inflammation and 
maturation of B cells as well as in 
lymphocyte and monocyte differentiation 
8.1 3.9 - 2.0 16.2 
KDR 
Kinase Insert Domain Receptor or Vascular 
Endothelial Growth Factor Receptor 2  
Plays a key role in the regulation of 
angiogenesis, vascular development and 
permeability and promotes proliferation, 
survival, migration and differentiation. It 








Table 3.8: List of common differentially expressed apoptosis-associated genes upon 
exposure to all 5 ITCs  in malignant melanoma (A375) cells (continued) 
NFKBIA 
NF-Kappa-B Inhibitor Alpha  
Encodes a member of the NFkB inhibitor 
family and interacts with REL dimers to 
inhibit NFkB/REL complexes which are 
involved in inflammatory responses  
2.0 2.0 - 2.0 2.0 
TNF 
Tumor Necrosis Factor  
Member of the tumor necrosis factor (TNF) 
superfamily – It binds to 
TNFRSF1A/TNFR1 and 
TNFRSF1B/TNFBR receptors and thus 
regulate various biological processes 
including cell proliferation, differentiation, 
apoptosis, lipid metabolism, and coagulation 
- - 2.0 2.0 2.0 
AKT1 
AKT Serine/Threonine Kinase 1 
Regulate a range of functions including 
metabolism, proliferation, cell survival, 
apoptosis, growth and angiogenesis as well 
as NFkB-dependent gene transcription  
- 0.5 - 0.5 0.5 
CHEK2 
Checkpoint Kinase 2  
It is a cell cycle checkpoint regulator and 
tumor suppressor, required for checkpoint-
mediated growth arrest, activation of DNA 
repair and regulates pro-apoptotic genes and 
apoptosis through p53 
0.5 0.5 - 0.5 0.5 
EGFR 
Epidermal Growth Factor Receptor  
Member of the protein kinase superfamily 
that interact with members of the epidermal 
growth factor family and activates complex 
downstream signaling cascades that regulate 
cell proliferation 
0.5 - 0.5 0.2 0.5 
PARP1 
Poly(ADP-Ribose) Polymerase 1  
Encodes the poly(ADP-ribosyl)transferase 
which is involved in the regulation of various 
crucial cellular processes such as 
differentiation, proliferation, tumor 
transformation and DNA repair  
0.5 0.5 - 0.5 0.5 
PIK3CB 
Phosphatidylinositol-4,5-Bisphosphate 3-
Kinase Catalytic Subunit Beta 
Is an isoform of the catalytic subunit of 
phosphoinositide 3-kinase PI3Kbeta 
(PI3KB) and is implicated in signaling 
pathways involved in cell growth, survival, 
proliferation, motility and morphology 
0.5 - - 0.5 0.5 
PRKCA 
Protein Kinase C Alpha  
Member of serine- and threonine-specific 
protein kinase family involved in diverse 
cellular processes, including cell 
proliferation, apoptosis, differentiation, 
migration, adhesion, transformation, 
angiogenesis, platelet function and 
inflammation 




Table 3.8: List of common differentially expressed apoptosis-associated genes upon 
exposure to all 5 ITCs  in malignant melanoma (A375) cells (continued) 
RPS6KA1 
Ribosomal Protein S6 Kinase A1 
Member of the ribosomal S6 kinase family 
of serine/threonine kinases that functions 
downstream the MAPK signaling pathway 
and thus control cell growth, proliferation, 
survival and differentiation. It is also 
associated with repression of pro-apoptotic 
function of BAD and DAPK1 
- 0.5 0.5 0.5 0.5 
RPS6KA4 
Ribosomal Protein S6 Kinase A4  
Member of the ribosomal S6 kinase family 
of serine/threonine kinases - Functions in the 
regulation of inflammatory genes, in the 
control of RELA transcriptional activity in 
response to TNF as well as of cell growth, 
proliferation, survival, differentiation and 
motility 
- 0.5 0.5 - 0.5 
RPS6KA5 
Ribosomal Protein S6 Kinase A5 
Serine/threonine-protein kinase, required for 
the regulation of inflammatory genes, while 
mediate activation of several immediate 
early genes, including proto-oncogenes  



























Results IIΙ – Characterization of the 
epigenetic response in respect to 












3.3 Characteristic Epigenetic Histone Modifications of A375 Cells in Response to ITCs 
Exposure 
In this part of the study, I aimed to characterize the epigenetic response, focusing on histone 
posttranslational modifications, in A375 cells, post exposure to 10 μΜ of each of the 5 ITCs 
for a period of 48hrs. To this end, we focused on determining protein expression levels of 
several enzymes involved in the epigenetic machinery as well as on their corresponding 
epigenetic marks on specific residues on two core histone proteins, H3 and H4 respectively. 
It should be noted, that western immunoblot data did not show any significant changes in 
differential expression patterns when compared to untreated (control) cells (presented in the 
supplementary section).  
3.3.1 ITCs Modulate Specific HDAC and HAT Protein Expression and Activity Levels in 
A375 Cells 
The effect of each ITC on protein expression levels of various HDACs (e.g. 1, 2, 4 and 6) 
and HATs (e.g. CBP, Acetyl CBP/p300, PCAF, and GCN5L2) was characterized in nuclear 
cell lysates of A375 cells exposed to 10 μM of each ITC over a period of 48hrs. Our data 
showed a significant decrease in protein expression levels of HDAC1, HDAC2, HDAC4 and 
HDAC6 after exposure to SFN, IBN, BITC and PEITC (Figs. 3.21a and c) while exposure 
to AITC diminished markedly the expression of HDAC4 and HDAC6 only when compared 
to untreated (control) cells (Figs. 3.21b and S5). Overall, our results showed a more profound 
reduction of HDAC 6 protein expression levels post exposure to all 5 ITCs. Among them, 





Figure 3.21: ITCs effect on HDAC protein expression levels in A375 cells. Cells were 
exposed to 10 µM of a) SFN or IBN, b) AITC and c) BITC or PEITC for 48 hrs. Western 
immunoblotting was used, in nuclear extracts, to determine the expression levels of HDACs 
1, 2, 4 and 6. Protein expression levels were quantified by densitometry relative to H3 or 




representative of three independent experiments. Statistical analysis performed by Student’s 
t-test and significance was set at *p < 0.05, **p < 0.01, ***p < 0.001 relative to 
corresponding controls. 
Furthermore, treatment of A375 cells with each ITC also reduced protein expression levels 
of specific HAT enzymes, notably CBP and acetyl CBP/p300. Interestingly, AITC was more 
potent against CBP (Fig. 3.22c) followed by BITC and PEITC (Fig. 3.22d) while all 5 ITCs 
exerted a similar inhibitory effect on acetyl CBP/p300 expression levels (Fig. 3.22). In 
addition, PCAF expression was diminished only by SFN (Fig. 3.22a) whereas a slight 
increase was reported after treatment with PEITC (Fig. 3.22d). In contrast, PCAF expression 
levels were similar to control under exposure to IBN, AITC and BITC (Figs. S6b, c and d). 
Finally, GCN5L2 expression levels were similar to control after exposure to all ITCs under 





Figure 3.22: ITCs effect on HAT protein expression levels in A375 cells. Western 
immunoblotting was used, in A375 nuclear extracts, to determine the expression levels of 




c) AITC and d) BITC or PEITC for 48 hrs. Densitometry was used to quantify the protein 
expression levels relative to H3 or TBP, Data were normalized to the untreated control (Ctrl) 
levels. Western blots are representative of three independent experiments. Statistical analysis 
performed by Student’s t-test and significance was set at *p < 0.05, **p < 0.01, ***p < 0.001 
relative to corresponding controls. 
Next, we determined the effect of ITCs on total nuclear HDAC and HAT activity levels 
under the same experimental conditions mentioned above. In general, exposure of A375 cells 
to each of the ITCs resulted in a slight, but statistically significant, reduction in total HDACs 
activities (Fig. 3.23a). When nuclear HATs activities were evaluated, our results showed that 
their levels were reduced in AITC-, BITC-and PEITC-exposed cells. Furthermore, BITC and 
PEITC were shown to exert a more potent inhibitory effect on total HAT activity. On the 
other hand, an increase in total HATs activity levels was observed under exposure to SFN 





Figure 3.23: The effect of ITCs on total HDAC and HAT activity levels in A375 cells.  
Cells were exposed to 10 µM of each ITC for 48 hrs and then a) total HDAC and b) total 
HAT activity levels were assessed using the Epigenase HDAC Activity/Inhibition Direct 
and the Epigenase HDAC Activity/Inhibition Direct assay kits, respectively. Data were 




independent experiments. Statistical analysis performed by Student’s t-test and significance 
was set at *p < 0.05, **p < 0.01, ***p < 0.001 relative to corresponding controls. 
3.3.2 Exposure to ITCs Affect the Expression of Specific Histone H4 and H3 Lysine 
Acetylation Marks in A375 Cells 
To further elucidate the effect of the observed changes of HDACs and HATs expression and 
activity levels, upon exposure to each ITC, we next focused on characterizing the acetylation 
profile of specific lysine residues on the tails of both H3 and H4 core histone proteins. To 
this end, total histone extracts of A375 cells exposed to 10μM of each ITC, were utilized for 
the determination of the acetylation patterns of H4 on lysines (K) 5, 8 and 12 and of H3 on 
lysines 9, 14, 18, 27 and 56. Diminished expression levels of AcH4K5, AcH4K8 and 
AcH4K12 were observed with SFN, AITC and BITC while IBN and PEITC reduced the 
expression of AcH4K8 and AcH4K12 only, relative to control (Fig. 3.24). In general, our 
results showed that AITC was more potent in  inhibiting  AcH4K8 and AcH4K12 protein 
expression levels,followed by BITC and PEITC, respectively. Finally, BITC exhibited a 





Figure 3.24: The effect of ITCs on specific lysine acetylation marks on H4 in A375 cells. 
Cells were exposed to 10 µM of a) SFN or IBN, b) AITC and c) BITC or PEITC for 48 hrs. 
Western immunoblotting was used, in total histone extracts, in order to assess the expression 
levels of the acetylation status of H4K5, H4K8 and H4K12. Protein expression levels were 




(Ctrl). In all experiments, blots are representative of three independent experiments. 
Statistical analysis performed by Student’s t-test and significance was set at *p < 0.05, 
**p < 0.01, ***p < 0.001 relative to corresponding controls. 
Regarding the acetylation pattern of H3, both SFN (Fig. 3.25a) and BITC (Fig. 3.25b) 
exerted a similar effect, resulting in the reduced expression of AcH3K9, AcH3K14 and 
AcH3K27. Moreover, BITC influenced to a greater extent the reduction in the expression of 
these marks and especially that of AcH3K56. On another note, PEITC slightly increased the 
levels of AcH3K14 and AcH3K56, without affecting the pattern of AcH3K9, AcH3K18 and 
AcH3K27 (Fig. 3.25b). In addition, IBN was shown to slightly decrease the acetylated levels 
of AcH3K27 while did not induce any significant changes in those of AcH3K9, AcH3K14 
and AcH3K18 (Fig. 3.25a). Interestingly, AITC had no effect on the acetylation profile of 





Figure 3.25: The effect of ITCs on specific lysine acetylation marks on H3 in A375 cells. 
Cells were exposed to 10 µM of a) SFN or IBN and b) BITC or PEITC for 48 hrs. Western 
immunoblotting was used, in total histone extracts, in order to evaluate the expression levels 
of the acetylation status of H3K9, H3K14, H3K18, H3K27 and H3K36. Protein expression 
levels were quantified by densitometry relative to H3 and the data were normalized to the 
untreated control (Ctrl). In all experiments, blots are representative of three independent 
experiments. Statistical analysis performed by Student’s t-test and significance was set at 




3.3.3 ITCs Modulate the Protein Expression Levels of Specific HMTs  
To assess the effect of each ITC on the protein expression levels of specific HMTs, western 
immunoblotting was utilized, on nuclear cell lysates of A375 cells exposed to each ITC for 
48hrs against various HMTs (e.g. G9a/EHMT2, ESET, RBBP, ASH2L, SET8 and SET7-9).  
Of those, only the expression levels of SET8, SET7-9 and ESET were affected after exposure 
to each ITC while the expression of G9a/EHMT2, RBBP and ASH2L were similar to those 
of the untreated control levels (Fig. S8) More specifically, our results showed that the 
expression levels of SET8 were significantly diminished in A375 cells exposed to IBN (Fig. 
3.26a) while unaffected under AITC (Fig. S8c) exposure. In contrast, its expression 
increased markedly under treatment with BITC and PEITC when compared to untreated cells 
(Fig. 3.26c). Furthermore, protein expression levels of SET7-9, showed a significant over-
expression post exposure to SFN and IBN (Fig. 3.26a) whereas in AITC, BITC and PEITC 
exposure those levels were significantly reduced (Figs. 3.26b and c). Finally, a significant 
elevation of ESET protein expression levels was observed after exposure to BITC and 





Figure 3.26: The effect of ITCs on specific HMTs protein expression levels in A375 
cells. Cells were exposed to 10 µM of a) SFN or IBN, b) AITC and c) BITC or PEITC, for 
48 hrs. Western immunoblotting was used in nuclear extracts to determine the expression 
levels of SET8, SET7-9 and ESET. Protein expression levels were quantified by 
densitometry relative to H3 or TBP and data were normalized to the untreated control (Ctrl). 




by Student’s t-test and significance was set at *p < 0.05, **p < 0.01, ***p < 0.001 relative to 
corresponding controls. 
3.3.4 Di- and tri-methylation Marks of Specific Lysine Residues on Histone H3 Found 
Differentially Affected in A375 Cells Treated with ITCs 
Next, we determined the effect of all 5 ITCs on the di- and tri-methylation levels of lysines 
(K) 4, 9, 27, 36 and 79 on histone H3. It was shown that exposure to SFN, IBN, BITC and 
PEITC over-expressed both di- and tri-methylation levels of K9 with BITC and PEITC 
having a more potent effect on H3K9me2, while IBN and PEITC against H3K9me3 (Figs. 
3.27 and 3.28). Furthermore, our results showed an increase in the protein levels of both di- 
and tri-methylation of K36 and 79, on H3, under exposure to SFN and IBN (Fig. 3.27a and 
Figs. 3.28a and b). On the other hand, BITC and PEITC did not significantly affect the 
expression of H3K36me3 and H3K79me3 (Fig. S9d) while they enhanced H3K79me2 levels 
(Fig. 3.28c). Also, BITC caused a reduction in H3K36me2 which, in turn, was not affected 
by PEITC (Fig. 3.28c). In addition, exposure to BITC and PEITC downregulated the 
expression levels of H3K27me2 (Fig. 3.28c), an effect which was not observed with SFN, 
IBN and AITC (Fig. S9). Also, AITC and BITC, significantly reduced the tri-methylation 
levels of H3K4 (Figs. 3.27b and c). Finally, AITC was shown to be more effective in 
downregulating H3K4me3 whereas did not affect the tri-methylation status of the other 





Figure 3.27: ITCs effect on the tri-methylation status of H3 specific lysine residues in 
A375 cells.  Western immunoblotting was used in total histone extracts of A375 cells 
exposed to 10 μΜ of a) SFN or IBN, b) AITC and c) BITC or PEITC, for 48hrs, in order to 
assess the tri-methylation status of lysines (K) 4, 9, 36 and 79 on histone H3. Protein 
expression levels were quantified by densitometry relative to H3 and the data were 
normalized to the untreated control (Ctrl). All blots are representative of three independent 
experiments. Statistical analysis performed by Student’s t-test and significance was set at 





Figure 3.28: ITCs effect on the di-methylation status of H3 specific lysine residues in 
A375 cells. Cells were exposed to 10 µM of a) IBN, b) SFN and c) BITC or PEITC for 
48 hrs and western immunoblotting was used, in total histone extracts, in order to determine 
the expression levels of di-methylated lysines (K) 9, 27, 36 and 79 on histone H3. Protein 
expression levels were quantified by densitometry relative to H3 and the data were 
normalized to the untreated control (Ctrl). All blots are representative of three independent 
experiments. Statistical analysis performed by Student’s t-test and significance was set at 




























The use of naturally occurring compounds, such as isothiocyanates (ITCs), to prevent 
melanoma initiation and progression has gained an increasing interest over the last years. 
Various studies, have focused on the potential of ITCs to inhibit melanogenesis, both in vitro 
(Arcidiacono et al., 2017; Hamsa et al., 2011; Huang et al., 2014; Huang et al., 2012; Lai et 
al., 2017; Y. S. Ma et al., 2017; Mantso et al., 2019; Mantso et al., 2016; Mitsiogianni, 
Mantso, et al., 2019; Mitsiogianni et al., 2020; Rudolf et al., 2014; Yuanfeng et al., 2015) 
and in vivo (Bansal et al., 2015; Do et al., 2010; Fisher et al., 2016; Ni et al., 2013; Ni et al., 
2014; Pradhan et al., 2010; P. Thejass & G. Kuttan, 2007b). All of these studies have 
demonstrated the multifactorial effect of ITCs in promoting melanoma cell death, via 
triggering multiple pathways, including apoptotic induction, cell cycle progression 
disruption, ROS production and mitochondrial depolarization, as well as blocking invasion 
and metastasis. In line with these observations, in this study, we have demonstrated that 5 
ITCs, namely SFN, IBN, AITC, BITC and PEITC were able to induce cytotoxicity, promote 
ROS formation, G2/M and G1 cell cycle growth arrest and cell death, in vitro in a range of 
human and rodent malignant melanoma cell lines. Our results showed that exposure to these 
ITCs, inhibited melanoma cancer cell growth in a concentration- and time-dependent manner 
in human A375 and murine B16F-10 melanoma as well as in human lymph node-derived 
metastatic melanoma Hs 294T cells. While human brain-derived metastaticVMM1 
melanoma on-melanoma epidermoid carcinoma (A431) and normal transformed (HaCaT) 
keratinocyte cells were found to be more resistant as indicated from their respective EC50 
values (Table 3.1). These findings are in agreement with the literature, as a number of studies 
have also documented that ITCs exert a diversecytotoxic effect among cancer cells and have 
a different sensitivity between cancer and normal cells (Hać et al., 2019; Konic-Ristic et al., 
2016; Nomura et al., 2005; Powolny & Singh, 2010; Trachootham et al., 2006; Tripathi et 
al., 2015). Differences in cell susceptibility in response to ITC exposure have been reported 
to be complex due to being attributed to multiple signalling pathways. According to such 
observations,  possible explanations acountable for such  versatile responses  may involve 
the following: i)  magnitude of ROS formation (an excessive increase in ROS level 
production above and beyond a particular  threshold enhances cellular vulnerability to excess 
oxidative damage)  (Loo, 2003; Powolny & Singh, 2010; Syed Alwi et al., 2012; 
Trachootham et al., 2006); ii)  glutathione (GSH) metabolism alongside with the glutathione 
S-transferase (GSTs) isoforms that are present in cells (intracellular GSH levels play a 
crucial role in ITC cellular accumulation and subsequently cytotoxicity) (Konic-Ristic et al., 




genes important in cell survival  such as NRF2, NFκB, Apaf-1 and Bax) (Batra et al., 2010; 
Choi et al., 2007; Syed Alwi et al., 2012). 
To this end, in order to better characterize the anti-proliferative effect of ITCs, in our in vitro 
model, we assessed the ability of all 5 ITCs to induce oxidative stress as a means of 
promoting cell death. According to our observations, ITCs stimulated an oxidative stress 
response in all 6 cell lines but the magnitude of ROS production was variable among 
different cell types as well as among different ITCs (Fig. 3.17 and Fig. S3). Particularly, our 
results demonstrated that ROS induction in primary melanoma cell line was considerably 
higher compared to metastatic one (mainly Hs294T) and non-malignant epidermoid 
carcinoma (A431), with the effect being intensified over longer periods of exposure. 
Interestingly, we observed a selective specificity of SFN, IBN, BITC and PEITC towards 
human malignant melanoma (A375) cells as far as ROS induction. A375 cells have been 
previously reported to be more vulnerable in oxidative stress induced by these ITCs. 
Furthermore, both BITC and PEITC have triggered ROS production at a highest magnitude 
in B16F-10, A431 and HaCaT cells. In line with these observations, other studies have also 
reported that ROS induction is a main mechanism capable of mediating  cell death in various 
cancer cell models including prostate (J. F. Lin et al., 2017), thyroid (Wang et al., 2015),  
breast cancer (Xiao et al., 2008), hepatocellular  (P. Pocasap et al., 2018), osteosarcoma (de 
Oliveira et al., 2014; Wu et al., 2011) and melanoma (Huang et al., 2014; Huang et al., 2012).  
Persistent ROS production seems to sensitize cancer cells to apoptosis-induced cell death as 
a mechanism by which anti-cancer agents (including ITCs) exert their cytotoxicity. A 
possible explanation for this effect is that although malignant cells are characterized by high 
levels of oxidative stress, being able to increase these levels even further (such as by ITCs) 
can trigger cell death and thus be toxic to these cells. On the contrary, normal cells usually 
have lower intracellular ROS levels and are therefore more resistant to ROS-inducing 
compounds thereby allowing the targeting of cancer cells (Gupta et al., 2014; Konic-Ristic 
et al., 2016; Trachootham et al., 2006). Apart from constitutive intracellular ROS levels, 
other important factor for the cancer cell fate are the GSH levels as well as the ITCs 
accumulation rate. In the literature, it is well documented that the mode of action and the 
intracellular accumulation of ITCs is based primarily on their ability to conjugate with 
intracellular GSH. ITCs accumulation depends on the cellular GSH levels and leads to GSH 
depletion. Exposure of cells to ITCs results in the rapid and high intracellular accumulation 
mainly through simple diffusion. ITCs-GSH conjugation by GSH transferases (GSTs), is 




trapping that prevents from diffusive efflux (Nakamura et al., 2018, Zhang, 2012). Zhang et 
al., investigated the molecular mechanism responsible for ITCs accumulation in human 
breast cancer cells and murine hepatoma cells (Zhang, 2000; Zhang, 2001). The initial ITC 
cellular uptake rates found to be closely correlated with ITC-GSH conjugation reaction, with 
increased cellular GSH levels resulting in enhanced cellular ITC uptake. Similarly, it was 
reported that ITC uptake rate was increased proportionaly with an increase in cellular GST 
activity levels. These set of experiments strongly suggests that ITCs are predominantly taken 
up by cells through GSH conjugation reactions and cellular GST promotes ITC uptake by 
enhancing the conjugation reaction (Zhang, 2000; Zhang, 2001). 
Therefore, GSH levels are of particular importance (for ITCs accumulation) in the context 
that a high intracellular GSH concentration results in greater ITCs influx. Rapid ITC 
accumulation in cells and the subsequent depletion of GSH due to ITC conjugation, increases 
cellular vulnerability to ROS-induced damage. This may explain ITCs selectivity towards 
cancer cells, as these cells reported to have higher intracellular GSH levels compared to 
normal cells and thus tend to be more sensitive to ITCs’ anticancer function (Gupta et al., 
2014; Konic-Ristic et al., 2016). In order to further delineate the ITCs’ mode of action, with 
respect to ROS generation, we assessed the intracellular GSH levels post exposure to each 
of the 5 ITCs. We observed a profound decrease of cellular GSH, mainly in A375 and 
Hs294T cells during the first 24hrs of exposure in comparison to GSH elevated levels upon 
prolonged exposure periods, suggesting the reduced capacity of GSH biosynthesis (Fig. 3.18 
and Fig. S4). In agreement, Zhang et al., showed that the rapid accumulation of BITC and 
SFN into murine hepatoma cells, led to a significant drop in GSH, while its levels reported 
to be rapidly replenished through synthesis. Interestingly it was mentioned that chronic 
exposure of cells to low concentration of ITCs (>24h) was associated with a mark increase 
in GSH levels, suggesting that a cycling mechanism is formed, where ITCs deplete GSH, 
subsequently stimulating its biosynthesis, which in turn may lead to more ITC accumulation 
in cells (Zhang, 2000). In addition, another proposed mechanism for the observed GSH 
recovery is based on the de novo synthesis of GSH. Specifically. it was reported that ITC-
GSH conjugates, once exported from cells, are not stable and they are hydrolyzed 
extracellularly into GSH and ITC. GSH found to be further degraded to cysteine and cysteine 
both of which are reabsorbed into cells, triggering GSH synthesis thus, resulting into a burst 
elevation of GSH (Xu & Thornalley, 2001). Overall, many studies agree in  that the net 
balance of ITC effects (e.g. on detoxification and pro-oxidant pathways) could influence the 




et al., 2004; Singh et al., 2005). In this study, we observed a differential response regarding 
ROS and GSH levels among all cell lines of our model, which could contribute to the 
observed selective toxicity of all 5 ITCs, a speculation that requires further investigation.  
To further characterize the cytotoxicity profile of all ITCs, we investigated their ability to 
inhibit cell cycle progression and promote cell death. The potential of ITCs to stimulate cell 
cycle arrest has been well-documented in the literature. Numerous studies have indicated 
ITCs association with G2/M cell cycle growth arrest and apoptotic induction in various 
cancer cell lines (Huang et al., 2014; Huang et al., 2012; Lau et al., 2010; K. C. Liu et al., 
2016; Mantso et al., 2019; Visanji et al., 2004; Wu et al., 2011). However, ITCs have been 
also found to effectively induce cell cycle arrest at different phases depending on the specific 
cell line used (Arumugam et al., 2020; P. Y. Chen et al., 2012; Cheng et al., 2019; Jadhav et 
al., 2007). For instance, exposure of human osteosarcoma cells to PEITC growth arrested 
cells in the G2/M phase while in the case of human oral squamous carcinoma cells, PEITC 
exposure resulted in G0/G1 growth arrest (P. Y. Chen et al., 2012; Huang et al., 2014). In 
line with these observations, exposure of two  neuroblastoma cell lines (HT92 and SK-N/-
SH) with IBN  inhibited  cell cycle  growth at G2/M and G0/G1 phases, respectively (Jadhav 
et al., 2007). Similarly, assessing the cell cycle distribution in our in vitro model, a quite 
similar pattern was illustrated as all ITCs had the capacity to induce cell cycle growth arrest 
at the G2/M phase in most cell lines that were utilized. The only exception was in the case 
of keratinocytes where exposure to SFN and IBN growth arrested cells at the G0/G1 phase 
of the cell cycle while in the case of VMM1 cells exposed to AITC, there was an 
accumulation of these cells in the S phase. These observations strongly support the notion 
that the effect of ITCs on cell cycle distribution depends significantly on the particular type 
of cancer cell utilized. In addition, we further characterized the effect of these 5 ITCs on 
their ability to promote cell death and apoptosis. To this end, we investigated the mode of 
cell death activation, by means of microarray-based RT-PCR expression profiling of various 
apoptosis-related genes as well as of flow cytometry analysis of relative levels of cellular 
apoptosis and/or necrosis. According to our results, it was apparent that all ITCs were 
capable of modulating the apoptotic response by mediating the differential expression of a 
number of genes representative of various stages in the apoptotic cascade (e.g., intrinsic, 
extrinsic, p53-dependent apoptosis, etc.) as well as of processes implicated in cell growth 
and survival in A375 cells (see Tables 3.2, 3.3, 3.4, 3.5, 3.6 and 3.7 – preliminary 
experiments). Interestingly, our results did not show the potent apoptotic induction (by 




levels of necrosis were observed and especially upon exposure to BITC and PEITC. The 
only exception was the case of Hs294T where significant apoptotic induction was reported.  
On the contrary, in A431 and HaCaT cells neither apoptosis nor necrosis were stimulated, 
demonstrating their resistance to the effect of ITCs. In the literature, there are reports 
demonstrating the unresponsiveness of melanoma cells to diverse apoptosis-mediated 
chemotherapeutics and that some of these agents could deviate from the typical, caspase-
dependent apoptotic processes, with a shift towards necrotic activation (Mijatovic et al., 
2011; Soengas & Lowe, 2003). This death mode switch is considered to be partially due to 
alterations in mitochondrial permeability and bioenergetics. Excessive ROS formation can 
lead to mitochondrial membrane permeabilization and disturb mitochondrial respiratory 
capacity and ATP production, resulting in programmed necrosis activation (Armstrong et 
al., 2018; Ouyang et al., 2012; Troyano et al., 2003). In another study, BITC was found to 
alter the mode of cell death in human cervical cancer HeLa cells from apoptosis to necrosis, 
by modulating the intracellular ATP levels. This study demonstrated the importance of ATP 
levels as well as ITCs concentration in the switching between  apoptosis and necrosis 
(Miyoshi et al., 2008). In addition, other studies have shown the ability of ITCs to promote 
both apoptotic and necrotic cancer cell death (Piman Pocasap et al., 2018; Trachootham et 
al., 2006) however, they do suggest that such exposure can favor the activation of necrosis 
but further studies are needed in order to enhance our current understanding.  
Another important observation in this study, is the differential cytotoxic activity of each of 
the 5 ITCs. According to their cytotoxicity profile, the following trend of potency was 
noticed: BEITC~PEITC > SFN~IBN>AITC. A similar toxicity pattern was also observed in 
leukemia cells exposed to SFN, ERN (erucin), IBN, AITC, BITC and PEITC (BITC~PEITC 
> ERN~IBN > AITC > SFN) (Jakubikova et al., 2005). These observations are in agreement 
with the current literature data, suggesting that the anti-cancer potential of ITCs is strongly 
associated with their structure and more specifically with specific differences such as those 
of the existence of functional groups like double bonds, benzene rings, sulfur or hydroxyl 
moiety etc. on their side chains. To this end, it is generally considered that the aromatic ITCs 
(e.g. BITC and PEITC) are more potent than the aliphatic (e.g. SFN and AITC) ones. In 
addition, the impact of a particular ITC activity may depend on the mechanism of biological 
function, cell type, etc. (Crichlow et al., 2012; Piman Pocasap et al., 2018; Rajendran et al., 
2013; X. Wang et al., 2011). To this end, a study has demonstrated that exposure of human 
colon cancer cells to AITC, SFN and other SFN-related ITCs (e.g. 6-SFN and 9-SFN) 




cell cycle growth arrest. Moreover, in the same study, it was shown that the potency of the 
ITC cytotoxicity increased proportionally based on the length of the alkyl chain in a manner 
where AITC<SFN < 6-SFN < 9-SFN (Rajendran et al., 2013). In another study, it was 
reported that the oxidation state of the sulfur atom as well as the presence of an aromatic 
ring on the ITC’s side chain are both important factors in modifying the anti-cancer potency 
of ITCs in hepatocellular cancer cells (Piman Pocasap et al., 2018). Overall, the results from 
both studies are in agreement with our data thereby strongly supporting the fact that 
structural variations largely affect the potency of anti-cancer capacity of any ITC. 
Then, we focused on investigating the interaction of ITCs with the epigenetic machinery in 
an attempt to enhance our current understanding as to how structurally distinct ITCs can 
influence gene expression and thus the potency of their function. For this reason, we 
concentrated on investigating the acetylation and methylation of specific lysine (K) residues 
on two major core histone proteins (H3 and H4) in human malignant melanoma (A375) cells. 
In general, it is well known that such histone posttranslational modifications are associated 
with the transcriptional regulation of various genes involved in very diverse functions like 
cell growth, proliferation as well as migration and so aberrant alterations in the expression 
levels of these proteins are considered to be implicated in the development and progression 
of melanoma (Boyle et al., 2005; Penta et al., 2018; K. Saha et al., 2013; Sarkar et al., 2015). 
Particularly, overexpression of class I and II HDACs has been associated with cancer 
progression and cell survival (Bai et al., 2015; J. Liu et al., 2016; Pan et al., 2010; Tsunoda 
et al., 2011; Z. Wang et al., 2014) as well as drug resistance (Krumm et al., 2016). Therefore, 
the pharmacological use of a range of HDAC inhibitors (HDACi) can potentially i) promote 
apoptosis and cell cycle growth arrest  (Flørenes et al., 2004; Peltonen et al., 2005; 
Yokoyama et al., 2008), ii) overcome resistance against various drugs currently used in 
clinical settings (Booth et al., 2017; Gallagher et al., 2018; Heijkants et al., 2017; Lai et al., 
2012; Maertens et al., 2019) and iii) enhance immunogenicity (Cheng et al., 2016; Laino et 
al., 2019; Lienlaf et al., 2016; Woan et al., 2015; Woods et al., 2015). To these ends, ITCs 
have been shown to exhibit an epigenetic modulatory capability thereby acting as potent 
HDAC inhibitors by disrupting the HAT/HDAC ratio and so inhibit cancer cell growth 
through regulation of the expression of critical tumor suppressor genes (Abbaoui et al., 2017; 
Boyanapalli et al., 2016; Okonkwo et al., 2018; Paul et al., 2018; Pledgie-Tracy et al., 2007; 
Rajendran et al., 2013; Yuanfeng et al., 2015). In agreement to these observations, we have 
also reported herein that SFN, IBN, BITC and PEITC significantly reduced the protein 




whereas AITC decreased only the expression of type II HDACs in human malignant 
melanoma (A375) cells. Finally, the reduction on the expression of class I (e.g. HDAC1, 
HDAC2) and class II (e.g. HDAC4, HDAC6) HDACs was shown to be accompanied by a 
decline of total HDAC activity levels, under exposure to all 5 ITCs.  
On another note, we also reported diminished expression levels of specific HATs, namely 
CBP and AcetylCBP/p300, in A375 cells, under exposure to all 5 ITCs. In addition PCAF 
protein levels were also found to be affected, but only under SFN and PEITC exposures by 
being either reduced or slightly increased respectively. These observations were followed by 
a reduction in total HAT activity levels, with a marked decrease noticed by BITC and PEITC 
exposures. In agreement with our data, PEITC and BITC have been also shown to inhibit 
both HDAC and HAT enzymes and consequently repress cancer cell growth (Batra et al., 
2010; C. Yu, A. Y. Gong, D. Chen, D. S. Leon, et al., 2013). On another note, HATs have 
long been known to act as important mediators in processes essential for cell survival 
including cell proliferation and cell cycle progression. It has been documented that down-
regulation of HATs, results in suppression of cell proliferation and apoptotic induction in 
various cancer cell lines (Gajer et al., 2015; Lu et al., 2018; Suryanarayanan et al., 2018; 
Suryanarayanan & Singh, 2015). Regarding melanoma, inhibition of these enzymes has been 
reported to stimulate a senescence-like phenotype and suppress cell growth (Bandyopadhyay 
et al., 2002; R. Wang et al., 2018; Yan et al., 2013). Although, a large body of evidence 
supports the significance of repressing these enzymes thereby inhibit cancer development, 
yet, there are reports that describe a tumour suppressor function for HATs, through p53 
acetylation (Jia et al., 2016; Kramer et al., 2015; Q. Li et al., 2016; Liu et al., 1999; Sakaguchi 
et al., 1998). This controversy lays on the diverse role of HATs that has been described in 
participating to both tumor-suppressive and pro-oncogenic processes. Consequently, 
targeting HATs in order to manage malignant development has gained great interest, over 
the last years, and so far a number of small molecule inhibitors have been developed and 
tested in preclinical trials as “next generation” cancer therapeutics (Attar & Kurdistani, 2017; 
Di Martile et al., 2016; Goodman & Smolik, 2000). Furthermore, we have assessed the 
impact of ITC on the acetylation status of specific lysine residues on the N-terminus tails of 
H3 and H4. Overall, we have observed reduced levels of specific histone acetylation marks 
on both H3 and H4, observations that are in agreement with the observed down-regulation 
of CBP/p300 and PCAF enzymes. It is generally known, that important target sites for the 
action of CBP/p300 are H4K8 and H4K5 as well as H3K14, H3K18, H3K27 and H3K56 




H4K8 and H3K9 acetylation (Attar & Kurdistani, 2017; Das et al., 2009; Dekker & Haisma, 
2009; Jin et al., 2011). Particularly, in this study, we observed diminished acetylation levels 
of H4K8 and H4K12, under exposure to all 5 ITCs. In addition, the acetylation levels of 
H4K5 were also found to be decreased, but only by SFN, AITC and BITC. Regarding the 
acetylation pattern of H3, reduced levels of AcH3K9, AcH3K14 and notably AcH3K27 were 
reported mainly by SFN and BITC exposure, while BITC also impaired the acetylation of 
K56. Loss of acetylation of these marks in various tumours, alongside with HAT inhibition, 
has been reported by others as well (Gajer et al., 2015; Lasko et al., 2018; Lu et al., 2018; 
Shidal et al., 2017), and have been associated with decreased cancer cell growth and 
metastatic potential. Alterations in the acetylation of histone marks have been linked with 
disease progression and so could act as potential diagnostic and/or prognostic biomarkers. 
Another important aspect in gene transcriptional regulation is methylation of histone proteins 
which is also associated with the extent of histone protein acetylation. To this end, we next 
investigated the expression levels of specific HMTs and subsequently of their corresponding 
methylation target marks.  Among the methyltransferases we have investigated, only 3 (e.g. 
SET8, SET7/9 and ESET) were found to be differentially regulated, by ITCs, in human 
malignant melanoma (A375) cells. Particularly, our results showed that all 5 ITCs 
differentially affected the expression of SET7/9. In particular, we observed a dramatic 
reduction on the protein expression levels of this histone methyltransferase after exposure of 
cells to AITC, BITC and PEITC whereas SFN and IBN significantly increased its 
expression. Similarly, SET8 was also found to be differentially affected by means of IBN 
exposure resulting in its diminished expression levels while BITC and PEITC increased its 
expression. In addition, BITC and PEITC exposure resulted in an overexpression of ESET. 
All these methyltransferases are important mediators of the methylation of H4K20 (SET8 
and SET7/9), H3K4 (SET7/9) and H3K9 (ESET) and play an important role in DNA damage 
responses, cell cycle progression and carcinogenesis. Apart from the effect on histones, these 
HMTs also regulate the methylation status of non-histone proteins, such as p53 (Dhayalan 
et al., 2011; Fei et al., 2015; Kouzarides, 2007; Montenegro et al., 2015; Wagner & Jung, 
2012). The role of SET7/9 in carcinogenesis seems to be controversial, exerting both tumour 
suppressor (Kurash et al., 2008; Liu et al., 2011) as well as oncogenic functions (Gu et al., 
2018; Takemoto et al., 2016) depending on different cancer types and cell context. For 
instance, in acute myeloid leukaemia, breast and gastric cancer, SET7/9 has been reported 
to induce apoptosis and prevent cell proliferation and migration (Akiyama et al., 2016; Gu 




the opposite effect, by inhibiting the apoptotic process (Gu et al., 2017). SET8 is another 
HMT with a controversial function. A large body of evidence supports the oncogenic role of 
this methyltransferase. In particular, increased levels of SET8 have been reported to be 
associated with decreased survival of gastric cancer and hepatocellular carcinoma cells (Guo 
et al., 2012; Shi et al., 2015). Furthermore, SET8 has been shown to increment prostate 
cancer proliferation through interaction with the androgen receptor (AR) (Yao et al., 2014) 
and enhance metastatic potential and invasiveness of breast cancer cells (Yang et al., 2012). 
In addition, SET8 downregulation resulted in reduced cell proliferation, prevented cell 
migration and sensitized breast cancer cells to DNA damage (B. Liu et al., 2016; N. Yu et 
al., 2013). On the other hand, down-regulation of SET8 decreased cell invasiveness and 
triggered metastasis in prostate cancer cells (Hou et al., 2016).  Moreover, stabilization and 
activation of SET8 reported to be essential for induction of senescence in melanoma cells 
treated with pevonedistat (Benamar et al., 2016). Also, reduced levels of H4K20 mono-
methylation (i.e. the main target of SET8) have been observed in melanoma tissues and are 
associated with increased proliferation rate of melanoma cells (Davis et al., 2017; Wang et 
al., 2012). Regarding ESET methyltransferase, its over-expression has been documented in 
various cancers by being associated with cancer progression and aggressiveness. In addition, 
increased levels of ESET are a common finding in human hepatocellular carcinomas where 
it promotes its progression and metastasis and is also a poor prognostic factor for these 
patients (Wong et al., 2016). Similar observations have been described in glioma 
(Spyropoulou et al., 2014) and prostate (Sun et al., 2014) cancer cell lines while ESET 
inhibition, in these cells, resulted in apoptosis and cell cycle growth arrest induction and 
decreased invasiveness and migratory ability. In melanoma, increased levels of ESET 
methyltransferase were shown to enhance melanoma onset and progression (Ceol et al., 
2011; Orouji et al., 2019). Moreover, the oncogenic role of this methyltransferase has been 
also described in other cancer models through its capacity to modulate cell proliferation, 
migration and drug sensitivity thereby suggesting its possible role as a potential target for 
new therapeutic strategies (Lu et al., 2019; Rodriguez-Paredes et al., 2014; Wu et al., 2018). 
In contrast, increased expression of ESET was shown to suppress leukemic transformation, 
by negatively regulating the expression of acute myeloid pro-leukemic genes (Ropa et al., 
2019). In agreement,  ESET was also found to prevent tumor development by repressing 
target genes of the WNT signaling cascade (Kim et al., 2012) and to indirectly regulate 
hypoxia-induced p53-dependent apoptosis (Olcina et al., 2016).  In addition, it also 




decreased expression of ESET has been reported to facilitate cancer progression and 
promote drug resistance (Du et al., 2018). To conclude, it is obvious that the available 
information regarding the role of HATs and HMTs in cancer aetiology are contradictory, 
with a number of studies indicating a tumour suppressor function while others show their 
involvement in tumour progression. Obviously, further studies are needed in order to 
improve our understanding on the wide range of functions of these enzymes as well as their 
interactions with other components of the epigenetic machinery during carcinogenesis. 
Given that these enzymes catalyze histone methylation, we next focused on the methylation 
landscape on the N-terminal tail of the H3 protein. In general, histone methylation, alongside 
with histone acetylation, are characteristic of the transcriptional state of their target genes. It 
is generally considered that actively transcribed genes are characterized by methylation on 
H3K4, H3K36 and H3K79 while methylation of H3K9, H3K27 and H4K20 are usually 
associated with gene silencing. However, the link between methylation and transcriptional 
activity is more complex, as the degree and the position of the methylation also determine 
gene transcriptional state. For example, tri-methylation of H3K9 and H3K27 is associated 
with gene transcriptional repression, while mono- and di-methylation of H3K9 usually 
results in activation of transcription. Increasing evidence supports the contribution of these 
epigenetic alterations to carcinogenesis and that dietary agents, including ITCs, are able to 
alter a number of these epigenetic events thereby regulating the transcriptional state of gene-
targets in cancer (Fuentes et al., 2015; Kouzarides, 2007; Penta et al., 2018; Varier & 
Timmers, 2011). To this end, we have assessed the methylation status of specific K residues 
on H3 post-exposure to all 5 ITCs. According to our results, both di- and tri- methylation 
status of specific K (H3K4, H3K9, H3K27, H3K36 and H3K79) residues were shown to be 
differentially affected by all ITCs. Common targets of most exposures were shown to be 
H3K9, H3K36 and H3K79. In particular, exposure to SFN, IBN, BITC and PEITC resulted 
in elevated levels of di- and tri-methylation of H3K9 as well as of di-methylation of H3K79. 
In addition, we observed an increase in H3K36me2 by SFN and IBN but diminished levels 
when exposed to BITC. Other studies have also demonstrated the potential of ITCs to target 
these marks and thus to modify the expression of multiple genes involved in processes 
important for cancer cell survival. PEITC exposure of human prostate cancer cells reported 
to increase the methylation content (mono-, di- and tri-methylation) of H3K4, alongside with 
an increase in H3 acetylation), while reduced the level of tri-methylated lysine 9 of H3 
thereby promoting cell cycle growth arrest and inhibition of cancer  growth  (Wang et al., 




isothiocyanate (PHI) in human leukemia cells. PHI enhanced significantly the content of 
acetylated histones H3 and H4 and further mediated methylation of H3K4 accompanied with 
a reduction on tri-methylated H3K9 levels as well as inducing cell cycle growth arrest and 
apoptotic cell death (Ma et al., 2006). In agreement to these observations, in skin cancer 
cells, SFN exposure decreased the expression of polycomb group (PcG) proteins and 
consequently reduced H3K27me3 resulting in the accumulation of cells in the G2/M phase 
(Balasubramanian et al., 2011). SFN was also shown to induce apoptosis and cell cycle 
growth arrest in human breast cancer cells via increased H3 and H4 acetylation and 
decreased content of H3K9me3 and H3K27me3 (Meeran et al., 2010; Sinha et al., 2015).   
The diverse patterns of these epigenetic marks can also give useful prognostic, diagnostic 
and therapeutic information in cancer (Park et al., 2008; Seligson et al., 2005). For instance, 
low levels of H3K4me2 is considered as a poor prognostic factor in breast cancer (Elsheikh 
et al., 2009). In accordance, decreased levels of H3K4me2, alongside with low levels of 
H3K9me2 and AcH3K18, were found to be associated with an overall decreased  survival 
of pancreatic adenocarcinoma cells (Manuyakorn et al., 2010). Low cellular levels of 
H3K4me2 and H3K18ac are also correlated with poorer clinical outcome in lung and 
kidney cancer patients (Seligson et al., 2009). Another significant prognostic marker in 
breast, ovarian and pancreatic cancers is H3K27me3, with lower levels indicating poorer 
patient’s survival probabilities (Wei et al., 2008). Therefore, the characterization of the 
distribution of these epigenetic marks in cancer, could lead to the identification and 







































The beneficial effects of phytochemicals in preventing chronic diseases, including cancer 
has been the subject of extensive studies during the last few decades. Among such 
phytochemicals, ITCs have raised the scientific interest due to their unique cancer chemo-
preventive properties. So far, a number of studies have provided evidence about the capacity 
of ITCs to exert multiple cytotoxic effects, including modulation of phase I and II enzymes, 
oxidative stress generation, inhibition of cell cycle progression, induction of apoptosis, 
prevention of metastasis and regulation of the epigenetic machinery. Overall, the ability of 
these agents to preferentially target cancer rather than normal cells, makes them excellent 
candidates for the development of new strategies against tumorigenesis. Among the various 
tumor-inhibitory effects of ITCs, their interactions with the epigenetic machinery have raised 
the scientific interest. Increasing evidence strongly supports their implication in a wide range 
of epigenetic components in various cancer models. However, in some cases the literature 
data seem to be controversial suggesting that further studies are needed in order to better 
understand the effect of these compounds on the complex epigenetic landscape. 
In this study we have focused our analysis on the potential of 5 ITCs, abundant in the most 
commonly consumed cruciferous vegetables, (e.g. SFN, IBN, AITC, BITC and PEITC) to 
act as epigenetic regulators in malignant melanoma.  To do so, we firstly assessed the anti-
melanoma effect of these ITCs in an in vitro model of malignant melanoma consisting of 
human [A375 (primary melanoma), VMM1 (brain metastasis), Hs294T (lymph node 
metastasis)] and murine (B16F-10) melanoma as well as human non-melanoma epidermoid 
carcinoma (A431) and non-tumorigenic immortalized keratinocyte (HaCaT) cell lines. 
Overall, our study provides evidence that ITCs are capable of exerting an anti-melanoma 
potential by inducing cell cycle growth arrest and apoptotic cell death in the above-
mentioned, well-defined in vitro experimental model.  
We observed, herein, a significant decrease in the viability of A375, Hs294T and B16F10 
while VMM1, A431 and HaCaT cells were less sensitive to ITCs exposure. More 
specifically, it was shown that the cytotoxicity potency was of the following order: 
BEITC~PEITC>SFN~IBN>AITC. Moreover, the observation that our experimental 
conditions of exposure to each of the ITCs do not induce damage to normal keratinocytes, 
(the cell type that surrounds melanocytes)  raises hopes for the potential development of a 
“safer” treatment option (i.e. potentially less side effects of toxicity to the surrounding 
normal, healthy keratinocytes) against melanoma. At the same time, the observed reduction 
in cell viability was accompanied with increased levels of ROS, an oxidative stress response 




enhancement of oxidative stress, a transient reduction of cellular GSH levels was observed 
but which were rapidly replenished upon longer exposure to each ITC. Such differential 
response to both ROS and GSH levels may contribute to the observed preferential targeting 
among the different cell types utilized in our in vitro melanoma model. However, this is 
more of a speculation than data-derived conclusion and so further studies are needed in order 
to investigate how alterations in oxidative stress and GSH homeostasis can affect 
intracellular accumulation of ITCs and consequently impact the potency of their 
cytotoxicity. 
ROS induction has also been implicated in ITCs-induced modulation of cell cycle growth 
arrest as well as apoptotic cell death.  Our data demonstrated the capacity of ITCs to 
accumulate cells at the G2/M phase (for most cell lines), G0/G1 phase (for HaCaT 
keratinocytes) and S phase (for VMM1 cells), suggesting that ITCs differentially affect cell 
cycle progression depending on the particular type of cancer cell. Furthermore, we observed 
an increase in necro-apoptotic cell populations, although in low levels in most cell lines, 
suggesting that the observed significant reduction in cell viability levels was probably 
attributed to cell cycle growth arrest instead of cell death. To this end, further work needed, 
focused on the investigation of the role of ROS in the stimulation of cell cycle growth arrest 
as well as cell death and how this is required for ITC-induced toxicity.  
The effect of ITCs in modulating the apoptotic process was also further assessed by utilizing 
an RT-PCR-based microarray approach. Specifically, various apoptosis-related genes were 
found to be diversely regulated in response to ITCs exposure. About 20 genes implicated in 
various apoptotic stages (e.g. intrinsic, extrinsic, p53-related, ER-mediated) and other 
functions important for cell survival and growth were shown to share a common profile 
among most of these exposures. In particular, two genes namely MDM2 (shown to be up-
regulated) and TRAF2 (shown to be down-regulated) appeared to be targeted by all 5 ITCs. 
Overall, these data support ITCs involvement in apoptotic processes, however, further work 
in needed in order to better understand the involvement of these critical genes in regulating 
the ITCs-induced apoptotic cell death processes. 
Finally, we have characterized the epigenetic profile of each ITC exposure in human 
malignant melanoma (A375) cells by means of assessing specific histone post-translational 
modifications. In general, all 5 ITCs exhibited the capacity to modulate the epigenetic 
machinery by acting as potent inhibitors of specific HDACs and HATs. These observations 
were accompanied by a significant reduction on the acetylation levels of H4K8 and H4K12 




HMTs (e.g. SET8, SET7/9 and ESET) were shown to be affected in a way where i) SET 7/9 
was a target for all 5 ITCS, ii) SET8 was targeted by IBN, BITC and PEITC while iii) ESET 
by BITC and PEITC only. Alongside with these observations, ITCs affected the di- and tri- 
methylation status of specific lysine (K) residues (e.g. H3K4, H3K9, H3K27, H3K36 and 
H3K79) of which H3K9, H3K36 and H3K79 appeared to be common targets under exposure 
to all ITCs. The influence of the five ITCs in A375 cells is summarized in figure 5.1, showing 
the comon epigenetic targets, identified in this study, for at least three of the ITCs of interest. 
Although these data strongly support the ability of ITCs to interact with the epigenome, 
further work is needed in order to elucidate how these epigenetic effects regulate gene 
transcriptional activity and subsequently cell survival and death. To my mind, these findings 
highlight novel insights as to how these 5 major ITCs differentially regulate the epigenome 
in ways compatible with their anti-cancer action in malignant melanoma. Overall, we have 
reported that ITCs could act as potent epigenetic regulators by inhibiting melanoma growth 
through modulation of methylation and acetylation marks thereby altering the transcriptional 
activity of various genes critical in processes that regulate cell growth, proliferation and 
mobility. Thus, the significance of our project lays on the detailed characterization of ITCs-
induced anti-melanoma function and their involvement in modulating the epigenome in ways 
compatible with such function. In this way, it is safe to assume their potential utilization as 
promising “next generation” epigenetic therapeutic agents for the better clinical management 
of malignant melanoma. 
 
Figure 5.1: Common Epigenetic targets of SFN, IBN, AITC, BITC and PEITC in 




of the 5 ITCs for 48hrs and the expression of the protein level of specific histone 
acetyltransferases (HAT), deacetylases (HDAC) and methyltransferases (HMT) together 
with acetylation and methylation marks on histones were evaluated by Western 
Immunoblotting. ITCs found to influence the expression and activity of various components 
of the epigenome. Epigenetic components, identified to be common targets of at least three 
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Figure S1: The ability of SFN, IBN, AITC, BITC and PEITC to induce cell cycle growth 
arrest in an in vitro model of malignant melanoma consisting of a) human malignant 
melanoma (A375), b) murine malignant melanoma (B16F10), c) brain-derived human 
metastatic melanoma (VMM1), d) lymph node-derived human metastatic melanoma 
(Hs294T), e) human non-melanoma epidermoid carcinoma (A431) and (f) human 
immortalized keratinocytes (HaCaT) cell lines. All cells were seeded in 100 mm dishes and 
next day were exposed to 10 µM of each ITC (separately) for 24 and 48 hrs. DNA 
accumulation in each phase of the cell cycle was determined by staining the pre-fixed cells 
with FxCycle PI/RNase fluorescent probe and measured the relative intensity of each phase 

























Figure S2: The ability of SFN, IBN, AITC, BITC and PEITC to induce cell death (e.g. 
apoptosis and necrosis) in an in vitro model of malignant melanoma consisting of a) human 
malignant melanoma (A375), b) murine malignant melanoma (B16F10), c) brain-derived 
human metastatic melanoma (VMM1), d) lymph node-derived human metastatic melanoma 
(Hs294T), e) non-melanoma human epidermoid carcinoma (A431) and f) human 
immortalized keratinocytes (HaCaT) cell lines. All cells were seeded in 100 mm dishes and 
next day were exposed to 10 µM of each ITC (separately) for 24 and 48 hrs. The mode of 
cell death was distinguished by the use of a caspase 3/7 fluorescent probe (for apoptosis) and 


























Figure S3: The effect of SFN, IBN, AITC, BITC and PEITC on generation of oxidative 
stress in an in vitro model of malignant melanoma consisting of a) human malignant 
melanoma (A375), b) murine malignant melanoma (B16F10), c) brain-derived human 
metastatic melanoma (VMM1), d) lymph node-derived human metastatic melanoma 
(Hs294T), e) non-melanoma human epidermoid carcinoma (A431) and f) human 
immortalized keratinocytes (HaCaT) cell lines. All cells were seeded in 100 mm dishes and 
next day were exposed to 10 µM of each ITC (separately) for 24 and 48 hrs. ROS induction 
levels were determined by using a DHR-123 fluorescent probe and the oxidative stress 


























Figure S4: The effect of SFN, IBN, AITC, BITC and PEITC on GSH levels in an in vitro 
model of malignant melanoma consisting of a) human malignant melanoma (A375), b) 
murine malignant melanoma (B16F10), c) brain-derived human metastatic melanoma 
(VMM1), d) lymph node-derived human metastatic melanoma (Hs294T), e) non-melanoma 
human epidermoid carcinoma (A431) and f) human immortalized keratinocytes (HaCaT) 
cell lines. All cells were seeded in 100 mm dishes and next day were exposed to 10 µM of 
each ITC (separately) for 24 and 48 hrs. Relative levels of GSH were determined using the 
Thiol Tracker fluorescent probe. The GSH levels were measured in the FITC region 















Figure S5: The effect of AITC on protein expression levels of HDAC 1 and HDAC2 in 
A375 cells exposed to 10 µM of AITC for 48 hrs. Western immunoblotting was used, in 







Figure S6: The effect of ITCs on protein expression levels of GCN5L2 and PCAF in A375 
cells exposed to 10 µM of a) SFN, b) IBN, c) AITC, d) BITC and PEITC for 48 hrs. Western 







Figure S7: The effect of ITCs on specific H3 lysine acetylation marks in A375 cells exposed 
to 10 µM of a) SFN or IBN, b) AITC and c) BITC or PEITC for 48 hrs. Western 
immunoblotting was used, in total histone extracts, in order to evaluate relevant protein 












Figure S8: The effect of ITCs on protein expression levels of specific HMTs in A375 cells 
exposed to 10 µM of a) SFN, b) IBN, c) AITC and d) BITC or PEITC for 48 hrs. Western 
immunoblotting was used in nuclear extracts to determine relevant protein expression levels 










Figure S9: The effect of ITCs on tri- and di-methylation status of specific lysine residues on 
H3. Western immunoblotting was used, in total histone extracts, of A375 cells exposed to 
10 μΜ of SFN (a,e), IBN, (b,f), AITC, (c,g) and BITC or PEITC (d,h) for 48hrs to assess 
relevant protein expression levels of H3K4me3, H3K27me3, H3K9me3, H3K36me3, 
H3K79me3, H3K4me2, H3K27me2, H3K9me2, H3K36me2 and H3K79me2. 
